PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 23921548-4 2013 However, sulfonylureas are ineffective for long-term treatments and ultimately result in the administration of insulin to control glucose levels. Sulfonylurea Compounds 9-22 insulin Homo sapiens 111-118 23921548-6 2013 A recent study demonstrating that this drug activates TRPA1, (6) a member of the Transient Receptor Potential (TRP) family of ion channels and a functional protein in insulin secreting cells, (7)(,) (8) has highlighted a possible role for TRPA1 as a potential mediator of sulfonylurea-induced toxicity. Sulfonylurea Compounds 272-284 insulin Homo sapiens 167-174 23434183-2 2013 Previously, all patients carrying an R201H mutation in the KCNJ11 gene showed successful switches from insulin to sulfonylurea. Sulfonylurea Compounds 114-126 insulin Homo sapiens 103-110 24150255-2 2013 Sulfonylureas bind to the regulatory subunit of the pancreatic beta cell potassium channel that controls insulin secretion. Sulfonylurea Compounds 0-13 insulin Homo sapiens 105-112 24150255-3 2013 Sulfonylureas also bind to and activate Epac2A, a member of the Epac family of cyclic adenosine monophosphate (cAMP)-binding proteins that promote insulin secretion through activation of the Ras-like guanosine triphosphatase Rap1. Sulfonylurea Compounds 0-13 insulin Homo sapiens 147-154 23350795-9 2013 CONCLUSIONS: These findings confirm low rates of clinically important hypoglycaemia using this method, and suggest that higher risk of hypoglycaemia may be suspected when patients needing insulin are younger, less obese and taking metformin and a sulphonylurea, and especially when A1c levels <=7.0% are attained with glargine dosage <=0.4 units/kg. Sulfonylurea Compounds 247-260 insulin Homo sapiens 188-195 23797471-10 2013 RESULTS: Therapies used as add-on to insulin include agents associated with weight gain (thiazolidinediones and sulfonylureas) and/or hypoglycemia (sulfonylureas), which, therefore, may exacerbate risks already present with insulin. Sulfonylurea Compounds 148-161 insulin Homo sapiens 224-231 23608551-0 2013 Continue with long term sulfonylureas in patients with mutations in the KCNJ11 gene when there is evidence of response even if insulin treatment is still required. Sulfonylurea Compounds 24-37 insulin Homo sapiens 127-134 24968533-1 2013 Optimal dosing of basal insulin is needed to achieve target fasting blood glucose and to avoid hypoglycaemia on the other hand in patients of type 2 diabetes on bedtime basal insulin and daytime sulfonylureas. Sulfonylurea Compounds 195-208 insulin Homo sapiens 24-31 23494446-7 2013 Sulfonylureas added to oral diabetes treatment (four trials) lowered HbA1c by 1.62% (18 mmol/mol; 95% CI 1.0, 2.24) compared with the other treatment, and sulfonylurea added to insulin (17 trials) lowered HbA1c by 0.46% (6 mmol/mol; 95% CI 0.24, 0.69) and lowered insulin dose. Sulfonylurea Compounds 0-13 insulin Homo sapiens 264-271 23149657-0 2013 Short duration of diabetes and disuse of sulfonylurea have any association with insulin cessation of the patients with type 2 diabetes in a clinical setting in Japan (JDDM 30). Sulfonylurea Compounds 41-53 insulin Homo sapiens 80-87 23372169-8 2013 RESULTS: In the same model, and using metformin monotherapy as the referent, the adjusted hazard ratio (aHR) for the primary end point was significantly increased for sulfonylurea monotherapy (1.436, 95% confidence interval [CI] 1.354-1.523), insulin monotherapy (1.808, 95% CI 1.630-2.005), and insulin plus metformin (1.309, 95% CI 1.150-1.491). Sulfonylurea Compounds 167-179 insulin Homo sapiens 243-250 23372169-8 2013 RESULTS: In the same model, and using metformin monotherapy as the referent, the adjusted hazard ratio (aHR) for the primary end point was significantly increased for sulfonylurea monotherapy (1.436, 95% confidence interval [CI] 1.354-1.523), insulin monotherapy (1.808, 95% CI 1.630-2.005), and insulin plus metformin (1.309, 95% CI 1.150-1.491). Sulfonylurea Compounds 167-179 insulin Homo sapiens 296-303 23149657-6 2013 In the patients who stopped insulin therapy, the duration of diabetes was significantly shorter and the daily insulin dosage at initiation and the prevalence of sulfonylurea pretreatment significantly lower compared with patients who continued on insulin. Sulfonylurea Compounds 161-173 insulin Homo sapiens 28-35 23149657-8 2013 Shorter duration of diabetes and disuse of sulfonylureas prior to insulin may associate with stopping insulin therapy as a near-normoglycemic remission in outpatients with T2DM in Japan. Sulfonylurea Compounds 43-56 insulin Homo sapiens 102-109 22699113-4 2012 RESULTS: A greater percentage of patients in the antidiabetic with insulin cohort reported experiencing hypoglycemia compared with patients from sulfonylurea (SU) without insulin and non-SU without insulin cohorts (50% vs. 21% and 12%, respectively; p<0.01 for both comparisons). Sulfonylurea Compounds 2-4 insulin Homo sapiens 67-74 23509454-2 2013 All sulfonylureas stimulate insulin secretion by the closure of ATP-sensitive potassium (KATP) channel. Sulfonylurea Compounds 4-17 insulin Homo sapiens 28-35 23637538-2 2013 Glucose-lowering medications that increase circulating insulin in a glucose-independent manner, such as insulin and sulfonylurea therapy, are the most common cause of hypoglycemia. Sulfonylurea Compounds 116-128 insulin Homo sapiens 55-62 23148347-9 2012 The average time in days to initiation on insulin in the sulphonylurea, rosiglitazone and pioglitazone group was 343, 252 and 339, respectively. Sulfonylurea Compounds 57-70 insulin Homo sapiens 42-49 23148347-10 2012 The cumulative hazard for starting insulin for sulphonylurea patients at 12, 24, 36 and 48 months was approximately three times higher compared to TZD patients. Sulfonylurea Compounds 47-60 insulin Homo sapiens 35-42 23078974-2 2012 Currently available oral antidiabetic drugs (OADs) attempt to correct the underlying pathophysiological dysfunctions leading to T2DM: insulin resistance for the insulin sensitizers (metformin and thiazolidinediones), and impaired insulin secretion for the insulin secretagogues (sulfonylureas, glinides and more recently incretin mimetics). Sulfonylurea Compounds 279-292 insulin Homo sapiens 134-141 23076984-12 2012 Subjects who initiated with sulfonylurea had a significantly (P < 0.001) higher incidence of insulin addition (2.8% vs. 1.4%) compared to those initiated with metformin within 1 year of follow-up. Sulfonylurea Compounds 28-40 insulin Homo sapiens 96-103 23076984-13 2012 The likelihood of initiating insulin was higher in subjects initiated with sulfonylurea than with metformin (adjusted odds ratio 1.82, 95% confidence interval [CI] 1.40-2.38; P < 0.001). Sulfonylurea Compounds 75-87 insulin Homo sapiens 29-36 23076984-14 2012 Sulfonylurea use was also significantly associated with a shorter time to insulin use compared to metformin (adjusted hazards ratio 2.10, 95% CI 1.83-2.39; P < 0.001). Sulfonylurea Compounds 0-12 insulin Homo sapiens 74-81 23076984-15 2012 CONCLUSION: In a cohort of older subjects with T2DM initiating antihyperglycemic therapy, new users of sulfonylurea monotherapy were more likely to receive insulin therapy and received it earlier than those starting with metformin. Sulfonylurea Compounds 103-115 insulin Homo sapiens 156-163 22533711-2 2012 Sulfonylureas act as insulin secretagogues by binding to the sulfonylurea receptor (SUR-1) encoded by the gene ABCC8. Sulfonylurea Compounds 0-13 insulin Homo sapiens 21-28 23019799-1 2012 The aim of this multicentre and observational study was to evaluate in a real life setting glycated haemoglobin A1(c), (HbA1c) as well as body weight outcomes in patients with type 2 diabetes in whom insulin was initiated after unsatisfactory response to exenatide, combined with maximal dosages of metformin and a sulfonylurea. Sulfonylurea Compounds 315-327 insulin Homo sapiens 200-207 23156508-0 2012 [Adverse effects of insulin secretagogues (sulfonylureas and glinides)]. Sulfonylurea Compounds 43-56 insulin Homo sapiens 20-27 22570146-13 2012 CONCLUSION: Hospitalized patients at increased risk for sulfonylurea-related hypoglycemia were those aged 65 years or older, those with a GFR of 30 ml/minute/1.73 m(2) or lower, and those who received concurrent intermediate- or long-acting insulin during inpatient sulfonylurea therapy. Sulfonylurea Compounds 56-68 insulin Homo sapiens 241-248 22257418-0 2012 Combination therapy with liraglutide and sulfonylurea for a type 2 diabetic patient with high titer of anti-insulin antibodies produced by insulin therapy. Sulfonylurea Compounds 41-53 insulin Homo sapiens 108-115 22257418-0 2012 Combination therapy with liraglutide and sulfonylurea for a type 2 diabetic patient with high titer of anti-insulin antibodies produced by insulin therapy. Sulfonylurea Compounds 41-53 insulin Homo sapiens 139-146 22768894-7 2012 Postprandial release of proinsulin was significantly greater in T2DM patients treated with SU plus MET than in those treated with GLA plus MET (p = .003). Sulfonylurea Compounds 91-93 insulin Homo sapiens 24-34 22768894-0 2012 In type 2 diabetes patients, insulin glargine is associated with lower postprandial release of intact proinsulin compared with sulfonylurea treatment. Sulfonylurea Compounds 127-139 insulin Homo sapiens 29-36 22978060-5 2012 Switching from insulin to sulfonylurea treatment leads to the definitive discontinuance of insulin therapy, improving metabolic control as well as the amelioration of the associated neurodevelopmental disabilities in the young girl in which an intermediate Development Delay, Epilepsy, Neonatal Diabetes syndrome was diagnosed. Sulfonylurea Compounds 26-38 insulin Homo sapiens 91-98 22471336-6 2012 RESULTS: Our results revealed the presence of the heterozygous missense mutation c. 679 G/A (E227K) in all three patients, who were all able to successfully transfer from insulin injections to an oral sulfonylurea, with improved glycemic control. Sulfonylurea Compounds 201-213 insulin Homo sapiens 171-178 22563248-5 2012 Insulin treatment is a key predictor of hypoglycemia, with one large population-based study reporting an overall prevalence of 7.1% (type 1 diabetes mellitus) and 7.3% (type 2 diabetes mellitus) in insulin-treated patients, compared with 0.8% in patients with type 2 diabetes treated with an oral sulfonylurea. Sulfonylurea Compounds 297-309 insulin Homo sapiens 0-7 22118705-2 2012 SUs are now known also to activate cAMP sensor Epac2 (cAMP-GEFII) to Rap1 signalling, which promotes insulin granule exocytosis. Sulfonylurea Compounds 0-3 insulin Homo sapiens 101-108 22563248-5 2012 Insulin treatment is a key predictor of hypoglycemia, with one large population-based study reporting an overall prevalence of 7.1% (type 1 diabetes mellitus) and 7.3% (type 2 diabetes mellitus) in insulin-treated patients, compared with 0.8% in patients with type 2 diabetes treated with an oral sulfonylurea. Sulfonylurea Compounds 297-309 insulin Homo sapiens 198-205 21901702-12 2011 SU (with or without metformin) gave poorer metabolic control compared to insulin alone (mean difference in glycosylated haemoglobin A1c (HbA1c) from baseline to end of study, for insulin compared to oral therapy: -1.3% (95% confidence interval (CI) -2.4 to -0.1; P = 0.03, 160 participants, four studies, follow-up/duration of therapy: 12, 30, 36 and 60 months; however, heterogeneity was considerable). Sulfonylurea Compounds 0-2 insulin Homo sapiens 179-186 23028231-3 2012 Glimepiride is a second-generation sulfonylurea that stimulates pancreatic beta cells to release insulin. Sulfonylurea Compounds 35-47 insulin Homo sapiens 97-104 23028231-6 2012 It can also be combined with other antihyperglycemic agents, including metformin and insulin, in patients who are not adequately controlled by sulfonylureas alone. Sulfonylurea Compounds 143-156 insulin Homo sapiens 85-92 22069291-1 2011 BACKGROUND: It has been reported that intervention with insulin in slowly progressive type 1 diabetic (SPIDDM) patients delays the progression to an insulin-dependent state compared to that with sulfonylureas. Sulfonylurea Compounds 195-208 insulin Homo sapiens 56-63 21959939-3 2011 The insufficient production and secretion of insulin can be increased by secretagogue drugs, like sulfonylureas and incretin mimetics/enhancers. Sulfonylurea Compounds 98-111 insulin Homo sapiens 45-52 21959939-7 2011 These mutations are able either to reduce or increase the insulin secretion and can modify the insulin response to sulfonylurea treatment. Sulfonylurea Compounds 115-127 insulin Homo sapiens 58-65 21901702-13 2011 In addition, there was evidence that SU caused earlier insulin dependence (proportion requiring insulin at two years was 30% in the SU group compared to 5% in conventional care group (P < 0.001); patients classified as insulin dependent was 64% (SU group) and 12.5% (insulin group, P = 0.007). Sulfonylurea Compounds 132-134 insulin Homo sapiens 96-103 21901702-13 2011 In addition, there was evidence that SU caused earlier insulin dependence (proportion requiring insulin at two years was 30% in the SU group compared to 5% in conventional care group (P < 0.001); patients classified as insulin dependent was 64% (SU group) and 12.5% (insulin group, P = 0.007). Sulfonylurea Compounds 132-134 insulin Homo sapiens 96-103 21901702-13 2011 In addition, there was evidence that SU caused earlier insulin dependence (proportion requiring insulin at two years was 30% in the SU group compared to 5% in conventional care group (P < 0.001); patients classified as insulin dependent was 64% (SU group) and 12.5% (insulin group, P = 0.007). Sulfonylurea Compounds 132-134 insulin Homo sapiens 96-103 21901702-13 2011 In addition, there was evidence that SU caused earlier insulin dependence (proportion requiring insulin at two years was 30% in the SU group compared to 5% in conventional care group (P < 0.001); patients classified as insulin dependent was 64% (SU group) and 12.5% (insulin group, P = 0.007). Sulfonylurea Compounds 132-134 insulin Homo sapiens 96-103 21901702-20 2011 AUTHORS" CONCLUSIONS: Two studies show SU leading to earlier insulin dependence and a meta-analysis of four studies with considerable heterogeneity showed poorer metabolic control if SU is prescribed for patients with LADA compared to insulin. Sulfonylurea Compounds 39-41 insulin Homo sapiens 61-68 21901702-13 2011 In addition, there was evidence that SU caused earlier insulin dependence (proportion requiring insulin at two years was 30% in the SU group compared to 5% in conventional care group (P < 0.001); patients classified as insulin dependent was 64% (SU group) and 12.5% (insulin group, P = 0.007). Sulfonylurea Compounds 37-39 insulin Homo sapiens 55-62 21901702-13 2011 In addition, there was evidence that SU caused earlier insulin dependence (proportion requiring insulin at two years was 30% in the SU group compared to 5% in conventional care group (P < 0.001); patients classified as insulin dependent was 64% (SU group) and 12.5% (insulin group, P = 0.007). Sulfonylurea Compounds 37-39 insulin Homo sapiens 96-103 21901702-13 2011 In addition, there was evidence that SU caused earlier insulin dependence (proportion requiring insulin at two years was 30% in the SU group compared to 5% in conventional care group (P < 0.001); patients classified as insulin dependent was 64% (SU group) and 12.5% (insulin group, P = 0.007). Sulfonylurea Compounds 37-39 insulin Homo sapiens 96-103 21901702-13 2011 In addition, there was evidence that SU caused earlier insulin dependence (proportion requiring insulin at two years was 30% in the SU group compared to 5% in conventional care group (P < 0.001); patients classified as insulin dependent was 64% (SU group) and 12.5% (insulin group, P = 0.007). Sulfonylurea Compounds 37-39 insulin Homo sapiens 96-103 21901702-13 2011 In addition, there was evidence that SU caused earlier insulin dependence (proportion requiring insulin at two years was 30% in the SU group compared to 5% in conventional care group (P < 0.001); patients classified as insulin dependent was 64% (SU group) and 12.5% (insulin group, P = 0.007). Sulfonylurea Compounds 132-134 insulin Homo sapiens 96-103 21901702-13 2011 In addition, there was evidence that SU caused earlier insulin dependence (proportion requiring insulin at two years was 30% in the SU group compared to 5% in conventional care group (P < 0.001); patients classified as insulin dependent was 64% (SU group) and 12.5% (insulin group, P = 0.007). Sulfonylurea Compounds 132-134 insulin Homo sapiens 96-103 21872103-0 2011 Comment: "Quantitative insulin and C peptide levels among ED patients with sulfonylurea-induced hypoglycemia". Sulfonylurea Compounds 75-87 insulin Homo sapiens 23-30 21477042-1 2011 AIM: Sulphonylureas (SUs) are among the most widely used oral hypoglycaemic drugs that stimulate insulin secretion. Sulfonylurea Compounds 21-24 insulin Homo sapiens 97-104 21410858-12 2011 There was significant insulin discontinuation, dose reduction and greater sulphonylurea discontinuation among insulin-treated patients. Sulfonylurea Compounds 74-87 insulin Homo sapiens 110-117 21477042-15 2011 Thus, SUs but not repaglinide may be used to influence insulin resistance beyond their effect on insulin liberation. Sulfonylurea Compounds 6-9 insulin Homo sapiens 55-62 21143106-7 2011 In routine clinical practice most patients stopped concomitant use of sulfonylureas when initiating insulin analogs and it is likely that this together with the lower dose of insulin influenced outcomes. Sulfonylurea Compounds 70-83 insulin Homo sapiens 100-107 21453253-6 2011 Various drug classes such as glitazones, newer sulfonylureas, angiotensin receptor blockers, ACE inhibitors and nicotinic acid exert beneficial effects on insulin resistance partly by increasing plasma adiponectin levels. Sulfonylurea Compounds 47-60 insulin Homo sapiens 155-162 21442682-6 2011 We found a lower risk of hospitalisation with MI among users of metformin (adjusted OR = 0.86, 95%CI: 0.78-0.95), insulin (adjusted OR = 0.92, 95%CI: 0.86-0.99) and among patients not receiving any antidiabetic pharmacotherapy (adjusted OR = 0.75, 95%CI: 0.71-0.79) compared with users of sulfonylureas. Sulfonylurea Compounds 289-302 insulin Homo sapiens 114-121 21550959-5 2011 CONCLUSION: In these post hoc analyses, patients with type 2 diabetes initiating premixed or basal insulin therapy and treated concomitantly with the OHA combination of metformin/thiazolidinedione at baseline demonstrated significantly greater A1C improvement with less hypoglycemia in comparison with patients treated with metformin/sulfonylurea. Sulfonylurea Compounds 334-346 insulin Homo sapiens 99-106 24843477-9 2011 NDM as a result of mutations in KCNJ11 and ABCC8 often responds to sulfonylureas, allowing transition from insulin therapy. Sulfonylurea Compounds 67-80 insulin Homo sapiens 107-114 21338921-1 2011 Commonly used as a treatment for Type II diabetes, sulfonylureas (SUs) stimulate insulin secretion from pancreatic beta cells by binding to sulfonylurea receptors. Sulfonylurea Compounds 51-64 insulin Homo sapiens 81-88 21338921-1 2011 Commonly used as a treatment for Type II diabetes, sulfonylureas (SUs) stimulate insulin secretion from pancreatic beta cells by binding to sulfonylurea receptors. Sulfonylurea Compounds 66-69 insulin Homo sapiens 81-88 21133673-2 2011 that antidiabetic sulfonylurea drugs promote insulin secretion by directly binding to exchange protein directly activated by cyclic AMP isoform 2 (Epac2) and activating its down-stream effector Rap1. Sulfonylurea Compounds 18-30 insulin Homo sapiens 45-52 21143106-7 2011 In routine clinical practice most patients stopped concomitant use of sulfonylureas when initiating insulin analogs and it is likely that this together with the lower dose of insulin influenced outcomes. Sulfonylurea Compounds 70-83 insulin Homo sapiens 175-182 20177722-7 2010 These findings suggest that postmenopausal women treated with insulin or thiazolidinedione have a high risk of vertebral fractures independent of age, body stature, blood glucose level, insulin secretion, or BMD whereas treatment with sulfonylurea is associated with a decreased risk. Sulfonylurea Compounds 235-247 insulin Homo sapiens 62-69 20804735-7 2010 This contrasted with the action of the sulfonylurea glibenclamide, which also induced insulin secretion under low-glucose conditions (2.8mM). Sulfonylurea Compounds 39-51 insulin Homo sapiens 86-93 22166651-9 2010 Multiple linear stepwise regression analysis showed that insulin doses correlated with body weight, FPG, diabetes duration, age and history of sulfonylurea treatment. Sulfonylurea Compounds 143-155 insulin Homo sapiens 57-64 20887914-0 2010 Quantitative insulin and C-peptide levels among ED patients with sulfonylurea-induced hypoglycemia-a prospective case series. Sulfonylurea Compounds 65-77 insulin Homo sapiens 13-20 20887914-0 2010 Quantitative insulin and C-peptide levels among ED patients with sulfonylurea-induced hypoglycemia-a prospective case series. Sulfonylurea Compounds 65-77 insulin Homo sapiens 25-34 20887914-2 2010 A recently published systematic review of 22 articles involving 76 patients with sulfonylurea-induced hypoglycemia (glucose <49 mg/dL) resulting from accidental ingestion or intentional overdose found that patients had an average serum insulin concentration of 3.9 muIU/mL or higher and an average serum C-peptide concentration of 1.4 ng/mL or higher. Sulfonylurea Compounds 81-93 insulin Homo sapiens 239-246 20887914-2 2010 A recently published systematic review of 22 articles involving 76 patients with sulfonylurea-induced hypoglycemia (glucose <49 mg/dL) resulting from accidental ingestion or intentional overdose found that patients had an average serum insulin concentration of 3.9 muIU/mL or higher and an average serum C-peptide concentration of 1.4 ng/mL or higher. Sulfonylurea Compounds 81-93 insulin Homo sapiens 307-316 20887914-4 2010 RESULTS: Thirteen of 14 study subjects had initial insulin and C-peptide levels consistent with the diagnosis of sulfonylurea-induced hypoglycemia as previously defined among patients presenting after overdose. Sulfonylurea Compounds 113-125 insulin Homo sapiens 63-72 20887914-5 2010 CONCLUSION: Patients presenting with hypoglycemia resulting from therapeutic sulfonylurea use demonstrate similar insulin and C-peptide levels as has previously been published among patients who presented with presumed overdose. Sulfonylurea Compounds 77-89 insulin Homo sapiens 114-121 20887914-5 2010 CONCLUSION: Patients presenting with hypoglycemia resulting from therapeutic sulfonylurea use demonstrate similar insulin and C-peptide levels as has previously been published among patients who presented with presumed overdose. Sulfonylurea Compounds 77-89 insulin Homo sapiens 126-135 20350924-9 2010 CONCLUSION: The addition of insulin glargine early in the diabetes treatment paradigm in patients for whom sulfonylurea or metformin monotherapy had failed resulted in significantly greater improvements in glycemic control in comparison with the addition of pioglitazone. Sulfonylurea Compounds 107-119 insulin Homo sapiens 28-35 19656320-0 2010 Successful sulfonylurea treatment of an insulin-naive neonate with diabetes mellitus due to a KCNJ11 mutation. Sulfonylurea Compounds 11-23 insulin Homo sapiens 40-47 19342262-2 2009 We describe here a rather different phenotype: two cases of adult diabetic patients-considered and treated as insulin-dependent diabetic patients since adolescence-who, in fact, turned out to be heterozygous for an ABCC8 mutation and able to successfully discontinue insulin while taking sulphonylurea treatment. Sulfonylurea Compounds 288-301 insulin Homo sapiens 110-117 21426008-1 2010 BACKGROUND: The sulfonylureas glibenclamide and glimepiride are oral antidiabetic drugs that stimulate insulin secretion by closing pancreatic ATP-dependent potassium channels. Sulfonylurea Compounds 16-29 insulin Homo sapiens 103-110 20361306-1 2010 The traditional sulfonylureas with long half-lives have sustained stimulatory effects on insulin secretion compared to the short-acting insulin secretagogue. Sulfonylurea Compounds 16-29 insulin Homo sapiens 89-96 20222815-1 2010 The sulfonylureas stimulate insulin release from pancreatic beta cells, and have been a cornerstone of Type 2 diabetes pharmacotherapy for over 50 years. Sulfonylurea Compounds 4-17 insulin Homo sapiens 28-35 20540435-4 2010 Sulphonylurea drugs stimulate insulin secretion by binding to and closing K(ATP) channels and thus bypassing beta cell metabolism stimulate the same chain of reactions as glucose. Sulfonylurea Compounds 0-13 insulin Homo sapiens 30-37 20205108-13 2010 This response was augmented by the addition of insulin to sulfonylurea in the incubation medium. Sulfonylurea Compounds 58-70 insulin Homo sapiens 47-54 23226049-6 2010 Many NDM patients with KCNJ11 and ABCC8 mutations can be successfully treated with sulfonylureas (SUs) that inhibit the K(ATP) channel, thus replacing the need for daily insulin injections. Sulfonylurea Compounds 83-96 insulin Homo sapiens 170-177 23226049-6 2010 Many NDM patients with KCNJ11 and ABCC8 mutations can be successfully treated with sulfonylureas (SUs) that inhibit the K(ATP) channel, thus replacing the need for daily insulin injections. Sulfonylurea Compounds 98-101 insulin Homo sapiens 170-177 19692134-9 2009 CONCLUSION: Continuing glimepiride (sulfonylureas) allows a better glycaemic control with less insulin daily dose compared with discontinuing glimepride. Sulfonylurea Compounds 36-49 insulin Homo sapiens 95-102 19021632-13 2009 We were able to transfer two patients off insulin to sulphonylurea (SU) and to reduce insulin dose in one other patient. Sulfonylurea Compounds 53-66 insulin Homo sapiens 42-49 19021632-13 2009 We were able to transfer two patients off insulin to sulphonylurea (SU) and to reduce insulin dose in one other patient. Sulfonylurea Compounds 68-70 insulin Homo sapiens 42-49 19950754-12 2009 Stimulated CP levels correlated best with all the parameters of glycaemic control in the group SU+MET (r -0.479 to -0.791; p < 0.01), and in the group SU+INS (r 0.382 to 0.635; p < 0.01). Sulfonylurea Compounds 95-98 insulin Homo sapiens 11-13 19950754-12 2009 Stimulated CP levels correlated best with all the parameters of glycaemic control in the group SU+MET (r -0.479 to -0.791; p < 0.01), and in the group SU+INS (r 0.382 to 0.635; p < 0.01). Sulfonylurea Compounds 154-157 insulin Homo sapiens 11-13 20425680-5 2010 A diabetes therapy with insulin or sulfonylureas, which leads to elevated exogenous or endogenous insulin levels, appears to be related with an increased cancer risk, whereas administration of metformin or thiazolidinediones, which is associated with a decrease of insulin concentrations, results in risk reduction. Sulfonylurea Compounds 35-48 insulin Homo sapiens 24-31 20425680-5 2010 A diabetes therapy with insulin or sulfonylureas, which leads to elevated exogenous or endogenous insulin levels, appears to be related with an increased cancer risk, whereas administration of metformin or thiazolidinediones, which is associated with a decrease of insulin concentrations, results in risk reduction. Sulfonylurea Compounds 35-48 insulin Homo sapiens 98-105 20425680-5 2010 A diabetes therapy with insulin or sulfonylureas, which leads to elevated exogenous or endogenous insulin levels, appears to be related with an increased cancer risk, whereas administration of metformin or thiazolidinediones, which is associated with a decrease of insulin concentrations, results in risk reduction. Sulfonylurea Compounds 35-48 insulin Homo sapiens 98-105 24843406-1 2010 Sulfonylureas (SU), commonly used in the treatment of type 2 diabetes mellitus (T2DM), stimulate insulin secretion by inhibiting adenosine triphosphate (ATP)-sensitive K(+) (KATP) channels in pancreatic beta-cells. Sulfonylurea Compounds 0-13 insulin Homo sapiens 97-104 24843406-1 2010 Sulfonylureas (SU), commonly used in the treatment of type 2 diabetes mellitus (T2DM), stimulate insulin secretion by inhibiting adenosine triphosphate (ATP)-sensitive K(+) (KATP) channels in pancreatic beta-cells. Sulfonylurea Compounds 15-17 insulin Homo sapiens 97-104 24843406-2 2010 SU are now known to also activate cyclic adenosine monophosphate (cAMP) sensor Epac2 (cAMP-GEFII) to Rap1 signaling, which promotes insulin secretion. Sulfonylurea Compounds 0-2 insulin Homo sapiens 132-139 19885647-12 2009 This response was augmented by the addition of insulin to sulfonylurea in the culture medium. Sulfonylurea Compounds 58-70 insulin Homo sapiens 47-54 18768334-5 2009 In general, alpha-glucosidase inhibitors delay carbohydrate absorption, metiglinides and sulfonylureas increase insulin supply, and biguanides and thiazolidinediones enhance insulin action. Sulfonylurea Compounds 89-102 insulin Homo sapiens 112-119 19774848-3 2009 Sulfonylurea treatment in theses patients reduces or eliminates the need for exogenous insulin. Sulfonylurea Compounds 0-12 insulin Homo sapiens 87-94 19298459-11 2009 Insulin sensitivity of FFA rose when pioglitazone was added to sulfonylurea (P<0.05), but decreased for gliclazide + metformin (P<0.05). Sulfonylurea Compounds 63-75 insulin Homo sapiens 0-7 19421967-10 2009 Patients on sulfonylureas and meglitinides have the highest incidence of hypoglycemia because of their pharmacological action of increasing insulin secretion. Sulfonylurea Compounds 12-25 insulin Homo sapiens 140-147 19175375-8 2009 Continuing metformin and/or sulphonylurea after start of therapy with basal long-acting insulin results in better glycaemic control with less insulin requirements, less weight gain and less hypoglycaemic events. Sulfonylurea Compounds 28-41 insulin Homo sapiens 88-95 19175375-8 2009 Continuing metformin and/or sulphonylurea after start of therapy with basal long-acting insulin results in better glycaemic control with less insulin requirements, less weight gain and less hypoglycaemic events. Sulfonylurea Compounds 28-41 insulin Homo sapiens 142-149 23105828-8 2009 From the findings we can infer that in long term diabetes treatment higher doses of insulin and combined therapy with insulin and metformin may be more beneficial than with low doses of insulin or sulfonyl urea alone. Sulfonylurea Compounds 197-210 insulin Homo sapiens 84-91 23105828-8 2009 From the findings we can infer that in long term diabetes treatment higher doses of insulin and combined therapy with insulin and metformin may be more beneficial than with low doses of insulin or sulfonyl urea alone. Sulfonylurea Compounds 197-210 insulin Homo sapiens 118-125 23105828-8 2009 From the findings we can infer that in long term diabetes treatment higher doses of insulin and combined therapy with insulin and metformin may be more beneficial than with low doses of insulin or sulfonyl urea alone. Sulfonylurea Compounds 197-210 insulin Homo sapiens 118-125 18548275-0 2009 Transition from insulin to sulfonylurea in a child with diabetes due to a mutation in KCNJ11 encoding Kir6.2--initial and long-term response to sulfonylurea therapy. Sulfonylurea Compounds 144-156 insulin Homo sapiens 16-23 18600596-3 2008 Since then, the ability of SU to stimulate the release of insulin from pancreatic beta-cells by the closure of ATP-sensitive K+-channels has been employed as one of the most widespread treatment options for T2DM. Sulfonylurea Compounds 27-29 insulin Homo sapiens 58-65 18784090-8 2008 In the sulfonylurea-insulin group, relative reductions in risk persisted at 10 years for any diabetes-related end point (9%, P=0.04) and microvascular disease (24%, P=0.001), and risk reductions for myocardial infarction (15%, P=0.01) and death from any cause (13%, P=0.007) emerged over time, as more events occurred. Sulfonylurea Compounds 7-19 insulin Homo sapiens 20-27 18191448-8 2008 We hypothesize that the improvement of glucose-stimulated insulin secretion by sulfonylurea compounds in type 2 diabetic patients is in part due to their capacity to raise mitochondrial calcium, which is beneficial for the generation of metabolic coupling factors. Sulfonylurea Compounds 79-91 insulin Homo sapiens 58-65 18600596-5 2008 In recent studies, SU has proven to be associated with increased beta-cell apoptosis, suggesting that SU may actually accelerate the progressive decrease in beta-cell mass, thereby promoting the need for insulin replacement. Sulfonylurea Compounds 102-104 insulin Homo sapiens 204-211 19275673-6 2009 In addition, a 0.5-0.7% reduction in glycated hemoglobin (HbA1c) levels was observed in metformin- or sulfonylurea-treated patients with type 2 diabetes and in drug-naive or insulin-treated diabetic patients. Sulfonylurea Compounds 102-114 insulin Homo sapiens 174-181 19050053-6 2009 RESULTS: Compared to the results of GIP alone, SU alone, or those results added together, coadministration of GIP and SU resulted in a more-than-additive increase in the peripheral insulin (P = 0.002) and C-peptide (P = 0.028) responses and furthermore, a more-than-additive increase in total (P = 0.01), early (P = 0.02), and late-phase (P = 0.02) insulin secretion. Sulfonylurea Compounds 2-4 insulin Homo sapiens 181-188 19050053-7 2009 CONCLUSION: We have demonstrated that inhibiting the K(ATP) channels of the diabetic beta-cell acutely using SU significantly increases both the peripheral insulin response to GIP and GIP-induced insulin secretion, indicating an ameliorated insulinotropic effect of GIP. Sulfonylurea Compounds 109-111 insulin Homo sapiens 156-163 19065048-7 2009 In contrast, the sulfonylurea tolbutamide, a specific blocker of KATP channels, closed KATP channels, elevated intracellular calcium levels, and stimulated insulin release in beta-V59M beta cells, indicating that events downstream of KATP channel closure remained intact. Sulfonylurea Compounds 17-29 insulin Homo sapiens 156-163 18801852-8 2008 Exogenous forms of insulin and agents that stimulate insulin secretion in a glucose-independent manner (such as sulfonylureas and glinides) increase the propensity for hypoglycemia during low- to moderate-intensity aerobic exercise. Sulfonylurea Compounds 112-125 insulin Homo sapiens 19-26 18571549-9 2008 Nonetheless, sulphonylurea treatment should be tried in patients with GCK-PNDM, particularly those with mutations resulting in less severe kinetic defects, in whom improved glycemic control may be obtained with lower doses of insulin. Sulfonylurea Compounds 13-26 insulin Homo sapiens 226-233 18551039-2 2008 As sulfonylurea stimulate insulin secretion by an increased influx of Ca, we hypothesized that this polymorphism is associated with the glucose-lowering effect and mortality risk in sulfonylurea users. Sulfonylurea Compounds 3-15 insulin Homo sapiens 26-33 18551039-2 2008 As sulfonylurea stimulate insulin secretion by an increased influx of Ca, we hypothesized that this polymorphism is associated with the glucose-lowering effect and mortality risk in sulfonylurea users. Sulfonylurea Compounds 182-194 insulin Homo sapiens 26-33 18397986-6 2008 RESULTS: The progression rate to an insulin-dependent state in the insulin group (three of 30, 10%) was lower than that in the SU group (13 of 30, 43%; P = 0.003, log-rank). Sulfonylurea Compounds 2-4 insulin Homo sapiens 36-43 18397831-9 2008 Our results demonstrate that elevated IL-12 serum levels in type 2 diabetics treated with sulphonylureas are induced especially by peripheral insulin resistance and beta cells dysfunction, as expressed by fasting serum proinsulin levels. Sulfonylurea Compounds 90-104 insulin Homo sapiens 142-149 18397831-9 2008 Our results demonstrate that elevated IL-12 serum levels in type 2 diabetics treated with sulphonylureas are induced especially by peripheral insulin resistance and beta cells dysfunction, as expressed by fasting serum proinsulin levels. Sulfonylurea Compounds 90-104 insulin Homo sapiens 219-229 18397986-6 2008 RESULTS: The progression rate to an insulin-dependent state in the insulin group (three of 30, 10%) was lower than that in the SU group (13 of 30, 43%; P = 0.003, log-rank). Sulfonylurea Compounds 2-4 insulin Homo sapiens 67-74 18378631-2 2008 Commonly used oral glucose-lowering agents include sulfonylureas, which are insulin secretagogues, and thiazolidinediones, which are insulin sensitizers. Sulfonylurea Compounds 51-64 insulin Homo sapiens 76-83 18246324-1 2008 In many countries, first- or second-line pharmacological treatment of patients with type 2 diabetes consists of sulfonylureas (such as glibenclamide [known as glyburide in the USA and Canada]), which stimulate the beta cell to secrete insulin. Sulfonylurea Compounds 112-125 insulin Homo sapiens 235-242 18227474-0 2008 Insulin as a first-line therapy in type 2 diabetes: should the use of sulfonylureas be halted? Sulfonylurea Compounds 70-83 insulin Homo sapiens 0-7 18215172-1 2008 The primary cause of hypoglycaemia in Type 2 diabetes is diabetes medication-in particular, those which raise insulin levels independently of blood glucose, such as sulphonylureas (SUs) and exogenous insulin. Sulfonylurea Compounds 181-184 insulin Homo sapiens 110-117 18025408-10 2008 CONCLUSIONS: Oral sulfonylurea therapy is safe and effective in the short term in most patients with diabetes due to SUR1 mutations and may successfully replace treatment with insulin injections. Sulfonylurea Compounds 18-30 insulin Homo sapiens 176-183 18156614-6 2008 The risk for non-fatal myocardial infarction and stroke increased significantly in patients on insulin (HR 1.73, 95% CI 1.26-2.37; P = 0.0007), whereas this risk was lower among those on metformin (HR 0.63, CI 0.42-0.95; P = 0.03) and unchanged with sulphonylureas (HR 0.81, 95% CI 0.57-1.14; P = 0.23). Sulfonylurea Compounds 250-264 insulin Homo sapiens 95-102 19410163-3 2008 Addition of insulin to sulfonylurea therapy, when maximal sulfonylurea does not adequately maintain fasting plasma glucose levels at < 108 mg/dL, has been found to be more effective than initiating insulin therapy after oral agents have failed to maintain glycemic control. Sulfonylurea Compounds 23-35 insulin Homo sapiens 12-19 19410163-3 2008 Addition of insulin to sulfonylurea therapy, when maximal sulfonylurea does not adequately maintain fasting plasma glucose levels at < 108 mg/dL, has been found to be more effective than initiating insulin therapy after oral agents have failed to maintain glycemic control. Sulfonylurea Compounds 58-70 insulin Homo sapiens 12-19 17069922-5 2007 All patients who had been treated with sulfonylureas needed basal insulin replacement. Sulfonylurea Compounds 39-52 insulin Homo sapiens 66-73 17976204-0 2007 Glycaemic responsiveness to long-term insulin plus sulphonylurea therapy as assessed by sulphonylurea withdrawal. Sulfonylurea Compounds 88-101 insulin Homo sapiens 38-45 17976204-1 2007 AIMS: To assess the effect of sulphonylurea (SU) in patients with Type 2 diabetes undergoing long-term combination therapy with insulin, by withdrawal of SU, and to identify clinically useful markers of long-term response. Sulfonylurea Compounds 30-43 insulin Homo sapiens 128-135 17976204-1 2007 AIMS: To assess the effect of sulphonylurea (SU) in patients with Type 2 diabetes undergoing long-term combination therapy with insulin, by withdrawal of SU, and to identify clinically useful markers of long-term response. Sulfonylurea Compounds 45-47 insulin Homo sapiens 128-135 17890232-7 2007 CONCLUSIONS: A single analogue-insulin formulation added to metformin and sulfonylurea resulted in a glycated hemoglobin level of 6.5% or less in a minority of patients at 1 year. Sulfonylurea Compounds 74-86 insulin Homo sapiens 31-38 17652641-10 2007 Treatment of the patient with the sulfonylurea glibenclamide not only enabled insulin therapy to be stopped, but also resulted in improvement in epilepsy and psychomotor abilities. Sulfonylurea Compounds 34-46 insulin Homo sapiens 78-85 17594390-5 2007 Sulfonylureas and thiazolidinediones exert their glucose-lowering effect through differing mechanisms of action - the sulfonylureas by stimulating insulin secretion, whereas the thiazolidinediones are insulin sensitisers. Sulfonylurea Compounds 0-13 insulin Homo sapiens 147-154 17594390-5 2007 Sulfonylureas and thiazolidinediones exert their glucose-lowering effect through differing mechanisms of action - the sulfonylureas by stimulating insulin secretion, whereas the thiazolidinediones are insulin sensitisers. Sulfonylurea Compounds 0-13 insulin Homo sapiens 201-208 17594390-5 2007 Sulfonylureas and thiazolidinediones exert their glucose-lowering effect through differing mechanisms of action - the sulfonylureas by stimulating insulin secretion, whereas the thiazolidinediones are insulin sensitisers. Sulfonylurea Compounds 118-131 insulin Homo sapiens 147-154 17594390-9 2007 This combination may be particularly effective in the early stages of the disease when beta-cell function is at its highest, allowing maximal benefit to be obtained from the insulin secretion-promoting abilities of the sulfonylureas and the beta-cell-protective effects of the thiazolidinediones. Sulfonylurea Compounds 219-232 insulin Homo sapiens 174-181 17452235-4 2007 In all, sulfonylurea treatment permitted cessation of insulin treatment, with improved glycemic control. Sulfonylurea Compounds 8-20 insulin Homo sapiens 54-61 17931842-13 2007 This analysis also has potentially important therapeutic consequences leading to transfer some patients, those with mutations in KCNJ11 and ABCC8 from insulin therapy to sulfonylureas. Sulfonylurea Compounds 170-183 insulin Homo sapiens 151-158 17316868-0 2007 Sulfonylurea and glinide reduce insulin content, functional expression of K(ATP) channels, and accelerate apoptotic beta-cell death in the chronic phase. Sulfonylurea Compounds 0-12 insulin Homo sapiens 32-39 17316868-3 2007 Chronic exposure of pancreatic beta-cells to sulfonylureas (glibenclamide or tolbutamide) and glinide (nateglinide) similarly impaired their acute effectiveness by reducing the insulin content and the number of functional K(ATP) channels on the plasma membrane. Sulfonylurea Compounds 45-58 insulin Homo sapiens 177-184 17316868-6 2007 Thus, reduction of the insulin content, reduction of the number of functional K(ATP) channels on the plasma membrane, and acceleration of apoptotic beta-cell death all are involved in impaired insulinotropic agent-induced acute insulin secretion in the chronic phase of sulfonylurea and glinide treatment. Sulfonylurea Compounds 270-282 insulin Homo sapiens 23-30 17636829-15 2007 There was evidence that SU caused earlier insulin dependence (insulin treated at two years: 60% (SU) and 5% (conventional care) (P < 0.001); classified insulin dependent: 64% (SU) and 12.5% (insulin group) (P = 0.007)). Sulfonylurea Compounds 24-26 insulin Homo sapiens 42-49 17636829-15 2007 There was evidence that SU caused earlier insulin dependence (insulin treated at two years: 60% (SU) and 5% (conventional care) (P < 0.001); classified insulin dependent: 64% (SU) and 12.5% (insulin group) (P = 0.007)). Sulfonylurea Compounds 24-26 insulin Homo sapiens 62-69 17636829-15 2007 There was evidence that SU caused earlier insulin dependence (insulin treated at two years: 60% (SU) and 5% (conventional care) (P < 0.001); classified insulin dependent: 64% (SU) and 12.5% (insulin group) (P = 0.007)). Sulfonylurea Compounds 24-26 insulin Homo sapiens 62-69 17636829-15 2007 There was evidence that SU caused earlier insulin dependence (insulin treated at two years: 60% (SU) and 5% (conventional care) (P < 0.001); classified insulin dependent: 64% (SU) and 12.5% (insulin group) (P = 0.007)). Sulfonylurea Compounds 24-26 insulin Homo sapiens 62-69 17561795-1 2007 BACKGROUND: Type 2 diabetes patients insufficiently controlled with sulfonylurea (SU) are commonly treated by switching to twice-daily premix insulin replacing SU. Sulfonylurea Compounds 68-80 insulin Homo sapiens 142-149 17561795-1 2007 BACKGROUND: Type 2 diabetes patients insufficiently controlled with sulfonylurea (SU) are commonly treated by switching to twice-daily premix insulin replacing SU. Sulfonylurea Compounds 82-84 insulin Homo sapiens 142-149 17213273-8 2007 Three patients with the KCNJ11 mutations (R201H and H46Y) were switched from insulin to SU, decreasing their glycosylated hemoglobin from 9.3-11.0% on insulin to 5.7-6.6% on SU treatment. Sulfonylurea Compounds 88-90 insulin Homo sapiens 151-158 17213273-8 2007 Three patients with the KCNJ11 mutations (R201H and H46Y) were switched from insulin to SU, decreasing their glycosylated hemoglobin from 9.3-11.0% on insulin to 5.7-6.6% on SU treatment. Sulfonylurea Compounds 174-176 insulin Homo sapiens 77-84 17258675-6 2007 Sulfonylureas and meglitinides (insulin secretagogues) stimulate insulin secretion and can cause hypoglycemia. Sulfonylurea Compounds 0-13 insulin Homo sapiens 65-72 17082235-1 2007 Most drugs currently employed in the treatment of type 2 diabetes either target the sulfonylurea receptor stimulating insulin release (sulfonylureas, glinides), or target the peroxisome proliferator-activated receptor (PPARgamma) improving insulin resistance (thiazolidinediones). Sulfonylurea Compounds 135-148 insulin Homo sapiens 118-125 17020435-6 2006 In addition, insulin-providing therapies, such as sulfonylureas and exogenous insulin, carry the risk of hypoglycaemia, and cannot fully address the complex hormonal irregularities that characterise Type 2 diabetes, including the role of glucagon hypersecretion. Sulfonylurea Compounds 50-63 insulin Homo sapiens 13-20 17087301-4 2006 Sulfonylurea remains the central drug in the management in insulin-independent patients without obesity. Sulfonylurea Compounds 0-12 insulin Homo sapiens 59-66 18357954-3 2007 Addition of insulin to sulfonylurea therapy, when maximal sulfonylurea does not adequately maintain fasting plasma glucose levels at <108 mg/dL, has been found to be more effective than initiating insulin therapy after oral agents have failed to maintain glycemic control. Sulfonylurea Compounds 23-35 insulin Homo sapiens 12-19 18357954-3 2007 Addition of insulin to sulfonylurea therapy, when maximal sulfonylurea does not adequately maintain fasting plasma glucose levels at <108 mg/dL, has been found to be more effective than initiating insulin therapy after oral agents have failed to maintain glycemic control. Sulfonylurea Compounds 58-70 insulin Homo sapiens 12-19 17192350-0 2007 Transfer to sulphonylurea therapy in adult subjects with permanent neonatal diabetes due to KCNJ11-activating [corrected] mutations: evidence for improvement in insulin sensitivity. Sulfonylurea Compounds 12-25 insulin Homo sapiens 161-168 17161222-3 2007 We have previously shown that whereas sulfonylureas reduce insulin extraction, metformin enhances HIE. Sulfonylurea Compounds 38-51 insulin Homo sapiens 59-66 18078023-3 2007 These defects have been treated in clinical praxis by use of oral insulin secretagogues (sulfonylureas/ glinides) or insulin, biguanides, and thiazolidinediones (TZDs) respectively. Sulfonylurea Compounds 89-102 insulin Homo sapiens 66-73 17296510-12 2006 Sulfonylureas close K(ATP) channels by binding with high affinity to SUR suggesting they could replace insulin in these patients. Sulfonylurea Compounds 0-13 insulin Homo sapiens 103-110 17296510-14 2006 We therefore designed a protocol to transfer and evaluate children who have insulin treated neonatal diabetes due to KCNJ11 mutation, from insulin to sulfonylurea. Sulfonylurea Compounds 150-162 insulin Homo sapiens 76-83 17047922-3 2006 Sulfonylureas, which bind to the sulfonylurea receptor 1 subunit of the K(ATP) channel, can replace insulin injections in patients with KCNJ11 mutations. Sulfonylurea Compounds 0-13 insulin Homo sapiens 100-107 16885550-7 2006 RESULTS: A total of 44 patients (90 percent) successfully discontinued insulin after receiving sulfonylureas. Sulfonylurea Compounds 95-108 insulin Homo sapiens 71-78 16925503-4 2006 The recent discovery that mutations in the KCNJ11 gene (encoding the Kir6.2 subunit of the K(ATP) channel) are the most common cause of permanent neonatal diabetes, has enabled children to stop insulin injections and achieve improved glycaemic control with high doses of sulphonylurea tablets. Sulfonylurea Compounds 271-284 insulin Homo sapiens 194-201 17003289-6 2006 The synergistic insulin-releasing effects of combinatorial GLP-1 and sulphonylurea/nateglinide were lost following PKA- or PKC-desensitisation, despite GLP-1 retaining an insulin-releasing effect, demonstrating that GLP-1 can induce insulin release under conditions where sulphonylureas and nateglinide are no longer effective. Sulfonylurea Compounds 69-82 insulin Homo sapiens 16-23 16885550-14 2006 This pharmacogenetic response to sulfonylureas may result from the closing of mutant K(ATP) channels, thereby increasing insulin secretion in response to incretins and glucose metabolism. Sulfonylurea Compounds 33-46 insulin Homo sapiens 121-128 16873787-9 2006 CONCLUSIONS: This study demonstrates that CrPic supplementation in subjects with type 2 diabetes who are taking sulfonylurea agents significantly improves insulin sensitivity and glucose control. Sulfonylurea Compounds 112-124 insulin Homo sapiens 155-162 16901797-4 2006 In our patient with type 2 diabetes, endogenous hyperinsulinism was confirmed by demonstrating elevated insulin and C-peptide levels during hypoglycemic episodes in the absence of sulfonylurea on a blood screen. Sulfonylurea Compounds 180-192 insulin Homo sapiens 53-60 16885550-11 2006 Sulfonylurea treatment increased insulin secretion, which was more highly stimulated by oral glucose or a mixed meal than by intravenous glucose. Sulfonylurea Compounds 0-12 insulin Homo sapiens 33-40 16631806-3 2006 As sulfonylureas act by enhancing insulin secretion, they are probably best used close to the time when diabetes is diagnosed when beta-cell function is at its greatest and their utility can be extended by judicious use in combination with agents that improve glycemia by different modes of action, including insulin. Sulfonylurea Compounds 3-16 insulin Homo sapiens 34-41 16631806-3 2006 As sulfonylureas act by enhancing insulin secretion, they are probably best used close to the time when diabetes is diagnosed when beta-cell function is at its greatest and their utility can be extended by judicious use in combination with agents that improve glycemia by different modes of action, including insulin. Sulfonylurea Compounds 3-16 insulin Homo sapiens 309-316 17491708-12 2006 The intriguing question to be answered in the future is whether an improvement in insulin action could be seen following the transfer of Kir6.2 mutation carriers to sulphonylurea compounds. Sulfonylurea Compounds 165-188 insulin Homo sapiens 82-89 16706122-10 2006 The variations of early-phase insulin secretion manifest a vary procedure of obvious deterioration by degrees from the newly diagnosed group to the secondary failure of sulfonylureas group in Type 2 diabetic patients. Sulfonylurea Compounds 169-182 insulin Homo sapiens 30-37 16502763-8 2006 In cases involving sulfonylureas, the etiology was deliberate self-poisoning in 62.7% and accidental in 31.9% (biguanides 60.5% and 29.1%, insulin 85.3% and 9.4%). Sulfonylurea Compounds 19-32 insulin Homo sapiens 139-146 16492219-1 2006 AIMS: The oral hypoglycaemic sulphonylurea glibenclamide stimulates endogenous insulin secretion through blockade of ATP-sensitive potassium (KATP) channels on pancreatic beta cells, but also blocks cardiovascular KATP channels, leading to increased peripheral vascular resistance and reduced peripheral blood flow in non-diabetic subjects. Sulfonylurea Compounds 29-42 insulin Homo sapiens 79-86 16367882-6 2006 RSG + SU significantly decreased HbA(1c), FPG, insulin resistance, plasma free fatty acids and medical care utilization and improved treatment satisfaction compared with uptitrated SU. Sulfonylurea Compounds 6-8 insulin Homo sapiens 47-54 16501671-9 2006 Insulin therapy group showed significantly decreased TC, TG, LDL-C, LDL-C/HDL-C levels compared with sulphonylurea and sulphonylurea plus metformin treated groups, however, no significant difference was noted in the levels of above mentioned parameters and controls. Sulfonylurea Compounds 101-114 insulin Homo sapiens 0-7 16501671-9 2006 Insulin therapy group showed significantly decreased TC, TG, LDL-C, LDL-C/HDL-C levels compared with sulphonylurea and sulphonylurea plus metformin treated groups, however, no significant difference was noted in the levels of above mentioned parameters and controls. Sulfonylurea Compounds 119-132 insulin Homo sapiens 0-7 16585812-6 2006 RESULTS: The adjusted rate ratio of an injurious crash was 1.4 (95% CI: 1.0-2.0) for current users of insulin monotherapy relative to non-users and 1.3 (95% CI: 1.0-1.7) for sulfonylurea and metformin combined. Sulfonylurea Compounds 174-186 insulin Homo sapiens 102-109 16585812-10 2006 CONCLUSIONS: L Elderly drivers treated with insulin monotherapy or a combination of sulfonylurea and metformin, especially at high doses, have a small increased risk of injurious crashes. Sulfonylurea Compounds 84-96 insulin Homo sapiens 44-51 16380479-1 2006 Use of sulfonylureas in diabetes treatment is based on their insulin-releasing effect on pancreatic beta-cells. Sulfonylurea Compounds 7-20 insulin Homo sapiens 61-68 16800161-7 2006 RESULTS: The combination therapy of rosiglitazone with metformin or sulfonylurea produces better glycaemic control than conventional care of metformin with sulfonylurea and insulin in most patients, extends the viability of oral therapy before requiring insulin, and typically leads to lifetime cost increases across all treatment types. Sulfonylurea Compounds 68-80 insulin Homo sapiens 254-261 16313276-6 2005 All currently marketed insulin secretagogues, sulfonylureas and glinides, target the beta-cell K(ATP) channels and reduce their opening probability. Sulfonylurea Compounds 46-59 insulin Homo sapiens 23-30 16425966-0 2006 Disproportionately elevated proinsulin levels in type 2 diabetic patients treated with sulfonylurea. Sulfonylurea Compounds 87-99 insulin Homo sapiens 28-38 16425966-3 2006 The association between sulfonylureas administration and secretory function of pancreatic beta-cells, especially concerning insulin precursor peptides, is not sufficiently elucidated. Sulfonylurea Compounds 24-37 insulin Homo sapiens 124-131 16425966-4 2006 Preliminary studies by our research group revealed that the fasting proinsulin serum concentration is significantly higher in type 2 diabetic patients treated with sulfonylureas than in a well-matched group treated with insulin only. Sulfonylurea Compounds 164-177 insulin Homo sapiens 68-78 16425966-4 2006 Preliminary studies by our research group revealed that the fasting proinsulin serum concentration is significantly higher in type 2 diabetic patients treated with sulfonylureas than in a well-matched group treated with insulin only. Sulfonylurea Compounds 164-177 insulin Homo sapiens 71-78 16425966-8 2006 CONCLUSION: The disproportionately high proinsulin levels are due to sulfonylureas therapy. Sulfonylurea Compounds 69-82 insulin Homo sapiens 40-50 16026380-2 2005 We studied the changes in insulin sensitivity, as assessed by the Quantitative Insulin Sensitivity Check Index (QUICKI), in patients with T2DM who used metformin or pioglitazone as monotherapy or in combination therapy with sulphonylurea. Sulfonylurea Compounds 224-237 insulin Homo sapiens 26-33 16123353-6 2005 These results have important implications for the use of insulinotropic SU drugs as an alternative therapy to insulin injections. Sulfonylurea Compounds 72-74 insulin Homo sapiens 57-64 16285076-7 2005 (5) Randomised comparative trials show that, when glycaemia is no longer controlled by a sulphonylurea plus metformin, adding a daily insulin injection is more effective in lowering HbA1c levels than the addition of acarbose and as effective as adding a glitazone. Sulfonylurea Compounds 89-102 insulin Homo sapiens 134-141 16123337-1 2005 Closure of ATP-sensitive K(+) channels (K(ATP) channels) in response to metabolically generated ATP or binding of sulfonylurea drugs stimulates insulin release from pancreatic beta-cells. Sulfonylurea Compounds 114-126 insulin Homo sapiens 144-151 16200937-2 2005 Each of these abnormalities can be partially reversed by a specific drug, an agent promoting insulin secretion (sulphonylurea or glinide), metformin and a thiazolidinedione (glitazone), respectively. Sulfonylurea Compounds 112-125 insulin Homo sapiens 93-100 15912128-1 2005 Sulfonylurea drugs, like glibenclamide, stimulate insulin secretion by blocking ATP-sensitive potassium channels on pancreatic beta cells. Sulfonylurea Compounds 0-12 insulin Homo sapiens 50-57 16026380-11 2005 Overall, pioglitazone + sulphonylurea significantly increased insulin sensitivity more than metformin + sulphonylurea. Sulfonylurea Compounds 24-37 insulin Homo sapiens 62-69 15936468-5 2005 The homeostasis assessment model of insulin resistance (HOMA-IR) in the 3rd SU group was decreased by more than 10% (p = 0.015), whereas no change was observed in the 2nd SU group. Sulfonylurea Compounds 76-78 insulin Homo sapiens 36-43 15929679-9 2005 Of the 1,451 patients treated with sulfonylurea 52% had elevated intact proinsulin values and increased prevalence of cardiovascular complications (odds ratio 1.45). Sulfonylurea Compounds 35-47 insulin Homo sapiens 72-82 15531505-3 2004 Tolbutamide-stimulated insulin secretion, demonstrated in 3 of these patients suggested that some PNDM patients may respond to oral sulfonylurea treatment. Sulfonylurea Compounds 132-144 insulin Homo sapiens 23-30 20496449-3 2005 Sulfonylureas are a class of oral hypoglycemics that reduce blood glucose levels by stimulating insulin secretion. Sulfonylurea Compounds 0-13 insulin Homo sapiens 96-103 15816204-0 2005 Progressive decrease of proinsulin secretion in sulphonylurea-treated type 2 diabetes. Sulfonylurea Compounds 48-61 insulin Homo sapiens 24-34 15816204-12 2005 In conclusion, proinsulin may play an important role in glucose control in SU-treated type 2 diabetes, but the effect is reduced in SUf patients. Sulfonylurea Compounds 75-77 insulin Homo sapiens 15-25 15642492-4 2005 Insulin content decreased significantly following culture with any sulphonylurea compound. Sulfonylurea Compounds 67-80 insulin Homo sapiens 0-7 15694373-1 2005 Glimepiride, a third-generation sulfonylurea (SU), exerts its effects mainly by stimulating insulin secretion but has also been shown to have pleiotropic effects. Sulfonylurea Compounds 32-44 insulin Homo sapiens 92-99 15694373-1 2005 Glimepiride, a third-generation sulfonylurea (SU), exerts its effects mainly by stimulating insulin secretion but has also been shown to have pleiotropic effects. Sulfonylurea Compounds 46-48 insulin Homo sapiens 92-99 15561904-1 2004 Insulin secretagogues (sulfonylureas and glinides) increase insulin secretion by closing the ATP-sensitive K+ channel (KATP channel) in the pancreatic beta-cell membrane. Sulfonylurea Compounds 23-36 insulin Homo sapiens 0-7 15448106-13 2004 Apparently insulin-dependent patients with mutations in Kir6.2 may be managed on an oral sulfonylurea with sustained metabolic control rather than insulin injections, illustrating the principle of pharmacogenetics applied in diabetes treatment. Sulfonylurea Compounds 89-101 insulin Homo sapiens 11-18 14565810-10 2003 RESULTS: Daily insulin dose (units/kg BW), weight gain, and number of hypoglycemic events were significantly lower (p < 0.01) in subjects receiving sulfonylureas in comparison with placebo. Sulfonylurea Compounds 151-164 insulin Homo sapiens 15-22 15125825-13 2004 CONCLUSIONS: Bedtime NPH insulin added to maximal therapy with sulfonylurea and metformin is an effective, simple, well-tolerated approach for patients with uncontrolled type 2 diabetes. Sulfonylurea Compounds 63-75 insulin Homo sapiens 25-32 14760321-7 2004 Hypoglycemic therapy including only insulin and/or sulfonylurea (insulin-providing; n = 1473) was associated with higher 90-day death/MI/SRI compared with therapy that included only biguanide and/or thiazolidinedione therapy (insulin-sensitizing; n = 100) (12.0% vs 5.0%); (adjusted OR, 2.1 [1.2, 3.7]). Sulfonylurea Compounds 51-63 insulin Homo sapiens 65-72 14760321-7 2004 Hypoglycemic therapy including only insulin and/or sulfonylurea (insulin-providing; n = 1473) was associated with higher 90-day death/MI/SRI compared with therapy that included only biguanide and/or thiazolidinedione therapy (insulin-sensitizing; n = 100) (12.0% vs 5.0%); (adjusted OR, 2.1 [1.2, 3.7]). Sulfonylurea Compounds 51-63 insulin Homo sapiens 65-72 14575972-8 2003 We assessed possible mechanisms for sulphonylurea sensitivity through insulin sensitivity, insulin secretory response to glucose and tolbutamide, and tolbutamide clearance. Sulfonylurea Compounds 36-49 insulin Homo sapiens 70-77 14606302-3 2003 There are five therapeutic options in type 2 diabetes: increase insulin release with sulfonylureas or glinides; increase insulin action with biguanides or glitazones; modify intestinal absorption of carbohydrate with a glucosidase inhibitor or absorption of fat with a lipase inhibitor; associate these drugs or use new therapeutic agents; administer exogenous insulin. Sulfonylurea Compounds 85-98 insulin Homo sapiens 64-71 15469778-4 2004 Combining an insulin secretagogue (ie, sulfonylurea or meglitinide) and an insulin sensitizer (ie, metformin or a glitazone) capitalizes on unique mechanisms of action and results in significant A1C lowering (SOR: C). Sulfonylurea Compounds 39-51 insulin Homo sapiens 13-20 15356061-5 2004 To evaluate the differential ability of both sulfonylureas and meglitinides to stimulate insulin release at modest hypoglycemia, we evaluated dextrose infusion rates necessary to maintain plasma glucose after oral administration of repaglinide (1 mg) or glipizide (5 mg) at euglycemia and again at modest hypoglycemia. Sulfonylurea Compounds 45-58 insulin Homo sapiens 89-96 15307693-6 2004 CONCLUSION: Application of YYHT principle in treating patients with diabetes mellitus type 2 of secondary failure to sulfonylurea agents could alleviate the peripheral resistance to insulin, inhibit TNF-alpha, and protect the vascular endothelial cells. Sulfonylurea Compounds 117-129 insulin Homo sapiens 182-189 15140339-0 2004 Pioglitazone as monotherapy or in combination with sulfonylurea or metformin enhances insulin sensitivity (HOMA-S or QUICKI) in patients with type 2 diabetes. Sulfonylurea Compounds 51-63 insulin Homo sapiens 86-93 15140339-5 2004 STUDY AIM: To evaluate the effect of PIO monotherapy and in combination therapy with sulfonylurea (SU) or metformin (MET) on insulin sensitivity as assessed by HOMA-S and QUICKI in a large group of patients (approximately 1000). Sulfonylurea Compounds 85-97 insulin Homo sapiens 125-132 15140339-5 2004 STUDY AIM: To evaluate the effect of PIO monotherapy and in combination therapy with sulfonylurea (SU) or metformin (MET) on insulin sensitivity as assessed by HOMA-S and QUICKI in a large group of patients (approximately 1000). Sulfonylurea Compounds 99-101 insulin Homo sapiens 125-132 15140339-17 2004 CONCLUSION: PIO monotherapy and combination therapy with SU or MET enhanced insulin sensitivity as evaluated by HOMA-S and QUICKI. Sulfonylurea Compounds 57-59 insulin Homo sapiens 76-83 15139733-3 2004 Sulphonylurea sensitivity in HNF-1alpha patients means that those on insulin from diagnosis can transfer to sulphonylureas and may improve glycaemic control. Sulfonylurea Compounds 0-13 insulin Homo sapiens 69-76 14737744-6 2004 RESULTS: After adjusting for other potential confounders (including age, duration of diabetes, BMI, hypertension, lipid profile, HbA1c, and insulin treatment), mortality was significantly higher in patients treated with combinations of sulfonylureas and biguanides than in the rest of the sample, (relative risk, RR: 2.08; 95% confidence interval, CI 1.18-3.67, and RR: 1.68; 95%CI 1.01-2.79 among women and men, respectively). Sulfonylurea Compounds 236-249 insulin Homo sapiens 140-147 14565810-11 2003 However, the daily insulin dose alone was significantly lower (p < 0.05) with glimepiride (0.49 +/- 0.10; mean +/- SE) than with other sulfonylureas (tolazamide 0.58 +/- 0.12, glyburide 0.59 +/- 0.12, glipizide GITS 0.59 +/- 0.14). Sulfonylurea Compounds 138-151 insulin Homo sapiens 19-26 14565810-13 2003 CONCLUSIONS: By lowering the daily insulin dose, sulfonylurea drugs appear to improve the sensitivity of exogenous insulin in subjects with type 2 diabetes mellitus manifesting lapse of glycemic control. Sulfonylurea Compounds 49-61 insulin Homo sapiens 35-42 14565810-13 2003 CONCLUSIONS: By lowering the daily insulin dose, sulfonylurea drugs appear to improve the sensitivity of exogenous insulin in subjects with type 2 diabetes mellitus manifesting lapse of glycemic control. Sulfonylurea Compounds 49-61 insulin Homo sapiens 115-122 12766121-12 2003 Insulin monotherapy decreased, as did insulin combination therapy with sulfonylureas. Sulfonylurea Compounds 71-84 insulin Homo sapiens 38-45 12568204-1 2002 BACKGROUND: The best method for glucose lowering in lean type 2 diabetes remains controversial and this study was undertaken to study the 24 hour insulin response of these diabetics to glimepiride, a sulfonylurea with distinctive properties. Sulfonylurea Compounds 200-212 insulin Homo sapiens 146-153 12606519-3 2003 Tests for pancreatic K(ATP) channels localized to insulin secretory granules led to the following observations: fluorescent sulfonylureas that bind the pancreatic K(ATP) channel specifically label intracellular punctate structures in cells of the endocrine pancreas. Sulfonylurea Compounds 124-137 insulin Homo sapiens 50-57 12409500-2 2002 The mechanism of action of sulfonylureas is to release insulin from pancreatic cells and they have been proposed to act on insulin-sensitive tissues to enhance glucose uptake. Sulfonylurea Compounds 27-40 insulin Homo sapiens 55-62 12409500-2 2002 The mechanism of action of sulfonylureas is to release insulin from pancreatic cells and they have been proposed to act on insulin-sensitive tissues to enhance glucose uptake. Sulfonylurea Compounds 27-40 insulin Homo sapiens 123-130 12409500-3 2002 The goal of the present study was to test the hypothesis that gliclazide, a second-generation sulfonylurea, could enhance insulin signaling in insulin-resistant skeletal muscle cells. Sulfonylurea Compounds 94-106 insulin Homo sapiens 122-129 12437993-13 2003 Sulfonylureas inhibit potassium conductance and are used to treat NIDDM by stimulation of insulin secretion across ATP-sensitive potassium channels in pancreatic beta-cell membranes. Sulfonylurea Compounds 0-13 insulin Homo sapiens 90-97 17682309-1 2003 Insulin resistance is a common finding in diabetes mellitus, and may serve as a measure of efficacy of therapies for diabetes mellitus: exercise, exogenous insulin, sulfonylureas, and PPAR gamma agonists, and as a possible marker for risk for developing type II diabetes mellitus. Sulfonylurea Compounds 165-178 insulin Homo sapiens 0-7 12489381-2 2002 Sulfonylureas improve glycemic control, restore the acute insulin response, and help improve beta-cell function in the short term. Sulfonylurea Compounds 0-13 insulin Homo sapiens 58-65 12520825-3 2002 Sulfonylureas continue to be the mainstay oral hypoglycaemic agents for type 2 diabetics because they are potent insulin secretagogues and cost-effective. Sulfonylurea Compounds 0-13 insulin Homo sapiens 113-120 11455676-0 2001 Comparison of the effects of three sulfonylureas on in vivo insulin action. Sulfonylurea Compounds 35-48 insulin Homo sapiens 60-67 12387036-0 2002 [Combination therapy of insulin sensitizer, thiazolidinedione drugs, and sulfonylurea]. Sulfonylurea Compounds 73-85 insulin Homo sapiens 24-31 12118200-2 2002 It has recently been demonstrated in healthy subjects that molecular variants of the gene encoding for the KATP subunit - sulfonylurea receptor gene (SUR1) are associated with a decreased response of insulin secretion to intravenous injection of tolbutamide, a sulfonylurea derivative. Sulfonylurea Compounds 122-134 insulin Homo sapiens 200-207 12067822-11 2002 CONCLUSION: Our study demonstrates that judicious replacement of sulfonylurea treatment with insulin therapy, together with dietary counseling, can result in a simultaneous improvement in the major stigmata of the metabolic syndrome, i.e. a significant improvement in glycemic control and lipid metabolism without unfavorable effects on body weight and blood pressure. Sulfonylurea Compounds 65-77 insulin Homo sapiens 93-100 12015189-9 2002 Among antidiabetic medicines, a sulfonylurea, gliclazide (but not glibenclamide or glimepiride), and an aldose reductase inhibitor, epalrestat, significantly inhibited these events; however, a new K(ATP)-channel blocker, netegulinide, a biguanide, metformine, or an insulin sensitizer, troglitazone, did not. Sulfonylurea Compounds 32-44 insulin Homo sapiens 266-273 12021091-6 2002 Insulin-treated SPIDDM patients had a sustained C peptide response (CPR), while most of sulfonylurea-treated patients progressed to an insulin-dependent state. Sulfonylurea Compounds 88-100 insulin Homo sapiens 135-142 11815455-0 2002 Sulfonylurea-mediated stimulation of insulin exocytosis via an ATP-sensitive K+ channel-independent action. Sulfonylurea Compounds 0-12 insulin Homo sapiens 37-44 11815455-1 2002 Several reports indicate that hypoglycemic sulfonylureas augment Ca(2+)-dependent insulin secretion via mechanisms other than inhibition of the ATP-sensitive K(+) channel. Sulfonylurea Compounds 43-56 insulin Homo sapiens 82-89 11356916-1 2001 Insulin secretion from MIN6 cells (a pancreatic beta-cell line) induced by high glucose (greater than 16.8 mM) was potentiated by a novel hypoglycemic agent [trans-4-(4-methylcyclohexyl)-4-oxobutyric acid (JTT-608)] (but not glibenclamide, a sulfonylurea). Sulfonylurea Compounds 242-254 insulin Homo sapiens 0-7 11318844-6 2001 Reductions in blood glucose levels resulted in improvement in insulin sensitivity (diet KITT 2.40 +/- 0.26-3.09 +/- 0.36, P < 0.01; sulphonylurea 2.24 +/- 0.16-2.94 +/- 0.18, P < 0.01; insulin 1.68 +/- 0.27-2.16 +/- 0.22%/min, P < 0.05), and decrease in sE-selectin levels (diet 88.4 +/- 14.9-66.2 +/- 10.8, P < 0.05; sulphonylurea 85.1 +/- 11.6-59.8 +/- 7.8, P < 0.01; insulin 84.4 +/- 8.7-66.8 +/- 7.4 ng/ml, P < 0.01), but no change in sVCAM-1 levels. Sulfonylurea Compounds 135-148 insulin Homo sapiens 62-69 23105297-11 2001 Sulfonylurea group resembled diabetics.In vitro incubation with insulin differentially affected the Na(+),K(+)-ATPase and serum butyrylcholinesterase activities. Sulfonylurea Compounds 0-12 insulin Homo sapiens 64-71 11128371-0 2000 A 12-h intravenous insulin infusion restores the beta-cell response torpidity to sulfonylureas in patients affected by type 2 diabetes. Sulfonylurea Compounds 81-94 insulin Homo sapiens 19-26 11879723-0 2002 Insulin responses to sulfonylureas. Sulfonylurea Compounds 21-34 insulin Homo sapiens 0-7 11815505-2 2002 OBJECTIVE: To evaluate the efficacy of the addition of insulin when maximal sulfonylurea therapy is inadequate in individuals with type 2 diabetes. Sulfonylurea Compounds 76-88 insulin Homo sapiens 55-62 11815505-6 2002 However, for patients randomized to an intensive policy with sulfonylurea (n = 339), insulin was added automatically if the fasting plasma glucose remained >108 mg/dl (6.0 mmol/l) despite maximal sulfonylurea doses. Sulfonylurea Compounds 61-73 insulin Homo sapiens 85-92 11815505-6 2002 However, for patients randomized to an intensive policy with sulfonylurea (n = 339), insulin was added automatically if the fasting plasma glucose remained >108 mg/dl (6.0 mmol/l) despite maximal sulfonylurea doses. Sulfonylurea Compounds 199-211 insulin Homo sapiens 85-92 11815505-7 2002 RESULTS: Over 6 years, approximately 53% of patients allocated to treatment with sulfonylurea required additional insulin therapy. Sulfonylurea Compounds 81-93 insulin Homo sapiens 114-121 11815505-10 2002 CONCLUSIONS: Early addition of insulin when maximal sulfonylurea therapy is inadequate can significantly improve glycemic control without promoting increased hypoglycemia or weight gain. Sulfonylurea Compounds 52-64 insulin Homo sapiens 31-38 11910976-4 2001 The same reasons apply to the weight gain observed at the beginning of treatment with sulfonylureas, even though patients usually gain less weight with sulfonyulreas than with insulin. Sulfonylurea Compounds 86-99 insulin Homo sapiens 176-183 11596159-3 2001 Sulfonylureas enhance insulin secretion by acting on a specific islet beta cell receptor. Sulfonylurea Compounds 0-13 insulin Homo sapiens 22-29 11585571-1 2001 Alpha-endosulfine has the sulfonylurea-like ability to block ATP-sensitive potassium (K(ATP)) channels, which can stimulate insulin secretion in beta cell. Sulfonylurea Compounds 26-38 insulin Homo sapiens 124-131 11547215-3 2001 Thiazolidinediones (TZD) are a new class of insulin sensitizers recently approved in Europe, in combination therapy with sulfonylureas or/and metformin, for the treatment of type 2 diabetes. Sulfonylurea Compounds 121-134 insulin Homo sapiens 44-51 11592575-2 2001 One class is sulfonylureas which primarily cause serum glucose reduction by stimulating the release of preformed insulin from the pancreatic islets. Sulfonylurea Compounds 13-26 insulin Homo sapiens 113-120 11473038-3 2001 The aim of the present study was to assess the impact of acute treatment and 5 weeks of sulfonylurea (gliclazide) treatment on insulin secretory dynamics in type 2 diabetic patients. Sulfonylurea Compounds 88-100 insulin Homo sapiens 127-134 11232737-10 2001 In general, a conservative and stepwise approach to the treatment of the elderly patient with type 2 diabetes is suggested; treatment may be initiated with monotherapy, followed by early intervention with a combination of oral agents including a sulphonylurea as a foundation insulin secretagogue in addition to a supplemental insulin sensitiser. Sulfonylurea Compounds 246-259 insulin Homo sapiens 276-283 11228051-6 2000 Sulfonylurea-treated subjects had a significant elevation in both proinsulin/C-peptide ratio and proinsulin/IRI ratio compared with diet-treated subjects, whereas nonsulfonylurea hypoglycemic agent-treated subjects did not. Sulfonylurea Compounds 0-12 insulin Homo sapiens 66-76 11228051-6 2000 Sulfonylurea-treated subjects had a significant elevation in both proinsulin/C-peptide ratio and proinsulin/IRI ratio compared with diet-treated subjects, whereas nonsulfonylurea hypoglycemic agent-treated subjects did not. Sulfonylurea Compounds 0-12 insulin Homo sapiens 77-107 11228051-7 2000 Multivariate analysis confirmed that sulfonylurea treatment and FPG were significant determinants of both fasting proinsulin/C-peptide ratio (P=0.006 and P=0.030, respectively) and proinsulin/IRI ratio (P=0.003 and P=0.016, respectively) in patients with Type 2 diabetes. Sulfonylurea Compounds 37-49 insulin Homo sapiens 114-124 11228051-7 2000 Multivariate analysis confirmed that sulfonylurea treatment and FPG were significant determinants of both fasting proinsulin/C-peptide ratio (P=0.006 and P=0.030, respectively) and proinsulin/IRI ratio (P=0.003 and P=0.016, respectively) in patients with Type 2 diabetes. Sulfonylurea Compounds 37-49 insulin Homo sapiens 125-134 11228051-7 2000 Multivariate analysis confirmed that sulfonylurea treatment and FPG were significant determinants of both fasting proinsulin/C-peptide ratio (P=0.006 and P=0.030, respectively) and proinsulin/IRI ratio (P=0.003 and P=0.016, respectively) in patients with Type 2 diabetes. Sulfonylurea Compounds 37-49 insulin Homo sapiens 181-191 10878751-0 2000 Novel sulfonylurea and non-sulfonylurea drugs to promote the secretion of insulin. Sulfonylurea Compounds 6-18 insulin Homo sapiens 74-81 11147570-1 2000 The hypoglycemic sulfonylurea drugs cause reduction of blood glucose predominantly via stimulation of insulin release from pancreatic beta cells. Sulfonylurea Compounds 17-29 insulin Homo sapiens 102-109 11078468-1 2000 Sulfonylureas are widely used to stimulate insulin secretion in type 2 diabetic patients because they close adenosine triphosphate-sensitive potassium (K(ATP)) channels in the pancreatic beta-cell membrane. Sulfonylurea Compounds 0-13 insulin Homo sapiens 43-50 11031747-3 2000 Sulfonylureas are well-known insulin secretagogues and have been widely used in the treatment of Type 2 diabetes. Sulfonylurea Compounds 0-13 insulin Homo sapiens 29-36 11475234-2 2000 In patients with type 2 diabetes treated with blood-glucose lowering agents of the sulphonylurea group, hypoglycaemia is less frequent than in insulin-treated patients. Sulfonylurea Compounds 83-96 insulin Homo sapiens 143-150 11087006-9 2000 A combination of insulin with a sulphonylurea agent is commonly used: the adjunctive effect of the sulphonylurea is dependent on pancreatic beta cell function. Sulfonylurea Compounds 99-112 insulin Homo sapiens 17-24 11450504-2 2000 However, in vivo results have been disputed because the amelioration of insulin action that follows sulfonylurea may represent the relief from glucose toxicity rather than a direct effect of the drug. Sulfonylurea Compounds 100-112 insulin Homo sapiens 72-79 10872292-6 2000 Among the stimulators of insulin secretion are the sulfonylureas (e.g. glibenclamide, glibonuride, glisoxepid, glimepiride), and the so-called prandial glucose regulators, such as repaglinide, which differ from the sulfonylureas both chemically and in their pharmacodynamic properties. Sulfonylurea Compounds 51-64 insulin Homo sapiens 25-32 10872292-6 2000 Among the stimulators of insulin secretion are the sulfonylureas (e.g. glibenclamide, glibonuride, glisoxepid, glimepiride), and the so-called prandial glucose regulators, such as repaglinide, which differ from the sulfonylureas both chemically and in their pharmacodynamic properties. Sulfonylurea Compounds 215-228 insulin Homo sapiens 25-32 10928401-5 2000 Sulfonylureas stimulate the production and release of insulin; these drugs must be used in patients with an intact pancreas. Sulfonylurea Compounds 0-13 insulin Homo sapiens 54-61 11242605-7 2000 CONCLUSION: When oral monotherapy fails (that is, glycosylated hemoglobin values exceed 8.0%) in patients with type 2 diabetes, combination therapy with a sulfonylurea and metformin is potentially effective in maintaining glycemic control and avoiding the addition of insulin or a thiazolidinedione for a mean duration of 7.9 years. Sulfonylurea Compounds 155-167 insulin Homo sapiens 268-275 11004427-1 2000 Sulfonylureas stimulate insulin secretion in type-2 diabetic patients by blocking ATP-sensitive (K(ATP)) potassium channels in the pancreatic beta-cell membrane. Sulfonylurea Compounds 0-13 insulin Homo sapiens 24-31 10746006-5 1999 In addition to non pharmacological (dietary, physical activity) approaches, several drugs were established as efficient therapies for type 2 diabetic patients: sulfonylureas acting by enhancing insulin secretion, metformin improving insulin resistance, or acarbose delaying carbohydrate intestinal absorption. Sulfonylurea Compounds 160-173 insulin Homo sapiens 194-201 10605995-4 1999 Two new long-acting sulfonylureas (glimepiride and extended-release glipizide) and a short-acting sulfonylurea-like agent (repaglinide) simply and reliably augment the patient"s insulin supply. Sulfonylurea Compounds 20-33 insulin Homo sapiens 178-185 10605995-4 1999 Two new long-acting sulfonylureas (glimepiride and extended-release glipizide) and a short-acting sulfonylurea-like agent (repaglinide) simply and reliably augment the patient"s insulin supply. Sulfonylurea Compounds 20-32 insulin Homo sapiens 178-185 11419922-8 2000 The dose of insulin was reduced from a baseline of 62 to 41 U per patient in the insulin-only treatment group, from 36 to 12 U per patient in the group treated with insulin and sulfonylurea, and from 28 to 11 U per patient in the group treated with insulin and metformin. Sulfonylurea Compounds 177-189 insulin Homo sapiens 12-19 11419922-9 2000 In the group treated with insulin, sulfonylurea, and metformin, the dose of insulin was decreased from 36 to 13 U. Sulfonylurea Compounds 35-47 insulin Homo sapiens 76-83 10580428-2 1999 Once insulin secretion becomes defective, as in type 2 diabetes, the most useful drugs to increase insulin release are sulfonylureas. Sulfonylurea Compounds 119-132 insulin Homo sapiens 5-12 10580428-2 1999 Once insulin secretion becomes defective, as in type 2 diabetes, the most useful drugs to increase insulin release are sulfonylureas. Sulfonylurea Compounds 119-132 insulin Homo sapiens 99-106 10332688-0 1999 Homeostasis model assessment as a clinical index of insulin resistance in type 2 diabetic patients treated with sulfonylureas. Sulfonylurea Compounds 112-125 insulin Homo sapiens 52-59 11228756-0 1999 Effect of acarbose on additional insulin therapy in type 2 diabetic patients with late failure of sulphonylurea therapy. Sulfonylurea Compounds 98-111 insulin Homo sapiens 33-40 10593133-2 1999 Its mechanism of action is partly similar to that of the sulphonylurea: the release of insulin from the pancreatic beta cells is stimulated by closure of ATP-dependent potassium channels. Sulfonylurea Compounds 57-70 insulin Homo sapiens 87-94 15251678-6 1999 In the past, when treatment with sulfonylureas was no longer effective, insulin therapy was inevitable. Sulfonylurea Compounds 33-46 insulin Homo sapiens 72-79 10643211-5 1999 The sulfonylureas as a group have been used for many years and act by stimulating insulin secretion. Sulfonylurea Compounds 4-17 insulin Homo sapiens 82-89 10462934-5 1999 Sulfonylurea therapy may increase insulin resistance and become a part of PI. Sulfonylurea Compounds 0-12 insulin Homo sapiens 34-41 10420477-3 1999 Analysis of the time course of electrophysiological processes coursing in them, showed appreciable changes in the time of the channel closing, which led to deceleration of insulin secretin starting from the moment of exposure to glucose or sulfonylurea agents till exocytosis of insulin quantum. Sulfonylurea Compounds 240-252 insulin Homo sapiens 172-179 10420477-3 1999 Analysis of the time course of electrophysiological processes coursing in them, showed appreciable changes in the time of the channel closing, which led to deceleration of insulin secretin starting from the moment of exposure to glucose or sulfonylurea agents till exocytosis of insulin quantum. Sulfonylurea Compounds 240-252 insulin Homo sapiens 279-286 10199151-1 1999 The main action of SU in the treatment of diabetes mellitus is the stimulation of insulin secretion, and the extrapancreatic action including stimulation of insulin actions in glycogen synthesis and inhibition of glucose production in liver is also reported. Sulfonylurea Compounds 19-21 insulin Homo sapiens 82-89 10102252-11 1999 Subjects who restarted sulfonylureas had an increase in both leptin levels (+1.9+/-9.0 ng/mL, p<0.05) and insulin levels (+23+/-65 pmol/L, p<0.05), despite significant overall weight loss (-7.4+/-4.0 kg, p<0.01). Sulfonylurea Compounds 23-36 insulin Homo sapiens 109-116 10102252-14 1999 Although physiological insulin changes did not independently influence changes in leptin concentration with weight loss, increases in insulin levels with sulfonylurea therapy were associated with increases in leptin levels despite weight loss. Sulfonylurea Compounds 154-166 insulin Homo sapiens 134-141 9826219-12 1998 In conclusion, endogenous insulin secretion is closely associated with body fat and serum leptin in diabetic subjects treated with diet therapy and SU. Sulfonylurea Compounds 148-150 insulin Homo sapiens 26-33 9737829-11 1998 The addition of metformin to treatment with insulin or sulfonylureas, either alone or in combination, significantly improved glycemic control and cholesterol levels and promoted weight loss in obese type 2 diabetic patients with insulin resistance. Sulfonylurea Compounds 55-68 insulin Homo sapiens 229-236 9856233-8 1998 High serum concentrations of insulin and C-peptide in combination with the psychiatric disorder led to the suspicion of abuse of sulfonylurea derivatives by the patient. Sulfonylurea Compounds 129-141 insulin Homo sapiens 29-36 9856233-8 1998 High serum concentrations of insulin and C-peptide in combination with the psychiatric disorder led to the suspicion of abuse of sulfonylurea derivatives by the patient. Sulfonylurea Compounds 129-141 insulin Homo sapiens 41-50 9649951-1 1998 PURPOSE: To determine the effect(s) on glucose control, insulin dose, and circulating insulin levels of the addition of a sulfonylurea (glipizide) to the treatment regimen of patients with insulin-requiring type 2 diabetes mellitus. Sulfonylurea Compounds 122-134 insulin Homo sapiens 86-93 9561345-2 1998 UNLABELLED: Glimepiride is a sulphonylurea agent that stimulates insulin release from pancreatic beta-cells and may act via extrapancreatic mechanisms. Sulfonylurea Compounds 29-42 insulin Homo sapiens 65-72 9627359-6 1998 On SU therapy, subjects had higher fasting and post-glucose load levels of intact proinsulin compared with B1 and I (fasting, 13.9 x/divided by 2.6 v 9.5 x/divided by 2.2 (P = .004) and 9.1 x/divided by 2.4 pmol x L(-1) (P = .01), respectively). Sulfonylurea Compounds 3-5 insulin Homo sapiens 82-92 10085698-0 1998 [Short-term intensive insulin therapy as a method of overcoming secondary failure of sulfonylureas in patients with type 2 diabetes (non-insulin-dependent)]. Sulfonylurea Compounds 85-98 insulin Homo sapiens 22-29 9652156-2 1998 The newly developed sulfonylurea (SU) derivative glimepiride has a marked insulin secretory effect both in vitro and in vivo, and is capable of increasing plasma insulin levels with approximately 50% in type 2 diabetes subjects. Sulfonylurea Compounds 20-32 insulin Homo sapiens 74-81 9652156-2 1998 The newly developed sulfonylurea (SU) derivative glimepiride has a marked insulin secretory effect both in vitro and in vivo, and is capable of increasing plasma insulin levels with approximately 50% in type 2 diabetes subjects. Sulfonylurea Compounds 20-32 insulin Homo sapiens 162-169 9652156-2 1998 The newly developed sulfonylurea (SU) derivative glimepiride has a marked insulin secretory effect both in vitro and in vivo, and is capable of increasing plasma insulin levels with approximately 50% in type 2 diabetes subjects. Sulfonylurea Compounds 34-36 insulin Homo sapiens 74-81 9652156-2 1998 The newly developed sulfonylurea (SU) derivative glimepiride has a marked insulin secretory effect both in vitro and in vivo, and is capable of increasing plasma insulin levels with approximately 50% in type 2 diabetes subjects. Sulfonylurea Compounds 34-36 insulin Homo sapiens 162-169 9545119-1 1998 Physical exercise is associated with a fall in serum insulin levels, whereas sulphonylurea administration increases insulin release. Sulfonylurea Compounds 77-90 insulin Homo sapiens 116-123 9649951-1 1998 PURPOSE: To determine the effect(s) on glucose control, insulin dose, and circulating insulin levels of the addition of a sulfonylurea (glipizide) to the treatment regimen of patients with insulin-requiring type 2 diabetes mellitus. Sulfonylurea Compounds 122-134 insulin Homo sapiens 86-93 9649951-11 1998 CONCLUSION: The addition of a sulfonylurea (glipizide) to insulin therapy in patients with insulin-requiring type 2 diabetes mellitus taking large doses of insulin results in a rapid and substantial improvement in glucose control despite a significant reduction in insulin dose. Sulfonylurea Compounds 30-42 insulin Homo sapiens 91-98 9649951-11 1998 CONCLUSION: The addition of a sulfonylurea (glipizide) to insulin therapy in patients with insulin-requiring type 2 diabetes mellitus taking large doses of insulin results in a rapid and substantial improvement in glucose control despite a significant reduction in insulin dose. Sulfonylurea Compounds 30-42 insulin Homo sapiens 91-98 9555358-5 1998 Until recently, the only pharmacological approaches to diabetes were sulfonylureas and insulin, which either augment insulin secretion or replace insulin, thus acting only on the insulin side of the equation. Sulfonylurea Compounds 69-82 insulin Homo sapiens 117-124 9555358-5 1998 Until recently, the only pharmacological approaches to diabetes were sulfonylureas and insulin, which either augment insulin secretion or replace insulin, thus acting only on the insulin side of the equation. Sulfonylurea Compounds 69-82 insulin Homo sapiens 117-124 9649951-11 1998 CONCLUSION: The addition of a sulfonylurea (glipizide) to insulin therapy in patients with insulin-requiring type 2 diabetes mellitus taking large doses of insulin results in a rapid and substantial improvement in glucose control despite a significant reduction in insulin dose. Sulfonylurea Compounds 30-42 insulin Homo sapiens 91-98 9506190-9 1998 In addition to the sulfonylureas, which work by stimulating insulin secretion, we now have metformin, which inhibits excessive hepatic glucose production; acarbose, which delays the absorption of carbohydrates in the gut; and troglitazone, which reduces insulin, resistance primarily in skeletal muscle. Sulfonylurea Compounds 19-32 insulin Homo sapiens 60-67 9550126-11 1997 These data indicate that pioglitazone enhances the insulin action in NIDDM patients on diet alone or SU, and thereby improves both plasma glucose level and lipid profiles. Sulfonylurea Compounds 101-103 insulin Homo sapiens 51-58 9451465-7 1997 The newly discovered possible physiological actions of the C-peptide molecule [suggesting a stimulatory effect of C-peptide on the Na+, K+ (ATPase) pump and on diabetic complications], cast a new light on all therapeutic approaches (like sulfonylurea class of compounds and whole pancreas or islet of Langerhans transplantation), which induce/replace both insulin and C-peptide secretion. Sulfonylurea Compounds 238-250 insulin Homo sapiens 59-68 9451465-7 1997 The newly discovered possible physiological actions of the C-peptide molecule [suggesting a stimulatory effect of C-peptide on the Na+, K+ (ATPase) pump and on diabetic complications], cast a new light on all therapeutic approaches (like sulfonylurea class of compounds and whole pancreas or islet of Langerhans transplantation), which induce/replace both insulin and C-peptide secretion. Sulfonylurea Compounds 238-250 insulin Homo sapiens 114-123 9451465-7 1997 The newly discovered possible physiological actions of the C-peptide molecule [suggesting a stimulatory effect of C-peptide on the Na+, K+ (ATPase) pump and on diabetic complications], cast a new light on all therapeutic approaches (like sulfonylurea class of compounds and whole pancreas or islet of Langerhans transplantation), which induce/replace both insulin and C-peptide secretion. Sulfonylurea Compounds 238-250 insulin Homo sapiens 114-123 9388085-11 1997 After adjusting for age, sex, race, socioeconomic status, disease duration, and severity of diabetes and comorbidities, insulin users had slightly more laboratory tests performed, 2.4 more outpatient visits per year, and almost 300 more fingersticks for home glucose testing per year compared with sulfonylurea users (all P<.01). Sulfonylurea Compounds 298-310 insulin Homo sapiens 120-127 10173307-2 1997 Many patients are insulin resistant, a condition that is not adequately remedied either by sulfonylureas or insulin, and usually worsens over time. Sulfonylurea Compounds 91-104 insulin Homo sapiens 18-25 9326676-2 1997 It is closed both by glucose metabolism and the sulfonylurea drugs that are used in the treatment of noninsulin-dependent diabetes mellitus, thereby initiating a membrane depolarization that activates voltage-dependent Ca2+ entry and insulin release. Sulfonylurea Compounds 48-60 insulin Homo sapiens 104-111 9322807-3 1997 Sulfonylureas (e.g., glyburide), which stimulate insulin secretion, have been reported either to increase or not to affect arterial pressure, whereas nonsulfonylurea agents with insulin-sensitizing properties, the biguanide metformin and various thiazolidinediones (eg, pioglitazone), have been reported to decrease arterial pressure in humans and rodents. Sulfonylurea Compounds 0-13 insulin Homo sapiens 49-56 9322807-11 1997 In contrast, sulfonylureas may directly induce a paradoxical vasoconstrictor response to insulin. Sulfonylurea Compounds 13-26 insulin Homo sapiens 89-96 9306041-9 1997 Among 40% of patients who had insulin deficiency (fasting c-peptide level < 0.33 nmol/1), GAD-Ab was present in half and these GAD-Ab(+) patients had significantly shorter duration of sulfonylurea treatment (3.3 +/- 2.3 versus 10.0 +/- 7.9 years; P = 0.018). Sulfonylurea Compounds 187-199 insulin Homo sapiens 30-37 9306041-11 1997 Almost all GAD-Ab(+) patients had insulin deficiency and most had been initially treated with sulfonylurea for a few years before depending on insulin. Sulfonylurea Compounds 94-106 insulin Homo sapiens 143-150 9159660-6 1997 Metformin and sulfonylureas, however, had diverse effects on body weight and fasting plasma insulin levels; both weight and insulin levels remained unchanged or decreased with metformin and increased with sulfonylureas. Sulfonylurea Compounds 14-27 insulin Homo sapiens 92-99 9279500-7 1997 There is intensive pharmaceutical research to find new drugs able to stimulate insulin secretion (new sulphonylurea or nonsulphonylurea derivatives, glucagon-like peptide-1), improve insulin action (thiazolidinediones, lipid interfering agents, glucagon antagonists, vanadium compounds) or reduce carbohydrate absorption (miglitol, amylin analogues, glucagon-like peptide-1). Sulfonylurea Compounds 102-115 insulin Homo sapiens 79-86 9279533-1 1997 Insulin release occurs in two phases; sulphonylurea derivatives may have different potencies in stimulating first- and second-phase insulin release. Sulfonylurea Compounds 38-51 insulin Homo sapiens 0-7 9279533-1 1997 Insulin release occurs in two phases; sulphonylurea derivatives may have different potencies in stimulating first- and second-phase insulin release. Sulfonylurea Compounds 38-51 insulin Homo sapiens 132-139 9260195-6 1997 Two samples from non-insulin-dependent diabetics under sulfonylurea treatment contained a fourfold lower content of IRI but the peptide distribution was comparable except for a low percentage (0.3) of proinsulin in one case. Sulfonylurea Compounds 55-67 insulin Homo sapiens 21-28 9260195-6 1997 Two samples from non-insulin-dependent diabetics under sulfonylurea treatment contained a fourfold lower content of IRI but the peptide distribution was comparable except for a low percentage (0.3) of proinsulin in one case. Sulfonylurea Compounds 55-67 insulin Homo sapiens 201-211 9237780-1 1997 We investigated how fasting or postprandial insulin levels were altered by treatment with acarbose or sulfonylureas. Sulfonylurea Compounds 102-115 insulin Homo sapiens 44-51 9237780-4 1997 In contrast, sulfonylurea treatment increased postprandial insulin and proinsulin levels. Sulfonylurea Compounds 13-25 insulin Homo sapiens 59-66 9237780-4 1997 In contrast, sulfonylurea treatment increased postprandial insulin and proinsulin levels. Sulfonylurea Compounds 13-25 insulin Homo sapiens 71-81 15989662-3 1997 To date, however, the sulfonylureas are the only insulin secretagogues available and even the most rapid acting of these fail to restore early insulin release in response to meals. Sulfonylurea Compounds 22-35 insulin Homo sapiens 49-56 9143853-9 1997 However, concern over the potential of these drugs to cause hypoglycaemia limits the choice to second generation sulphonylureas, agents that preserve the first phase of insulin release and have non-biologically active metabolites that are promptly eliminated. Sulfonylurea Compounds 113-127 insulin Homo sapiens 169-176 9143853-11 1997 The combination of a sulphonylurea and metformin can be effective in patients in whom insulin would otherwise be required. Sulfonylurea Compounds 21-34 insulin Homo sapiens 86-93 9159660-6 1997 Metformin and sulfonylureas, however, had diverse effects on body weight and fasting plasma insulin levels; both weight and insulin levels remained unchanged or decreased with metformin and increased with sulfonylureas. Sulfonylurea Compounds 14-27 insulin Homo sapiens 124-131 9159660-6 1997 Metformin and sulfonylureas, however, had diverse effects on body weight and fasting plasma insulin levels; both weight and insulin levels remained unchanged or decreased with metformin and increased with sulfonylureas. Sulfonylurea Compounds 205-218 insulin Homo sapiens 124-131 8941458-10 1996 Combined insulin-sulfonylurea treatment was almost 20% more expensive than twice-daily administration of insulin alone. Sulfonylurea Compounds 17-29 insulin Homo sapiens 9-16 9100556-3 1997 Because of their structural similarities to sulfonylureas, sulfonamides are liable to facilitate hypoglycemia by increasing insulin release in susceptible individuals. Sulfonylurea Compounds 44-57 insulin Homo sapiens 124-131 9285204-5 1997 In contrast, GLP-1 glucose-dependently stimulates insulin secretion in diet- and sulfonylurea-treated Type 2-diabetic patients and also in patients under insulin therapy long after sulfonylurea secondary failure. Sulfonylurea Compounds 81-93 insulin Homo sapiens 50-57 9380804-1 1997 The aim of the study was to find out which model of insulin therapy in patients with noninsulin-dependent diabetes mellitus with secondary inefficacy of sulphonylurea is most effective for glycemia normalization, inhibition of late complications, prevention of atherosclerosis and better quality of life. Sulfonylurea Compounds 153-166 insulin Homo sapiens 52-59 8941458-10 1996 Combined insulin-sulfonylurea treatment was almost 20% more expensive than twice-daily administration of insulin alone. Sulfonylurea Compounds 17-29 insulin Homo sapiens 105-112 8864638-5 1996 The survival of patients treated with glibenclamide, insulin or diet alone is longer after the first attack of angina pectoris or after first acute myocardial infarction compared with those on other investigated sulphonylurea therapy. Sulfonylurea Compounds 212-225 insulin Homo sapiens 53-60 8894498-7 1996 This justifies the use of insulin-releasing drugs with a rapid onset of action, e.g. the sulphonylurea glipizide. Sulfonylurea Compounds 89-102 insulin Homo sapiens 26-33 8911978-4 1996 When a single injection of insulin taken in the evening is added to a sulfonylurea at the time of secondary failure of the sulfonylurea alone, glycemic control is quite simply and consistently restored to acceptable levels. Sulfonylurea Compounds 70-82 insulin Homo sapiens 27-34 8911978-4 1996 When a single injection of insulin taken in the evening is added to a sulfonylurea at the time of secondary failure of the sulfonylurea alone, glycemic control is quite simply and consistently restored to acceptable levels. Sulfonylurea Compounds 123-135 insulin Homo sapiens 27-34 8911979-2 1996 A variety of factors, such as regulatory processes, glucose absorption, insulin sensitivity, might prevent the definition of a clear concentration-effect relationship for sulfonylureas. Sulfonylurea Compounds 171-184 insulin Homo sapiens 72-79 9036569-7 1996 Further impairment of insulin secretion is the indication for sulfonylurea and/or insulin application. Sulfonylurea Compounds 62-74 insulin Homo sapiens 22-29 8908377-1 1996 OBJECTIVE: To compare results obtained with metformin versus those obtained with DNA-recombinant insulin in obese patients with NIDDM suffering from secondary failure to sulfonylureas. Sulfonylurea Compounds 170-183 insulin Homo sapiens 97-104 8914439-7 1996 Sulfonylureas might be another candidates of drug intervention to IGT whose insulin secretory abilities are markedly reduced. Sulfonylurea Compounds 0-13 insulin Homo sapiens 76-83 8911991-7 1996 Sulfonylureas, in contrast to insulin, seem able to inhibit the fibrinolytic system, possibly via the stimulating effect of proinsulin on the endothelial PAI-1 expression. Sulfonylurea Compounds 0-13 insulin Homo sapiens 124-134 8628999-1 1996 Hypoglycemic sulfonylureas represent a group of clinically useful antidiabetic compounds that stimulate insulin secretion from pancreatic beta cells. Sulfonylurea Compounds 13-26 insulin Homo sapiens 104-111 8572835-16 1996 CONCLUSIONS: Combination therapy with insulin and sulfonylurea may be a more appropriate and a suitable option to insulin monotherapy in subjects with non-insulin-dependent diabetes in whom primary or secondary failure to sulfonylurea developed. Sulfonylurea Compounds 50-62 insulin Homo sapiens 114-121 8572835-16 1996 CONCLUSIONS: Combination therapy with insulin and sulfonylurea may be a more appropriate and a suitable option to insulin monotherapy in subjects with non-insulin-dependent diabetes in whom primary or secondary failure to sulfonylurea developed. Sulfonylurea Compounds 222-234 insulin Homo sapiens 38-45 9026680-4 1996 Both NPH and ultralent insulin therapy have been demonstrated to be effective in ameliorating metabolic control in NIDDM patients with secondary failure to sulfonylureas. Sulfonylurea Compounds 156-169 insulin Homo sapiens 23-30 8621013-10 1996 In the SU group, GAD antibody status was persistently positive in three NIDDM patients (NS vs. insulin group). Sulfonylurea Compounds 7-9 insulin Homo sapiens 95-102 8750768-1 1995 To examine whether sulfonylureas inhibit the metabolic clearance rate (MCR) of insulin, 19 healthy young subjects participated in two experiments. Sulfonylurea Compounds 19-32 insulin Homo sapiens 79-86 8544897-4 1995 The treatment of type 2 (non-insulin-dependent) diabetes mellitus with sulphonylurea derivatives (SU), which exert their insulinotropic effect by closing the K+[ATP] channels of the pancreatic beta-cell, is customary. Sulfonylurea Compounds 71-84 insulin Homo sapiens 29-36 7484707-3 1995 With chronic administration, sulfonylureas improve the diabetic patient"s insulin activity by increasing cellular insulin receptors and reducing insulin postreceptor defects. Sulfonylurea Compounds 29-42 insulin Homo sapiens 74-81 7484707-3 1995 With chronic administration, sulfonylureas improve the diabetic patient"s insulin activity by increasing cellular insulin receptors and reducing insulin postreceptor defects. Sulfonylurea Compounds 29-42 insulin Homo sapiens 114-121 7484707-3 1995 With chronic administration, sulfonylureas improve the diabetic patient"s insulin activity by increasing cellular insulin receptors and reducing insulin postreceptor defects. Sulfonylurea Compounds 29-42 insulin Homo sapiens 114-121 8846678-1 1995 Combination therapy with insulin and sulphonylurea has gained acceptance in management of subjects with Type 2 (non-insulin-dependent) diabetes mellitus. Sulfonylurea Compounds 37-50 insulin Homo sapiens 116-123 8529760-0 1995 Comparison between acarbose, metformin, and insulin treatment in type 2 diabetic patients with secondary failure to sulfonylurea treatment. Sulfonylurea Compounds 116-128 insulin Homo sapiens 44-51 8591697-2 1995 In this study, we investigated the effect of sulfonylurea (SU) treatment on serum proinsulin levels and proinsulin/insulin ratio (PI/I) during oral glucose tolerance test in patients with Type 2 diabetes. Sulfonylurea Compounds 59-61 insulin Homo sapiens 82-92 7652727-8 1995 Insulin treatment should be considered only when combined treatment with metformin and sulfonylurea is contraindicated or leads to insufficient blood glucose control. Sulfonylurea Compounds 87-99 insulin Homo sapiens 0-7 8529509-8 1995 Sulfonylureas may exert some suppressive action on the liver and may maintain a portal-peripheral venous insulin gradient. Sulfonylurea Compounds 0-13 insulin Homo sapiens 105-112 7591687-0 1995 Insulin-dependent diabetes of pregnancy treated with the combination of sulfonylurea and insulin. Sulfonylurea Compounds 72-84 insulin Homo sapiens 0-7 8591697-0 1995 Elevated ratio of summed serum proinsulin to insulin response after oral glucose load in type 2 diabetes decreases following sulfonylurea treatment. Sulfonylurea Compounds 125-137 insulin Homo sapiens 31-41 8591697-0 1995 Elevated ratio of summed serum proinsulin to insulin response after oral glucose load in type 2 diabetes decreases following sulfonylurea treatment. Sulfonylurea Compounds 125-137 insulin Homo sapiens 34-41 8591697-2 1995 In this study, we investigated the effect of sulfonylurea (SU) treatment on serum proinsulin levels and proinsulin/insulin ratio (PI/I) during oral glucose tolerance test in patients with Type 2 diabetes. Sulfonylurea Compounds 45-57 insulin Homo sapiens 82-92 8591697-2 1995 In this study, we investigated the effect of sulfonylurea (SU) treatment on serum proinsulin levels and proinsulin/insulin ratio (PI/I) during oral glucose tolerance test in patients with Type 2 diabetes. Sulfonylurea Compounds 59-61 insulin Homo sapiens 104-114 8591697-2 1995 In this study, we investigated the effect of sulfonylurea (SU) treatment on serum proinsulin levels and proinsulin/insulin ratio (PI/I) during oral glucose tolerance test in patients with Type 2 diabetes. Sulfonylurea Compounds 45-57 insulin Homo sapiens 85-92 8591697-2 1995 In this study, we investigated the effect of sulfonylurea (SU) treatment on serum proinsulin levels and proinsulin/insulin ratio (PI/I) during oral glucose tolerance test in patients with Type 2 diabetes. Sulfonylurea Compounds 59-61 insulin Homo sapiens 85-92 8591697-7 1995 Insulin response during OGTT markedly increased after SU therapy. Sulfonylurea Compounds 54-56 insulin Homo sapiens 0-7 8591697-8 1995 Summed value of insulin (sigma I) increased from 634 to 1064 pmol/l after SU (P < 0.01), whereas summed proinsulin (sigma PI) did not change significantly (146 and 159 pmol/l), resulting in a significant decrease in sigma PI/sigma I (23.6-15.1%, P < 0.05). Sulfonylurea Compounds 74-76 insulin Homo sapiens 25-32 8591697-9 1995 We conclude that the disproportionate elevation of proinsulin during OGTT in patients with Type 2 diabetes can be reduced after glycemic control by SU treatment, chiefly by a selective increase in insulin response. Sulfonylurea Compounds 148-150 insulin Homo sapiens 51-61 8591697-9 1995 We conclude that the disproportionate elevation of proinsulin during OGTT in patients with Type 2 diabetes can be reduced after glycemic control by SU treatment, chiefly by a selective increase in insulin response. Sulfonylurea Compounds 148-150 insulin Homo sapiens 54-61 7833494-6 1994 The differences in efficacy and secondary failure rate between sulfonylureas may be related to the mechanism of insulin release from the beta-cell and the more physiological action of gliclazide could partly explain this. Sulfonylurea Compounds 63-76 insulin Homo sapiens 112-119 7762486-7 1995 Insulin is indicated in patients with type II diabetes during times of acute stress, infection, surgery and pregnancy, and if the patient is allergic to sulfonylureas. Sulfonylurea Compounds 153-166 insulin Homo sapiens 0-7 7725640-3 1995 By combined treatment, i.e. by adding small amounts of insulin to the original treatment with sulphonylurea antidiabetics or by adding sulphonylurea to large insulin doses, it is possible to compensate the patient as effectively as with insulin treatment alone. Sulfonylurea Compounds 94-107 insulin Homo sapiens 55-62 7725640-5 1995 Finally the author evaluates the effect of combined treatment from data in the literature as well as his own experience which indicate that to achieve equal metabolic compensation combined treatment with sulphonylurea and insulin requires substantially lower insulin doses, as compared with insulin treatment only. Sulfonylurea Compounds 204-217 insulin Homo sapiens 259-266 7725640-5 1995 Finally the author evaluates the effect of combined treatment from data in the literature as well as his own experience which indicate that to achieve equal metabolic compensation combined treatment with sulphonylurea and insulin requires substantially lower insulin doses, as compared with insulin treatment only. Sulfonylurea Compounds 204-217 insulin Homo sapiens 259-266 7867884-10 1994 The present study shows that human islets can respond to stimulation with glucose and sulphonylurea with oscillations in [Ca2+]i, which is the signal probably underlying the oscillations in plasma insulin levels observed in healthy subjects. Sulfonylurea Compounds 86-99 insulin Homo sapiens 197-204 7821127-9 1994 CONCLUSIONS: Addition of metformin to sulfonylurea-treated patients with NIDDM with less than optimal glycemic control was associated with improved glycemic control, lower postprandial insulin and TG concentrations, and a decrease in postprandial concentration of TG-rich lipoproteins of intestinal origin. Sulfonylurea Compounds 38-50 insulin Homo sapiens 185-192 7536208-7 1995 Proinsulin levels were higher in sulfonylurea-treated patients, but there was no significant correlation between IGFBP-1 and proinsulin within any individual group. Sulfonylurea Compounds 33-45 insulin Homo sapiens 0-10 7587604-9 1995 It is shown that combined therapy with sulfonylurea and insulin is effective in NIDDM patients, especially in those with secondary failure of beta-cell function and the combined therapy may be used in NIDDM patients during the transitional period from treatment with sulfonylurea alone to traditional insulin cure. Sulfonylurea Compounds 39-51 insulin Homo sapiens 301-308 7587604-9 1995 It is shown that combined therapy with sulfonylurea and insulin is effective in NIDDM patients, especially in those with secondary failure of beta-cell function and the combined therapy may be used in NIDDM patients during the transitional period from treatment with sulfonylurea alone to traditional insulin cure. Sulfonylurea Compounds 267-279 insulin Homo sapiens 56-63 8075474-9 1994 Sulphonylurea drugs stimulate insulin secretion from beta-cells, and may be a useful adjunct to nonpharmacological therapy. Sulfonylurea Compounds 0-13 insulin Homo sapiens 30-37 8077888-1 1994 OBJECTIVES: To study the effect of insulin and sulfonylurea (SU) therapy on glycaemic control, insulin resistance and cardiovascular risk factors in type 2 diabetic subjects. Sulfonylurea Compounds 61-63 insulin Homo sapiens 95-102 8077888-10 1994 Levels of triglycerides and apolipoprotein B were significantly reduced during insulin treatment (1.8 +/- 0.2 to 1.5 +/- 0.2 mmol L-1, P = 0.03 and 1.58 +/- 0.1 to 1.40 +/- 0.08 g L-1, P = 0.003), and insulin prevented a reduction in the levels of high-density lipoprotein (HDL) cholesterol and apolipoprotein A-1 and an increase in Lp(a) lipoprotein observed in the SU group. Sulfonylurea Compounds 367-369 insulin Homo sapiens 79-86 8039433-17 1994 However, once the hyperglycemia and the insulin resistance is ameliorated during treatment with diet or sulphonylurea drugs the activation of GS improves. Sulfonylurea Compounds 104-117 insulin Homo sapiens 40-47 8033529-0 1994 Effect of sulphonylurea therapy on plasma insulin, intact and 32/33 split proinsulin in subjects with type 2 diabetes mellitus. Sulfonylurea Compounds 10-23 insulin Homo sapiens 42-49 8033529-0 1994 Effect of sulphonylurea therapy on plasma insulin, intact and 32/33 split proinsulin in subjects with type 2 diabetes mellitus. Sulfonylurea Compounds 10-23 insulin Homo sapiens 74-84 8415209-13 1993 It is concluded that in patients with non-insulin-dependent (type 2) diabetes the second generation sulphonylurea derivatives are associated with lower risk of alcohol intolerance in case of its incidental ingestion in small amounts. Sulfonylurea Compounds 100-113 insulin Homo sapiens 42-49 8033529-4 1994 At diagnosis, the sulphonylurea requiring group were more hyperglycaemic (p < 0.0001), less obese (p < 0.05) and more insulin deficient with a lower 30 min insulin (p < 0.0002) than the diet group. Sulfonylurea Compounds 18-31 insulin Homo sapiens 124-131 8033529-10 1994 Final fasting glucose following sulphonylurea therapy was positively correlated with the initial intact and 32/33 split proinsulin and the fasting glucose following dietary treatment. Sulfonylurea Compounds 32-45 insulin Homo sapiens 120-130 7991936-0 1994 Metabolic clearance rate of insulin in type 2 diabetic patients treated with combined insulin and sulfonylurea therapy. Sulfonylurea Compounds 98-110 insulin Homo sapiens 28-35 8296132-5 1994 Patients with normal or slightly increased body weight should profit best from sulfonylureas that stimulate insulin production. Sulfonylurea Compounds 79-92 insulin Homo sapiens 108-115 8404429-1 1993 OBJECTIVE: To ascertain whether the effect of sulfonylureas on glucose-mediated insulin release persists for years to decades in patients with maturity-onset diabetes of the young. Sulfonylurea Compounds 46-59 insulin Homo sapiens 80-87 8403824-0 1993 The acute effect of preprandial exogenous and endogenous sulphonylurea-stimulated insulin secretion on postprandial glucose excursions in patients with type 2 diabetes. Sulfonylurea Compounds 57-70 insulin Homo sapiens 82-89 8375246-8 1993 Nondiabetic subjects and NIDDM patients who were withdrawn from sulfonylurea therapy had impaired insulin secretion during a 75-g oral glucose tolerance test, with similar basal levels as nondiabetic subjects (54 +/- 12 vs. 42 +/- 6 pM), but reduced peak insulin levels (126 +/- 30 vs. 468 +/- 102 pM, P < 0.01). Sulfonylurea Compounds 64-76 insulin Homo sapiens 98-105 8415212-6 1993 The mechanism of metabolic improvement of patients with type 2 diabetes and secondary failure of sulphonylurea derivatives, which follows the addition of gliclazide to insulin, is not fully clarified. Sulfonylurea Compounds 97-110 insulin Homo sapiens 168-175 1387073-11 1992 CONCLUSION: Combined insulin-sulfonylurea therapy leads to modest improvement in glycemic control compared with insulin therapy alone. Sulfonylurea Compounds 29-41 insulin Homo sapiens 21-28 8454981-6 1993 Insulin therapy is required in patients with hyperosmolar state, infection, or other forms of stress, or in those who fail to respond to treatment with oral sulfonylurea. Sulfonylurea Compounds 157-169 insulin Homo sapiens 0-7 8475636-6 1993 In non obese type II diabetic patients sulfonylureas are advantageous because of meal related stimulation of endogenous insulin which runs the physiological way with first pass through the liver. Sulfonylurea Compounds 39-52 insulin Homo sapiens 120-127 8475636-7 1993 Therefore, sulfonylurea treatment should be continued when secondary failure indicates the need for exogenous insulin. Sulfonylurea Compounds 11-23 insulin Homo sapiens 110-117 8212978-7 1993 Numerous studies have shown that a combination of insulin and sulphonylurea is more effective than insulin alone in the treatment of patients with NIDDM after secondary failure to oral drugs, leading to better glucose profiles and/or decreased insulin needs. Sulfonylurea Compounds 62-75 insulin Homo sapiens 99-106 8212978-7 1993 Numerous studies have shown that a combination of insulin and sulphonylurea is more effective than insulin alone in the treatment of patients with NIDDM after secondary failure to oral drugs, leading to better glucose profiles and/or decreased insulin needs. Sulfonylurea Compounds 62-75 insulin Homo sapiens 99-106 8435988-0 1993 Changes in glucose disposal and cellular insulin binding in obese black Southern African patients with type 2 diabetes mellitus before and after sulphonylurea therapy. Sulfonylurea Compounds 145-158 insulin Homo sapiens 41-48 1456195-3 1992 Sulfonylureas stimulate endogenous insulin production, increase peripheral sensitivity to insulin and suppress hepatic glucose production. Sulfonylurea Compounds 0-13 insulin Homo sapiens 35-42 1456195-3 1992 Sulfonylureas stimulate endogenous insulin production, increase peripheral sensitivity to insulin and suppress hepatic glucose production. Sulfonylurea Compounds 0-13 insulin Homo sapiens 90-97 1289019-6 1992 After 2 months of insulin treatment, a further improvement was achieved by a low dose of sulfonylurea in these patients who were formerly considered unresponsive to oral antidiabetic agents. Sulfonylurea Compounds 89-101 insulin Homo sapiens 18-25 1478610-3 1992 Binding of sulfonylureas causes closure of the ATP-sensitive K(+)-channel and thereby initiates a chain of events eventually leading to the release of insulin. Sulfonylurea Compounds 11-24 insulin Homo sapiens 151-158 8375268-0 1993 Effect of a sulfonylurea (gliclazide) treatment on insulin sensitivity and glucose-mediated glucose disposal in patients with non-insulin-dependent diabetes mellitus (NIDDM). Sulfonylurea Compounds 12-24 insulin Homo sapiens 51-58 8483872-3 1993 Secondary failure of SU therapy 20 years after the initial diagnosis led to insulin therapy. Sulfonylurea Compounds 21-23 insulin Homo sapiens 76-83 8449244-13 1993 Furthermore, sulfonyl urea agents may be indicated for treating these patients, probably by increasing insulin sensitivity. Sulfonylurea Compounds 13-26 insulin Homo sapiens 103-110 1468283-0 1992 Chronic sulfonylurea therapy augments basal and meal-stimulated insulin secretion while attenuating insulin responses to sulfonylurea per se. Sulfonylurea Compounds 8-20 insulin Homo sapiens 64-71 1468283-0 1992 Chronic sulfonylurea therapy augments basal and meal-stimulated insulin secretion while attenuating insulin responses to sulfonylurea per se. Sulfonylurea Compounds 8-20 insulin Homo sapiens 100-107 1468283-0 1992 Chronic sulfonylurea therapy augments basal and meal-stimulated insulin secretion while attenuating insulin responses to sulfonylurea per se. Sulfonylurea Compounds 121-133 insulin Homo sapiens 100-107 1464414-0 1992 The effect of insulin treatment on HbA1c, body weight and lipids in type 2 diabetic patients with secondary-failure to sulfonylureas. Sulfonylurea Compounds 119-132 insulin Homo sapiens 14-21 1628875-12 1992 Among the various drugs interfering with insulin secretion, sulfonylureas, such as tolbutamide and glibenclamide, directly inhibit ATP-dependent K+ channels in the B cell membrane and thereby initiate insulin release. Sulfonylurea Compounds 60-73 insulin Homo sapiens 41-48 1600834-3 1992 Sulfonylureas lower blood glucose concentrations primarily by stimulating insulin secretion. Sulfonylurea Compounds 0-13 insulin Homo sapiens 74-81 1556950-1 1992 Intensive insulin treatment, when combined with sulfonylurea drugs, may enhance remissions in new-onset type I diabetic patients. Sulfonylurea Compounds 48-60 insulin Homo sapiens 10-17 1595776-1 1992 Combined insulin and sulfonylurea therapy for type 2 diabetes may improve the effectiveness of a single injection of insulin, thereby postponing the need for multiple injections. Sulfonylurea Compounds 21-33 insulin Homo sapiens 117-124 1752344-0 1991 Restoration of sensitivity to sulfonylurea after strict glycaemic control with insulin in non-obese type 2 diabetic subjects. Sulfonylurea Compounds 30-42 insulin Homo sapiens 79-86 1523352-19 1992 The very low insulin dose used in this study could be explained by complementary effects of metformin and bedtime insulin on hepatic glucose output and a putative decrease in peripheral resistance attributable both to sulfonylurea and metformin. Sulfonylurea Compounds 218-230 insulin Homo sapiens 13-20 1919450-0 1991 Type II diabetic subjects with secondary failure: treatment with prebreakfast mixed ultralente and regular insulin with a sulfonylurea. Sulfonylurea Compounds 122-134 insulin Homo sapiens 107-114 1919450-1 1991 BACKGROUND: Combination therapy with sulfonylurea and insulin is reported to be effective in several recent reports on the management of non-insulin-dependent diabetes mellitus (NIDDM) and secondary failure to sulfonylurea. Sulfonylurea Compounds 210-222 insulin Homo sapiens 54-61 1919450-3 1991 Since a subcutaneous injection of Ultralente insulin exerts its peak effect between 16 and 18 hours after injection, its prebreakfast administration is likely to inhibit overnight hepatic glucose production, which is a primary modulator of fasting plasma glucose, a major determinant of diurnal glycemia in NIDDM: Moreover, the simultaneous administration of regular insulin tends to improve glycemia during the premeal and immediate postmeal period before the onset of sulfonylurea-induced insulin secretion. Sulfonylurea Compounds 470-482 insulin Homo sapiens 45-52 1919450-9 1991 CONCLUSIONS: Adjuvant therapy with sulfonylurea and a single prebreakfast subcutaneous injection of mixed Ultralente and regular insulin may be an effective and practical therapeutic option in the management of NIDDM with secondary failure to sulfonylurea. Sulfonylurea Compounds 243-255 insulin Homo sapiens 129-136 1752344-3 1991 The reintroduction of the sulfonylurea after insulin withdrawal resulted in a persistent satisfactory long-term control (300 days) in all, but two diabetics responded no more after about 3 and 4 months of clinical remission (good control on sulfonylurea). Sulfonylurea Compounds 26-38 insulin Homo sapiens 45-52 1872301-12 1991 Possible effects of sulfonylureas on glucagon secretion and on the metabolism of free fatty acids (FFAs) may also contribute to improved sensitivity of the liver to the suppressive action of insulin, since these agents appear to reduce plasma glucagon and FFA concentrations. Sulfonylurea Compounds 20-33 insulin Homo sapiens 191-198 1828656-12 1991 When a sulfonylurea agent was used, less exogenous insulin was needed, but fasting serum insulin levels were not different between the treatment groups. Sulfonylurea Compounds 7-19 insulin Homo sapiens 51-58 1948807-1 1991 Sulfonylureas act as hypoglycemic agents by stimulating insulin secretion and improving insulin sensibility by a post-receptor mechanism. Sulfonylurea Compounds 0-13 insulin Homo sapiens 56-63 1908182-10 1991 In conclusion, sulfonylurea treatment of NIDDM enhances insulin-stimulated peripheral glucose utilization in part through a potentiation of insulin action on adipose tissue glucose transport and lipogenesis and skeletal muscle glycogen synthase. Sulfonylurea Compounds 15-27 insulin Homo sapiens 56-63 1908182-10 1991 In conclusion, sulfonylurea treatment of NIDDM enhances insulin-stimulated peripheral glucose utilization in part through a potentiation of insulin action on adipose tissue glucose transport and lipogenesis and skeletal muscle glycogen synthase. Sulfonylurea Compounds 15-27 insulin Homo sapiens 140-147 1872309-6 1991 A lower ambient glucose level should favor the stimulatory effect of sulfonylureas on insulin secretion. Sulfonylurea Compounds 69-82 insulin Homo sapiens 86-93 1872309-7 1991 Sulfonylurea treatment should increase the portal inflow of secreted insulin with a resultant increase in insulin levels draining into liver, thus reducing postprandial hepatic glucose output. Sulfonylurea Compounds 0-12 insulin Homo sapiens 69-76 1872309-8 1991 Moreover, sulfonylureas might improve insulin action on its target tissue (i.e., muscle), thus increasing overall insulin-mediated glucose metabolism. Sulfonylurea Compounds 10-23 insulin Homo sapiens 38-45 1872309-8 1991 Moreover, sulfonylureas might improve insulin action on its target tissue (i.e., muscle), thus increasing overall insulin-mediated glucose metabolism. Sulfonylurea Compounds 10-23 insulin Homo sapiens 114-121 1872302-5 1991 Gliclazide is a second-generation sulfonylurea drug whose efficacy in the treatment of NIDDM, alone or in combination with insulin, has been widely demonstrated. Sulfonylurea Compounds 34-46 insulin Homo sapiens 123-130 1936483-0 1991 Sulfonylurea-metformin-combination versus sulfonylurea-insulin-combination in secondary failures of sulfonylurea monotherapy. Sulfonylurea Compounds 42-54 insulin Homo sapiens 55-62 1886478-6 1991 Obese, non-insulin dependent diabetes mellitus subjects on sulfonylurea therapy alone increased insulin levels but failed to improve insulin sensitivity or glucose levels. Sulfonylurea Compounds 59-71 insulin Homo sapiens 11-18 1886478-6 1991 Obese, non-insulin dependent diabetes mellitus subjects on sulfonylurea therapy alone increased insulin levels but failed to improve insulin sensitivity or glucose levels. Sulfonylurea Compounds 59-71 insulin Homo sapiens 96-103 2000364-4 1991 Drug treatment may consist of a sulfonylurea to increase insulin secretion and improve insulin resistance or of exogenous insulin to achieve glucose control and avoid the dangers of chronic hyperglycemia. Sulfonylurea Compounds 32-44 insulin Homo sapiens 57-64 2000364-4 1991 Drug treatment may consist of a sulfonylurea to increase insulin secretion and improve insulin resistance or of exogenous insulin to achieve glucose control and avoid the dangers of chronic hyperglycemia. Sulfonylurea Compounds 32-44 insulin Homo sapiens 87-94 1777653-0 1991 Effect of sulphonylurea on glucose-stimulated insulin secretion in healthy and non-insulin dependent diabetic subjects: a dose-response study. Sulfonylurea Compounds 10-23 insulin Homo sapiens 46-53 1777653-1 1991 The effect of a rapid-acting sulphonylurea, glipizide, on the dose-response relationship between the beta-cell response (insulin and C-peptide secretion) and the ambient plasma glucose concentration was examined in 12 healthy and 6 non-insulin-dependent diabetic subjects. Sulfonylurea Compounds 29-42 insulin Homo sapiens 121-128 1777653-1 1991 The effect of a rapid-acting sulphonylurea, glipizide, on the dose-response relationship between the beta-cell response (insulin and C-peptide secretion) and the ambient plasma glucose concentration was examined in 12 healthy and 6 non-insulin-dependent diabetic subjects. Sulfonylurea Compounds 29-42 insulin Homo sapiens 133-142 1826243-0 1991 Comparison of basal and prandial insulin therapy in patients with secondary failure of sulphonylurea therapy. Sulfonylurea Compounds 87-100 insulin Homo sapiens 33-40 1794267-2 1991 In addition to their pancreatic effects sulfonylureas have been reported to have insulin-like and insulin-potentiating actions in vitro with respect both to glucose transport and glycogen synthase activation in isolated adipocytes and hepatocytes from rats. Sulfonylurea Compounds 40-53 insulin Homo sapiens 81-88 1794267-2 1991 In addition to their pancreatic effects sulfonylureas have been reported to have insulin-like and insulin-potentiating actions in vitro with respect both to glucose transport and glycogen synthase activation in isolated adipocytes and hepatocytes from rats. Sulfonylurea Compounds 40-53 insulin Homo sapiens 98-105 2127573-0 1990 Partial recovery of insulin secretion and action after combined insulin-sulfonylurea treatment in type 2 (non-insulin-dependent) diabetic patients with secondary failure to oral agents. Sulfonylurea Compounds 72-84 insulin Homo sapiens 20-27 1980453-6 1990 Combination insulin-sulfonylurea treatment may improve the response to sulfonylureas, although long-term well-controlled trials have not been conducted. Sulfonylurea Compounds 20-32 insulin Homo sapiens 12-19 1980453-6 1990 Combination insulin-sulfonylurea treatment may improve the response to sulfonylureas, although long-term well-controlled trials have not been conducted. Sulfonylurea Compounds 71-84 insulin Homo sapiens 12-19 1980453-7 1990 Short-term insulin treatment may restore response to sulfonylureas. Sulfonylurea Compounds 53-66 insulin Homo sapiens 11-18 2276309-9 1990 In some, addition of a sulfonylurea to insulin may reduce hyperglycemia, the insulin dose, or both. Sulfonylurea Compounds 23-35 insulin Homo sapiens 39-46 2276309-9 1990 In some, addition of a sulfonylurea to insulin may reduce hyperglycemia, the insulin dose, or both. Sulfonylurea Compounds 23-35 insulin Homo sapiens 77-84 2137755-10 1990 Combination of insulin with the sulphonylurea glipizide in secondary failure Type 2 diabetic patients leads to increased insulin-mediated peripheral glucose disposal. Sulfonylurea Compounds 32-45 insulin Homo sapiens 121-128 2122177-1 1990 Sulfonylureas are used in the treatment of non-insulin-dependent diabetes mellitus (NIDDM) largely because of their ability to enhance insulin secretion and possibly to potentiate insulin action. Sulfonylurea Compounds 0-13 insulin Homo sapiens 47-54 2209344-9 1990 Thus, the comparison has been made between treatments with a smaller insulin dose with sulfonylurea and a larger insulin dose without sulfonylurea. Sulfonylurea Compounds 87-99 insulin Homo sapiens 69-76 2209344-11 1990 In such a patient, combined insulin-sulfonylurea therapy predominantly stimulates basal insulin secretion, resulting in more effective suppression of hepatic glucose production and lower fasting plasma glucose. Sulfonylurea Compounds 36-48 insulin Homo sapiens 28-35 2209346-0 1990 Mechanisms of sulfonylurea-induced insulin release. Sulfonylurea Compounds 14-26 insulin Homo sapiens 35-42 2209346-1 1990 The mechanisms responsible for the stimulation of insulin release from the pancreatic beta-cell by hypoglycemic sulfonylureas are reviewed herein. Sulfonylurea Compounds 112-125 insulin Homo sapiens 50-57 2115686-9 1990 The combination of glibenclamide and insulin (administered with the Novo Pen injector) is a safe and effective form of therapy in secondary failure of sulfonylurea, and is well accepted due to the mild start into insulin therapy. Sulfonylurea Compounds 151-163 insulin Homo sapiens 37-44 2272604-1 1990 Recent data suggests that one of the major actions of sulfonylureas is to potentiate the anabolic cellular effects of insulin. Sulfonylurea Compounds 54-67 insulin Homo sapiens 118-125 2242080-3 1990 In comparison to the monotherapy with sulfonylurea, the combination with transdermal insulin showed in 4 of the 6 patients a significant reduction of the daily mean blood sugar values as well as a slight increase of insulin serum concentrations. Sulfonylurea Compounds 38-50 insulin Homo sapiens 85-92 2242080-6 1990 The results suggest, that in suited patients an improvement of sulfonylurea therapy by combination with transdermal insulin is possible. Sulfonylurea Compounds 63-75 insulin Homo sapiens 116-123 2209344-0 1990 Combined insulin-sulfonylurea therapy in treatment of NIDDM. Sulfonylurea Compounds 17-29 insulin Homo sapiens 9-16 2209344-8 1990 Nevertheless, the insulin dose has been reduced by 20-30% to avoid hypoglycemia after adding sulfonylurea to insulin. Sulfonylurea Compounds 93-105 insulin Homo sapiens 18-25 2115686-0 1990 [Insulin-sulfonylurea combination therapy in secondary therapy failure with sulfonylurea compounds. Sulfonylurea Compounds 9-21 insulin Homo sapiens 1-8 2115686-0 1990 [Insulin-sulfonylurea combination therapy in secondary therapy failure with sulfonylurea compounds. Sulfonylurea Compounds 76-88 insulin Homo sapiens 1-8 2127273-0 1990 Effect of sulphonylurea therapy on insulin sensitivity in non insulin dependent diabetics. Sulfonylurea Compounds 10-23 insulin Homo sapiens 35-42 2127273-3 1990 All the three commonly used sulphonylurea drugs improved insulin sensitivity after 4 weeks of therapy. Sulfonylurea Compounds 28-41 insulin Homo sapiens 57-64 2192850-0 1990 Combination insulin-sulfonylurea therapy. Sulfonylurea Compounds 20-32 insulin Homo sapiens 12-19 2192850-3 1990 Insulin-sulfonylurea therapy is probably not clinically useful in most patients with insulin-dependent diabetes mellitus. Sulfonylurea Compounds 8-20 insulin Homo sapiens 0-7 2192850-6 1990 The mechanisms by which insulin-sulfonylurea therapy improves glycemic regulation and decreases insulin requirements involve an increase in endogenous insulin secretion and possibly some extrapancreatic actions of the sulfonylureas on muscle and liver. Sulfonylurea Compounds 32-44 insulin Homo sapiens 24-31 2192850-6 1990 The mechanisms by which insulin-sulfonylurea therapy improves glycemic regulation and decreases insulin requirements involve an increase in endogenous insulin secretion and possibly some extrapancreatic actions of the sulfonylureas on muscle and liver. Sulfonylurea Compounds 218-231 insulin Homo sapiens 24-31 2179710-1 1990 The effects of the insulin-releasing sulfonylurea tolbutamide on the cytoplasmic Ca2+ concentration [( Ca2+]i) in individual pancreatic beta-cells or suspensions of beta-cells were analyzed using the probe fura-2 and dual-wavelength fluorometry. Sulfonylurea Compounds 37-49 insulin Homo sapiens 19-26 2171690-1 1990 Addition of phenobarbital, an inducer of the liver mixed function oxidase system, to sulphonylurea regimen improves insulin sensitivity and intracellular glucose handling in patients with non-insulin dependent diabetes mellitus. Sulfonylurea Compounds 85-98 insulin Homo sapiens 116-123 2195610-5 1990 Such data are to caution the clinician against premature stimulation of endogenous insulin release by sulfonylureas or against too early initiation of insulin treatment in Type 2 diabetes. Sulfonylurea Compounds 102-115 insulin Homo sapiens 83-90 34566892-3 2021 Patients with NDM caused by KATP channel mutations are sensitive to sulfonylurea (SU) treatment; therefore, their clinical management can be improved by replacing insulin with oral agents. Sulfonylurea Compounds 68-80 insulin Homo sapiens 163-170 34825567-3 2021 Sulfonylurea drugs, commonly used in type 2 diabetes mellitus treatment, bind to the octamer KATP channels composed of four pore-forming Kir6.2 and four SUR1 subunits and increase the probability of insulin release. Sulfonylurea Compounds 0-12 insulin Homo sapiens 199-206 34748819-2 2021 Pharmacological targeting of the beta-cell to increase insulin secretion is typically utilised, however, extended use of common drugs such as sulfonylureas are known to result in secondary failure. Sulfonylurea Compounds 142-155 insulin Homo sapiens 55-62 2408182-2 1990 The aim of this kind of therapy is to take advantage of the physiological way of endogenous insulin, stimulated by sulfonylureas. Sulfonylurea Compounds 115-128 insulin Homo sapiens 92-99 34726745-15 2021 Conclusions and Relevance: In this cohort study, deintensification of sulfonylurea and/or insulin therapy within 100 days after a hypoglycemia-associated ED visit or hospitalization occurred in fewer than 50% of older adults with diabetes; however, these deintensification rates may be increasing over time, and deintensification of insulin was likely underestimated because of challenges in capturing changes to insulin dosing using administrative claims data. Sulfonylurea Compounds 70-82 insulin Homo sapiens 333-340 34726745-15 2021 Conclusions and Relevance: In this cohort study, deintensification of sulfonylurea and/or insulin therapy within 100 days after a hypoglycemia-associated ED visit or hospitalization occurred in fewer than 50% of older adults with diabetes; however, these deintensification rates may be increasing over time, and deintensification of insulin was likely underestimated because of challenges in capturing changes to insulin dosing using administrative claims data. Sulfonylurea Compounds 70-82 insulin Homo sapiens 413-420 34566892-3 2021 Patients with NDM caused by KATP channel mutations are sensitive to sulfonylurea (SU) treatment; therefore, their clinical management can be improved by replacing insulin with oral agents. Sulfonylurea Compounds 82-84 insulin Homo sapiens 163-170 34566892-14 2021 Glycemic control on SU treatment was better than on insulin treatment: HbA1c and blood glucose level decreased from 7.58% +- 4.63% and 19.04 +- 14.09 mmol/L when treated with insulin to 5.8 +- 0.94% and 6.87 +- 3.46 mmol/L when treated with SU, respectively. Sulfonylurea Compounds 20-22 insulin Homo sapiens 175-182 34566892-14 2021 Glycemic control on SU treatment was better than on insulin treatment: HbA1c and blood glucose level decreased from 7.58% +- 4.63% and 19.04 +- 14.09 mmol/L when treated with insulin to 5.8 +- 0.94% and 6.87 +- 3.46 mmol/L when treated with SU, respectively. Sulfonylurea Compounds 241-243 insulin Homo sapiens 52-59 34539410-10 2021 Sulfonylureas, insulin secretagogues, are the earliest and most widely used oral hypoglycemic drugs used for type-2 diabetes. Sulfonylurea Compounds 0-13 insulin Homo sapiens 15-22 34099169-4 2021 In pancreatic beta-cells, channels comprising SUR1 and Kir6.2 mediate glucose-stimulated insulin secretion and are the targets of antidiabetic sulfonylureas. Sulfonylurea Compounds 143-156 insulin Homo sapiens 89-96 34083248-7 2021 Prior sulfonylurea use was associated with greater odds of hospitalization and prior insulin use with hospitalization and death among patients with diabetes; among all participants, statin use was associated with lower mortality and ARB use with lower odds of hospitalization. Sulfonylurea Compounds 6-18 insulin Homo sapiens 85-92 2515048-7 1989 These results suggest that a short-term period of meal-related insulin treatment (which normalized prandial glycemia) increases residual beta-cell function in NIDDM subjects who failed long-term sulfonylurea administration. Sulfonylurea Compounds 195-207 insulin Homo sapiens 63-70 35466084-10 2022 The use of sulfonylurea agents in patients with HNF1A-MODY can reduce dependence on insulin therapy and provide successful glycemic control. Sulfonylurea Compounds 11-23 insulin Homo sapiens 84-91 34254494-4 2021 CONCLUSION: An early genetic diagnosis of neonatal diabetes mellitus is highly beneficial because early switch from insulin to sulfonylurea is safe, avoids unnecessary insulin therapy and promotes sustained improvement of glycaemic control on long-term follow-up. Sulfonylurea Compounds 127-139 insulin Homo sapiens 168-175 35512857-6 2022 Insulin outflow significantly increased upon stimulation with 10 muM glimepiride, a member of the sulfonylurea class of drugs, ex vivo. Sulfonylurea Compounds 98-110 insulin Homo sapiens 0-7 35443346-16 2022 CONCLUSION: Amongst the OAD"s used in type 2 diabetes mellitus patients in this study, total number of hyperglycemic and hypoglycemic episodes were found to be more in patients taking sulfonylurea as compared with DPP4 inhibitors when used in combination with metformin with or without insulin. Sulfonylurea Compounds 184-196 insulin Homo sapiens 286-293 2673707-0 1989 Combined insulin-sulfonylurea treatment of type II diabetes. Sulfonylurea Compounds 17-29 insulin Homo sapiens 9-16 2507265-1 1989 Although insulin and sulfonylureas often have additive clinical effects when used in combination for type II (non-insulin-dependent) diabetes, these results are variable and a clinical role for this approach is not yet established. Sulfonylurea Compounds 21-34 insulin Homo sapiens 114-121 2702344-7 1989 Pathogenetic aspects of the insulin independent diabetes mellitus therapy with particular reference to the role of sulfonylurea derivatives are also discussed. Sulfonylurea Compounds 115-127 insulin Homo sapiens 28-35 2771398-4 1989 Higher insulin requirement was found only with patients whose sulphonylurea resistance made later necessary the insulin therapy. Sulfonylurea Compounds 62-75 insulin Homo sapiens 7-14 2771398-4 1989 Higher insulin requirement was found only with patients whose sulphonylurea resistance made later necessary the insulin therapy. Sulfonylurea Compounds 62-75 insulin Homo sapiens 112-119 2697484-2 1989 Plasma glucose (BG) and insulin (IRI) response to glucose loading (OGTT) was investigated before and after placebo and phenobarbitone (PB) therapy in patients with glucose intolerance and NIDDM treated with diet only, sulphonylureas (SU) plus metformin (M) or insulin. Sulfonylurea Compounds 234-236 insulin Homo sapiens 0-37 2666061-7 1989 Thus, insulin-sulfonylurea treatment may be a safe and effective solution in type 2 diabetic patients with secondary failure to sulfonylureas, particularly in those with significant residual endogenous insulin secretion. Sulfonylurea Compounds 128-141 insulin Homo sapiens 6-13 3143264-4 1988 Interest in combination therapy stems in part from residual concern that hyperinsulinemia may contribute to the development of atherosclerosis, and to evidence that the sulfonylureas, especially the second-generation drugs, improve sensitivity to the glycolytic effects of insulin, thereby reducing insulin resistance. Sulfonylurea Compounds 169-182 insulin Homo sapiens 273-280 3149825-0 1988 [Effect of insulin therapy on lipoprotein concentrations in secondary sulfonylurea treatment failures in menopause]. Sulfonylurea Compounds 70-82 insulin Homo sapiens 11-18 3149825-3 1988 Sulfonylurea secondary failures in the menopause which were euglycaemic after a 6-week insulin therapy (n = 20) revealed at this date a higher HDL-cholesterol, lower triglycerides and a more favourable quotient total cholesterol/HDL-cholesterol as well as a shorter duration of diabetes than the female patients with more unfavourable condition of glycaemia (n = 20). Sulfonylurea Compounds 0-12 insulin Homo sapiens 87-94 3141755-6 1988 This study suggests that any enhancement of insulin sensitivity by sulphonylurea treatment in persons with insulin-dependent diabetes mellitus is only minor and clinically-unimportant. Sulfonylurea Compounds 67-80 insulin Homo sapiens 44-51 3054969-15 1988 Combination insulin-sulfonylurea therapy should be reserved for patients failing to achieve acceptable glycemic control when insulin and sulphonylurea are used separately. Sulfonylurea Compounds 20-32 insulin Homo sapiens 12-19 3054354-4 1988 Type II diabetics being treated with sulfonylureas also are at some increased risk of developing hypoglycemia during or following exercise, although this is less of a problem than occurs with insulin treatment. Sulfonylurea Compounds 37-50 insulin Homo sapiens 192-199 3148787-3 1988 Maintaining the effects of sulfonylurea action insulin should be added in as small amounts as possible to avoid hyperinsulinemia and to ameliorate hyperglycemia. Sulfonylurea Compounds 27-39 insulin Homo sapiens 47-54 3310252-0 1987 Combination insulin-sulfonylurea therapy in type II diabetes mellitus. Sulfonylurea Compounds 20-32 insulin Homo sapiens 12-19 3289869-4 1988 Type II (non-insulin-dependent) diabetic patients treated with sulfonylureas are also at some increased risk of developing hypoglycemia during or after exercise, although this poses less of a problem than with insulin treatment. Sulfonylurea Compounds 63-76 insulin Homo sapiens 13-20 3289869-4 1988 Type II (non-insulin-dependent) diabetic patients treated with sulfonylureas are also at some increased risk of developing hypoglycemia during or after exercise, although this poses less of a problem than with insulin treatment. Sulfonylurea Compounds 63-76 insulin Homo sapiens 210-217 3218908-0 1988 Significance of insulin receptors in the action of sulphonylurea drugs. Sulfonylurea Compounds 51-64 insulin Homo sapiens 16-23 3318259-0 1987 The addition of glipizide to insulin therapy in type-II diabetic patients with secondary failure to sulfonylureas is useful only in the presence of a significant residual insulin secretion. Sulfonylurea Compounds 100-113 insulin Homo sapiens 29-36 3041937-1 1988 The influence of sulfonylurea drugs in enhancing the effect of endogenous insulin is well documented. Sulfonylurea Compounds 17-29 insulin Homo sapiens 74-81 3073882-11 1988 The molar ratio of proinsulin to insulin was 1:6 in healthy subjects, 1:1 in insulinoma patients and 10:1 in sulphonylurea induced hypoglycaemic patients. Sulfonylurea Compounds 109-122 insulin Homo sapiens 19-29 3290919-6 1988 Insulin therapy is required for type I diabetic patients, and it may also be an appropriate therapy for all type II patients who do not become rapidly normoglycemic following diet and oral sulfonylurea treatment. Sulfonylurea Compounds 189-201 insulin Homo sapiens 0-7 3126626-0 1988 Glibenclamide improves the response to insulin treatment in non-insulin-dependent diabetics with second failure to sulfonylurea therapy. Sulfonylurea Compounds 115-127 insulin Homo sapiens 39-46 3126626-7 1988 It is suggested that therapy with insulin and glibenclamide is an appropriate treatment regimen for NIDDM patients with second failure to sulfonylurea therapy. Sulfonylurea Compounds 138-150 insulin Homo sapiens 34-41 3042339-0 1988 The combined treatment with insulin and sulfonylurea in non-insulin-dependent diabetic patients with secondary failure. Sulfonylurea Compounds 40-52 insulin Homo sapiens 60-67 3118579-0 1987 [Long-term effect of combination glibenclamide-insulin treatment in the secondary failure of sulfonylurea therapy--results of a one-year double blind study]. Sulfonylurea Compounds 93-105 insulin Homo sapiens 47-54 3315640-3 1987 Fasting serum C-peptide immunoreactivity (CPR) was significantly lower at the period of insulin treatment (SU: 1.93 +/- 1.01, insulin: 1.47 +/- 0.79 ng/ml, p less than 0.05), but there was no difference in the increase in serum CPR (maximal--fasting) (delta serum CPR) during glucagon stimulation in the two periods of treatment (SU: 1.70 +/- 0.72, insulin: 1.47 +/- 0.98 ng/ml). Sulfonylurea Compounds 107-109 insulin Homo sapiens 14-23 2959438-8 1987 In type 2 diabetic patients who continue to have fasting hyperglycaemia on maximal sulphonylurea therapy, fasting normoglycaemia can be achieved easily, without minimal changes in diet or lifestyle, by means of a basal insulin supplement. Sulfonylurea Compounds 83-96 insulin Homo sapiens 219-226 3315640-3 1987 Fasting serum C-peptide immunoreactivity (CPR) was significantly lower at the period of insulin treatment (SU: 1.93 +/- 1.01, insulin: 1.47 +/- 0.79 ng/ml, p less than 0.05), but there was no difference in the increase in serum CPR (maximal--fasting) (delta serum CPR) during glucagon stimulation in the two periods of treatment (SU: 1.70 +/- 0.72, insulin: 1.47 +/- 0.98 ng/ml). Sulfonylurea Compounds 107-109 insulin Homo sapiens 88-95 3315640-3 1987 Fasting serum C-peptide immunoreactivity (CPR) was significantly lower at the period of insulin treatment (SU: 1.93 +/- 1.01, insulin: 1.47 +/- 0.79 ng/ml, p less than 0.05), but there was no difference in the increase in serum CPR (maximal--fasting) (delta serum CPR) during glucagon stimulation in the two periods of treatment (SU: 1.70 +/- 0.72, insulin: 1.47 +/- 0.98 ng/ml). Sulfonylurea Compounds 330-332 insulin Homo sapiens 14-23 3315640-3 1987 Fasting serum C-peptide immunoreactivity (CPR) was significantly lower at the period of insulin treatment (SU: 1.93 +/- 1.01, insulin: 1.47 +/- 0.79 ng/ml, p less than 0.05), but there was no difference in the increase in serum CPR (maximal--fasting) (delta serum CPR) during glucagon stimulation in the two periods of treatment (SU: 1.70 +/- 0.72, insulin: 1.47 +/- 0.98 ng/ml). Sulfonylurea Compounds 330-332 insulin Homo sapiens 88-95 3315640-5 1987 Fasting serum CPR was significantly lower during the period of insulin treatment (insulin: 1.39 +/- 0.64, SU: 2.21 +/- 0.86 ng/ml, p less than 0.025), but delta serum CPR during glucagon stimulation still showed no significant difference between the two periods (insulin: 1.97 +/- 1.16, SU: 2.33 +/- 1.57 ng/ml). Sulfonylurea Compounds 106-108 insulin Homo sapiens 63-70 3552593-13 1987 Combined insulin and sulphonylurea drugs reduce insulin requirements only in insulin-dependent diabetics with some endogenous insulin secretion, whereas metformin reduces insulin requirement in C-peptide negative insulin-dependent diabetes mellitus. Sulfonylurea Compounds 21-34 insulin Homo sapiens 48-55 3308442-8 1987 In patients treated with sulfonylurea, the fasting ketone body level, especially 3-OHB, was significantly lower than that of diabetics treated with insulin or diet alone, whereas the fasting plasma glucose level and its postprandial increase were higher than those of the others. Sulfonylurea Compounds 25-37 insulin Homo sapiens 148-155 3310832-9 1987 After hyperglycaemic clamps at 7.5, 10 and 15 mmol/L glucose, type II diabetics both on and off sulphonylurea, were found to have lower proinsulin concentrations compared with normal subjects, commensurate with the diabetics" lower insulin responses. Sulfonylurea Compounds 96-109 insulin Homo sapiens 136-146 3304783-11 1987 Our study shows that short term insulin therapy in patients with NIDDM who had failed on diet alone has advantages over sulphonylurea therapy in that it achieves better diabetic control and an improved B-cell response to glucose stimulation. Sulfonylurea Compounds 120-133 insulin Homo sapiens 32-39 2884060-9 1987 Plasma proinsulin formed a higher percentage of the immunoreactive insulin in fasting plasma samples of both A (36%) and B (43%) than in less hyperglycaemic MODs on diet alone (26%) or sulphonylurea therapy (17%) and the glucose stimulated proinsulin content was even higher (A, 50%; B, 53%; MODs, diet, 19%; sulphonylureas, 16%). Sulfonylurea Compounds 185-198 insulin Homo sapiens 7-17 2884060-9 1987 Plasma proinsulin formed a higher percentage of the immunoreactive insulin in fasting plasma samples of both A (36%) and B (43%) than in less hyperglycaemic MODs on diet alone (26%) or sulphonylurea therapy (17%) and the glucose stimulated proinsulin content was even higher (A, 50%; B, 53%; MODs, diet, 19%; sulphonylureas, 16%). Sulfonylurea Compounds 185-198 insulin Homo sapiens 10-17 3552593-13 1987 Combined insulin and sulphonylurea drugs reduce insulin requirements only in insulin-dependent diabetics with some endogenous insulin secretion, whereas metformin reduces insulin requirement in C-peptide negative insulin-dependent diabetes mellitus. Sulfonylurea Compounds 21-34 insulin Homo sapiens 48-55 3543616-1 1987 Sulfonylureas seem to have similar mechanisms of action, including an acceleration and increase of insulin secretion, an increase of the systemic availability of insulin, and probably indirectly, an increase of insulin action. Sulfonylurea Compounds 0-13 insulin Homo sapiens 99-106 3543616-1 1987 Sulfonylureas seem to have similar mechanisms of action, including an acceleration and increase of insulin secretion, an increase of the systemic availability of insulin, and probably indirectly, an increase of insulin action. Sulfonylurea Compounds 0-13 insulin Homo sapiens 162-169 3524573-0 1986 Characterization of the sulfonylurea-induced potentiation of the insulin response in cultured 3T3 adipocytes. Sulfonylurea Compounds 24-36 insulin Homo sapiens 65-72 3553408-0 1986 Combined chlorpropamide-insulin in the treatment of non-insulin-dependent diabetes mellitus with secondary failure of sulfonylurea therapy. Sulfonylurea Compounds 118-130 insulin Homo sapiens 24-31 3545931-1 1986 We studied the influence of chronic sulfonylurea treatment on glucose metabolism and beta-cell secretory activity in diabetic patients requiring insulin after secondary failure to oral drugs. Sulfonylurea Compounds 36-48 insulin Homo sapiens 145-152 3545931-7 1986 We suggest that combining a sulfonylurea with insulin can be useful in insulin-requiring type-2 diabetics who still secrete some endogenous insulin. Sulfonylurea Compounds 28-40 insulin Homo sapiens 71-78 3545931-7 1986 We suggest that combining a sulfonylurea with insulin can be useful in insulin-requiring type-2 diabetics who still secrete some endogenous insulin. Sulfonylurea Compounds 28-40 insulin Homo sapiens 71-78 3524573-1 1986 Studies were carried out to determine the role of sulfonylureas in the regulation of insulin-sensitive hexose uptake in cultured 3T3 adipocytes. Sulfonylurea Compounds 50-63 insulin Homo sapiens 85-92 3524573-2 1986 Exposure (0-72 hr) of cells to the sulfonylurea-derivative tolbutamide (0.05-0.3 mg/ml) induced a time- and concentration-dependent potentiation of the stimulatory effect of insulin on hexose uptake (500 vs 340%). Sulfonylurea Compounds 35-47 insulin Homo sapiens 174-181 3524573-9 1986 It is concluded that sulfonylureas act by influencing synthesis of protein(s) which potentiate the effect of insulin on hexose uptake. Sulfonylurea Compounds 21-34 insulin Homo sapiens 109-116 3527524-0 1986 The effect of short term intensive insulin therapy in non-insulin-dependent diabetics who had failed on sulphonylurea therapy. Sulfonylurea Compounds 104-117 insulin Homo sapiens 35-42 3517644-6 1986 We conclude that treatment with sulfonylureas or exogenous insulin results in equivalent improvement in insulin action in patients with non-insulin-dependent diabetes mellitus. Sulfonylurea Compounds 32-45 insulin Homo sapiens 104-111 3084315-7 1986 The data suggest that the use of combined sulfonylurea and insulin therapy may be beneficial to type II diabetic patients with residual insulin secretion and poor glycemic control under insulin therapy alone. Sulfonylurea Compounds 42-54 insulin Homo sapiens 136-143 3788659-0 1986 Sulfonylurea stimulated C-peptide responses in insulin-dependent diabetic children. Sulfonylurea Compounds 0-12 insulin Homo sapiens 24-33 3901745-1 1985 Effects of sulfonylureas on insulin receptors. Sulfonylurea Compounds 11-24 insulin Homo sapiens 28-35 3936738-1 1985 The effect of sulphonylurea therapy for 3 weeks on glucose-stimulated insulin secretion and insulin resistance was studied in Type 2 diabetic patients. Sulfonylurea Compounds 14-27 insulin Homo sapiens 70-77 3936738-3 1985 At this isoglycaemic level (mean 11 mmol/l), plasma insulin levels increased from 6.9 mU/l on diet alone to 12.1 mU/l on sulphonylurea treatment (p less than 0.01). Sulfonylurea Compounds 121-134 insulin Homo sapiens 52-59 3891264-2 1985 Some physicians initially treat patients having non-insulin-dependent diabetes with oral sulfonylureas because they fear greater compliance problems with insulin therapy. Sulfonylurea Compounds 89-102 insulin Homo sapiens 52-59 3923028-1 1985 To assess whether the beneficial effects of salicylates compounds and sulfonylureas on insulin secretion in patients with noninsulin-dependent diabetes mellitus could be ascribed to inhibition of prostaglandin E (PGE) synthesis, insulin responses to iv glucose pulses were determined in diabetic patients during infusion of lysine acetylsalicylate (LAS) or tolbutamide, with or without a concurrent infusion of PGE2. Sulfonylurea Compounds 70-83 insulin Homo sapiens 87-94 3931463-2 1985 In adipocytes from patients with type II non-insulin-dependent diabetes, there is increasing evidence indicating that sulfonylureas ameliorate a post-receptor defect in insulin action by potentiating the insulin-stimulated glucose transport normally seen in these cells. Sulfonylurea Compounds 118-131 insulin Homo sapiens 45-52 3931463-2 1985 In adipocytes from patients with type II non-insulin-dependent diabetes, there is increasing evidence indicating that sulfonylureas ameliorate a post-receptor defect in insulin action by potentiating the insulin-stimulated glucose transport normally seen in these cells. Sulfonylurea Compounds 118-131 insulin Homo sapiens 169-176 3931463-7 1985 This suggests that the molecular mechanism of sulfonylurea-enhanced insulin-stimulated glucose transport is the recruitment of glucose transporters from an intracellular microsomal storage pool to the plasma membrane. Sulfonylurea Compounds 46-58 insulin Homo sapiens 68-75 3902422-1 1985 Sulfonylurea agents have been well documented to be effective in type II diabetes mellitus by increasing insulin secretion as well as by enhancing cellular binding of endogenous insulin. Sulfonylurea Compounds 0-12 insulin Homo sapiens 105-112 2994471-3 1985 Failure to control blood sugar levels with sulfonylurea drugs may lead to combining this therapy with insulin or administering insulin alone, regardless of patients" weights. Sulfonylurea Compounds 43-55 insulin Homo sapiens 102-109 2994471-3 1985 Failure to control blood sugar levels with sulfonylurea drugs may lead to combining this therapy with insulin or administering insulin alone, regardless of patients" weights. Sulfonylurea Compounds 43-55 insulin Homo sapiens 127-134 3920907-0 1985 Serum C-peptide levels determine glycemic responses in type II diabetic patients treated with combined insulin and sulfonylurea agent. Sulfonylurea Compounds 115-127 insulin Homo sapiens 6-15 2951064-0 1985 Effect of sulphonylurea administration on insulin secretion and amino acid metabolism in non-insulin-dependent diabetic patients. Sulfonylurea Compounds 10-23 insulin Homo sapiens 42-49 3918399-0 1985 Reversal of insulin resistance in adipose tissue of non-insulin-dependent diabetics by treatment with diet and sulphonylurea. Sulfonylurea Compounds 111-124 insulin Homo sapiens 12-19 6434794-2 1984 Recently in vitro evidence has been presented that sulfonylurea derivatives exert their chronic extrapancreatic effect by increasing the number of cellular insulin receptors. Sulfonylurea Compounds 51-63 insulin Homo sapiens 156-163 2578686-1 1985 We describe insulin binding and insulin-mediated RNA synthesis on seven human fibroblasts strains in culture initiated from skin biopsies in the presence of three oral antidiabetic agents, Metformin, Gliquidone, and a non-sulfonylurea antidiabetic drug (B X DF 591 ZW), which belong to different chemical classes. Sulfonylurea Compounds 222-234 insulin Homo sapiens 32-39 6398258-1 1984 Indirect evidence suggests that sulfonylureas, in addition to stimulating insulin release, exert additional effects at extrapancreatic levels which are of value in the management of type 2 diabetes. Sulfonylurea Compounds 32-45 insulin Homo sapiens 74-81 6398258-7 1984 In the absence of endogenous insulin release, these data strongly suggest that the two sulfonylureas employed enhance in vivo the peripheral sensitivity to insulin. Sulfonylurea Compounds 87-100 insulin Homo sapiens 156-163 6434794-11 1984 It is concluded that sulfonylurea treatment is a valuable adjunct in reducing the insulin resistance in insulin treated type II diabetics. Sulfonylurea Compounds 21-33 insulin Homo sapiens 82-89 6428842-0 1984 Sulfonylureas improve insulin binding and insulin action in non-insulin-dependent diabetes mellitus. Sulfonylurea Compounds 0-13 insulin Homo sapiens 22-29 6428120-7 1984 The mechanism of this action is due at least partly to sulphonylurea-induced stimulation of endogenous insulin secretion. Sulfonylurea Compounds 55-68 insulin Homo sapiens 103-110 6376026-6 1984 During sulfonylurea therapy this effect initially causes an increase in insulin level. Sulfonylurea Compounds 7-19 insulin Homo sapiens 72-79 6376026-8 1984 In NIDD patients with mild to moderate hyperglycemia (fasting plasma glucose less than 200 mg/dl), chronic sulfonylurea therapy results in the maintenance of near-normal insulin levels, but at a lower plasma glucose level. Sulfonylurea Compounds 107-119 insulin Homo sapiens 170-177 6428842-0 1984 Sulfonylureas improve insulin binding and insulin action in non-insulin-dependent diabetes mellitus. Sulfonylurea Compounds 0-13 insulin Homo sapiens 42-49 6376026-9 1984 In patients with more severely impaired B-cell function, whose insulin levels before therapy are subnormal despite marked hyperglycemia, there is a net absolute increase in insulin levels during chronic sulfonylurea administration. Sulfonylurea Compounds 203-215 insulin Homo sapiens 63-70 6376026-9 1984 In patients with more severely impaired B-cell function, whose insulin levels before therapy are subnormal despite marked hyperglycemia, there is a net absolute increase in insulin levels during chronic sulfonylurea administration. Sulfonylurea Compounds 203-215 insulin Homo sapiens 173-180 6376026-10 1984 Thus, some NIDD patients may show an increase in basal insulin levels during chronic sulfonylurea therapy while others may not; however, all patients who respond to sulfonylureas demonstrate increased B-cell sensitivity to glucose. Sulfonylurea Compounds 85-97 insulin Homo sapiens 55-62 6376031-4 1984 Not all insulin-sensitive tissues and processes are equally affected by sulfonylureas. Sulfonylurea Compounds 72-85 insulin Homo sapiens 8-15 6376031-6 1984 Impairment of proinsulin biosynthesis and in some instances inhibition of nutrient-stimulated insulin secretion may follow chronic (greater than several months) administration of sulfonylureas. Sulfonylurea Compounds 179-192 insulin Homo sapiens 14-24 6376031-7 1984 The acute sulfonylurea-stimulated secretion of insulin is probably the result of sulfonylurea binding to the beta cell plasma membrane followed by alterations in ionic fluxes. Sulfonylurea Compounds 10-22 insulin Homo sapiens 47-54 6376031-7 1984 The acute sulfonylurea-stimulated secretion of insulin is probably the result of sulfonylurea binding to the beta cell plasma membrane followed by alterations in ionic fluxes. Sulfonylurea Compounds 81-93 insulin Homo sapiens 47-54 6376033-0 1984 The impact of sulfonylurea treatment upon the mechanisms responsible for the insulin resistance in type II diabetes. Sulfonylurea Compounds 14-26 insulin Homo sapiens 77-84 6376034-0 1984 Prolonged sulfonylurea administration decreases insulin resistance and increases insulin secretion in non-insulin-dependent diabetes mellitus: evidence for improved insulin action at a postreceptor site in hepatic as well as extrahepatic tissues. Sulfonylurea Compounds 10-22 insulin Homo sapiens 48-55 6376034-0 1984 Prolonged sulfonylurea administration decreases insulin resistance and increases insulin secretion in non-insulin-dependent diabetes mellitus: evidence for improved insulin action at a postreceptor site in hepatic as well as extrahepatic tissues. Sulfonylurea Compounds 10-22 insulin Homo sapiens 81-88 6376034-1 1984 To determine whether long-term sulfonylurea therapy ameliorates glucose homeostasis in patients with NIDDM predominantly by improving insulin secretion or by improving insulin action, we evaluated changes in fasting plasma glucose concentrations, intravenous glucose tolerance, glucose-stimulated insulin secretion, facilitation of glucose disposal by exogenous insulin, and erythrocyte insulin receptor binding before and after prolonged (congruent to 4 mo) administration of tolazamide to 18 patients with NIDDM. Sulfonylurea Compounds 31-43 insulin Homo sapiens 134-141 6734405-0 1984 Effects of biguanides and sulfonylureas on insulin receptors in cultured cells. Sulfonylurea Compounds 26-39 insulin Homo sapiens 43-50 6428842-4 1984 In our studies we have found that sulfonylureas possess a selective regulatory in vivo effect on the cellular insulin binding to monocytes, independent of the diet and changes in plasma glucose and insulin concentrations. Sulfonylurea Compounds 34-47 insulin Homo sapiens 110-117 6428842-5 1984 Furthermore, we found in in vitro studies that sulfonylureas affect the insulin receptors in a direct way. Sulfonylurea Compounds 47-60 insulin Homo sapiens 72-79 6428842-6 1984 Thus, insulin binding to monocytes was increased during sulfonylurea treatment in both normal volunteers and patients with NIDDM. Sulfonylurea Compounds 56-68 insulin Homo sapiens 6-13 6428842-7 1984 On the other hand, sulfonylureas seem to improve insulin action in NIDDM patients only. Sulfonylurea Compounds 19-32 insulin Homo sapiens 49-56 6428842-8 1984 We conclude that the increased insulin binding in patients with NIDDM, induced by sulfonylurea treatment, may be of importance for the improved insulin action found in these patients. Sulfonylurea Compounds 82-94 insulin Homo sapiens 31-38 6428842-8 1984 We conclude that the increased insulin binding in patients with NIDDM, induced by sulfonylurea treatment, may be of importance for the improved insulin action found in these patients. Sulfonylurea Compounds 82-94 insulin Homo sapiens 144-151 6428844-0 1984 Oral sulfonylurea agents suppress hepatic glucose production in non-insulin-dependent diabetic individuals. Sulfonylurea Compounds 5-17 insulin Homo sapiens 68-75 6428111-1 1984 The common denominator of the numerous data collected from experimental studies on isolated organs, on healthy subjects and on diabetic patients, is a specific effect of sulfonylureas on insulin release in the presence (or absence) of glucose. Sulfonylurea Compounds 170-183 insulin Homo sapiens 187-194 6421560-0 1984 [Combination therapy with insulin and sulfonylurea in secondary failure of sulfonylurea therapy]. Sulfonylurea Compounds 75-87 insulin Homo sapiens 26-33 6421560-6 1984 Combination treatment with sulphonylurea and insulin in secondary failures thus, in the short term, reduces insulin requirement; but in the long term it is not significantly different from insulin treatment alone. Sulfonylurea Compounds 27-40 insulin Homo sapiens 108-115 6421560-6 1984 Combination treatment with sulphonylurea and insulin in secondary failures thus, in the short term, reduces insulin requirement; but in the long term it is not significantly different from insulin treatment alone. Sulfonylurea Compounds 27-40 insulin Homo sapiens 108-115 6373546-0 1984 The effect of sulphonylurea therapy on in vivo insulin sensitivity in non-insulin dependent diabetics. Sulfonylurea Compounds 14-27 insulin Homo sapiens 47-54 6337181-5 1983 These results are consistent with the hypothesis that sulfonylureas suppress glucagon secretion by augmenting insulin secretion, an effect that falling glucose levels can mask. Sulfonylurea Compounds 54-67 insulin Homo sapiens 110-117 6320319-1 1983 The concept that hypoglycemic sulfonylureas stimulate Ca2+ inflow and insulin release in the pancreatic B-cell by causing the gating of voltage-sensitive Ca2+ channels was tested by comparing the cationic and secretory response of perifused pancreatic islets to gliclazide and/or an increase in extracellular K+ concentration. Sulfonylurea Compounds 30-43 insulin Homo sapiens 70-77 6320319-5 1983 These findings support the view that the depolarization of the B-cell membrane plays a critical role in the stimulus-secretion coupling of sulfonylurea-induced insulin release. Sulfonylurea Compounds 139-151 insulin Homo sapiens 160-167 6191388-4 1983 Sulfonylureas may enhance insulin sensitivity of peripheral tissues, particularly by raising the decreased number of insulin receptors in type II diabetics. Sulfonylurea Compounds 0-13 insulin Homo sapiens 26-33 6191388-4 1983 Sulfonylureas may enhance insulin sensitivity of peripheral tissues, particularly by raising the decreased number of insulin receptors in type II diabetics. Sulfonylurea Compounds 0-13 insulin Homo sapiens 117-124 6191388-8 1983 Pointers in the same direction emerged from our own results in a study on the influence of sulfonylureas added to insulin therapy on insulin sensitivity in type I diabetics. Sulfonylurea Compounds 91-104 insulin Homo sapiens 133-140 6430037-0 1984 Effect of sulfonylurea on glucose, insulin and C-peptide responses to a meal stimulus in a patient with type 2 diabetes and liver disease. Sulfonylurea Compounds 10-22 insulin Homo sapiens 47-56 6430037-1 1984 The influence of two sulfonylureas on blood glucose and plasma immunoreactive insulin (IRI) and C-peptide responses to a standardized meal was investigated in a patient with type 2 diabetes and a liver disease with enhanced peripheral levels of liver enzymes. Sulfonylurea Compounds 21-34 insulin Homo sapiens 78-85 6430037-5 1984 Sulfonylureas thus seem to have beneficial effects in this diabetic patient, who had a liver disease and markedly elevated basal levels of plasma IRI and C-peptide concentrations. Sulfonylurea Compounds 0-13 insulin Homo sapiens 154-163 6369972-4 1983 Successful treatment of noninsulin-dependent diabetes mellitus with sulfonylureas is associated with onset of of the disease at 40 years of age or later, normal or increased body weight, duration of disease less than five years, and a history of either no previous insulin therapy or therapy with less than 20 units of insulin per day. Sulfonylurea Compounds 68-81 insulin Homo sapiens 27-34 6369972-4 1983 Successful treatment of noninsulin-dependent diabetes mellitus with sulfonylureas is associated with onset of of the disease at 40 years of age or later, normal or increased body weight, duration of disease less than five years, and a history of either no previous insulin therapy or therapy with less than 20 units of insulin per day. Sulfonylurea Compounds 68-81 insulin Homo sapiens 265-272 6360742-7 1983 Twenty-nine of the 35 insulin-treated Type 2 diabetics had secondary failure to sulfonylureas and were treated with insulin at the time of the study. Sulfonylurea Compounds 80-93 insulin Homo sapiens 22-29 6354732-1 1983 Several studies have indicated that the long-term effectiveness of sulfonylurea therapy in the treatment of type-II diabetics is due to a potentiation of insulin action. Sulfonylurea Compounds 67-79 insulin Homo sapiens 154-161 6401922-7 1983 In addition, sulfonylureas enhanced stimulation of hexose uptake by the insulin mimickers, hydrogen peroxide and vitamin K5. Sulfonylurea Compounds 13-26 insulin Homo sapiens 72-79 6337482-2 1983 The effects of diet, exercise, sulfonylurea compounds, and exogenous insulin on in vivo insulin-stimulated glucose uptake have been reviewed in this presentation. Sulfonylurea Compounds 31-43 insulin Homo sapiens 88-95 6401923-0 1983 Insulin resistance in noninsulin-dependent diabetes mellitus: impact of sulfonylurea agents in vivo and in vitro. Sulfonylurea Compounds 72-84 insulin Homo sapiens 0-7 6401923-5 1983 Therapy with the second-generation sulfonylurea compound glyburide enhances overall insulin responsiveness without altering insulin binding. Sulfonylurea Compounds 35-47 insulin Homo sapiens 84-91 6759246-4 1982 Mean (+/- SEM) fasting plasma insulin levels increased slightly from 15 +/- 2 micronU/ml following sulfonylurea treatment, and the total plasma insulin response to the test meal increased by 63%. Sulfonylurea Compounds 99-111 insulin Homo sapiens 30-37 7155128-6 1982 The data indicate that the Ca2+ fluxes associated with sulfonylurea-stimulated insulin secretion do not result from the Ca2+ -ionophoretic properties of the drugs but rather reflect depolarization of the beta-cells. Sulfonylurea Compounds 55-67 insulin Homo sapiens 79-86 6800910-0 1982 Comparison of diurnal serum insulin levels during short term treatments with sulfonylurea and with insulin in non-insulin dependent diabetes. Sulfonylurea Compounds 77-89 insulin Homo sapiens 28-35 7047169-0 1982 Influence of sulfonylureas on the secretion, disposal and effect of insulin. Sulfonylurea Compounds 13-26 insulin Homo sapiens 68-75 7033271-0 1982 Comparison of the in vitro effect of biguanides and sulfonylureas on insulin binding of its receptors in target cells. Sulfonylurea Compounds 52-65 insulin Homo sapiens 69-76 7340695-4 1981 Similarly non-insulin-dependent, maturity onset diabetics, even without overweight, have low numbers of binding sites, which are increased by diet or after treatment by sulfonylureas. Sulfonylurea Compounds 169-182 insulin Homo sapiens 14-21 7033271-1 1982 The in vitro effects of two biguanides (phenformin and metformin) and four sulfonylureas (tolbutamide, glyburide, gliclazide, and glisolamide) on insulin binding to its receptors were studied in four cultured cell lines: human skin fibroblasts, IM-9 lymphoblasts, MCF-7 human mammary carcinoma, and H35 rat hepatoma. Sulfonylurea Compounds 75-88 insulin Homo sapiens 146-153 7033271-9 1982 Therefore, these studies suggest that: 1) in vitro, biguanides enhance insulin binding to its receptors in a variety of cell types; 2) this effect of biguanides doesn"t depend on new receptor synthesis; it is a result of changes in the affinity of the insulin receptor; and 3) in contrast to the biguanides, the sulfonylureas do not have a major direct effect on insulin binding to its receptors in most cell types. Sulfonylurea Compounds 312-325 insulin Homo sapiens 252-259 7046346-0 1981 Effects of sulfonylurea on the secretion and disposition of insulin and C-peptide. Sulfonylurea Compounds 11-23 insulin Homo sapiens 60-67 7028551-8 1981 These findings suggest that changes in basal or pre-stimulus plasma glucose during therapy with sulphonylurea drugs may be expected to influence the second phase insulin responses to glucose challenge. Sulfonylurea Compounds 96-109 insulin Homo sapiens 162-169 522809-2 1979 Serum insulin was measured after maximal stimulation in 213 patients with apparent secondary failure of treatment with sulfonylureas. Sulfonylurea Compounds 119-132 insulin Homo sapiens 6-13 6247604-3 1980 Intravenous infusion of verapamil, an organic antagonist of calcium transport into cells, produced a marked and significant inhibition of glucose-, glucagon- and sulfonylurea-induced increases in serum insulin in normal subjects. Sulfonylurea Compounds 162-174 insulin Homo sapiens 202-209 6990182-4 1980 Insulin action may be increased by sulfonylureas, possibly by alterations in intracellular cyclic AMP content, or by weight-reducing diets. Sulfonylurea Compounds 35-48 insulin Homo sapiens 0-7 6990182-5 1980 Insulin secretion may be increased by gastrointestinal hormones, sulfonylureas, serotonin antagonists, or weight-reducing diets. Sulfonylurea Compounds 65-78 insulin Homo sapiens 0-7 6776763-7 1980 In accordance with the augmented physiologic insulin release in the morning, a single morning dose of sulfonylureas may be the preferable dosage regimen in the treatment of elderly insulin-independent diabetics of moderate degree. Sulfonylurea Compounds 102-115 insulin Homo sapiens 45-52 6776763-7 1980 In accordance with the augmented physiologic insulin release in the morning, a single morning dose of sulfonylureas may be the preferable dosage regimen in the treatment of elderly insulin-independent diabetics of moderate degree. Sulfonylurea Compounds 102-115 insulin Homo sapiens 181-188 6772676-0 1980 Direct in vitro effect of a sulfonylurea to increase human fibroblast insulin receptors. Sulfonylurea Compounds 28-40 insulin Homo sapiens 70-77 6772676-7 1980 These findings may explain the well known extrapancreatic effect of sulfonylurea agents to improve insulin-mediated tissue glucose metabolism. Sulfonylurea Compounds 68-80 insulin Homo sapiens 99-106 522809-5 1979 Following conclusions were drawn: Sulfonylurea treatment is indicated if the increase of serum insulin is more than 300%. Sulfonylurea Compounds 34-46 insulin Homo sapiens 95-102 522809-7 1979 The determination of serum insulin after maximal stimulation in patients with apparent secondary failure of sulfonylurea treatment has a diagnostic as well as a prognostic value. Sulfonylurea Compounds 108-120 insulin Homo sapiens 27-34 111449-1 1979 The effect of two second generation sulphonylureas, gliquidone and glibenclamide, on insulin secretion has been studied in the basal state and in combination with glucose infusions in normal controls, patients with mild maturity-onset diabetes, and subjects with normal glucose tolerance but low insulin response. Sulfonylurea Compounds 36-50 insulin Homo sapiens 85-92 111449-7 1979 Addition of sulphonylurea induced a left shift in the dose-response relationships in controls and low insulin responders; under these conditions the effect of glibenclamide was more pronounced than that of gliquidone. Sulfonylurea Compounds 12-25 insulin Homo sapiens 102-109 478080-0 1979 Effects of long term sulfonylurea therapy on plasma insulin and fasting lipid levels. Sulfonylurea Compounds 21-33 insulin Homo sapiens 52-59 445991-3 1979 Recent studies investigating the mechanism of action of sulfonylurea drugs show that these agents probably exert their antidiabetic action by increasing insulin sensitivity and ameliorating the insulin resistance, rather than by increasing insulin secretion. Sulfonylurea Compounds 56-68 insulin Homo sapiens 153-160 573232-2 1979 There was no significant difference in blood glucose concentration between the two groups although serum insulin concentration was significantly higher in the group treated by sulphonylurea therapy alone. Sulfonylurea Compounds 176-189 insulin Homo sapiens 105-112 445991-3 1979 Recent studies investigating the mechanism of action of sulfonylurea drugs show that these agents probably exert their antidiabetic action by increasing insulin sensitivity and ameliorating the insulin resistance, rather than by increasing insulin secretion. Sulfonylurea Compounds 56-68 insulin Homo sapiens 194-201 445991-3 1979 Recent studies investigating the mechanism of action of sulfonylurea drugs show that these agents probably exert their antidiabetic action by increasing insulin sensitivity and ameliorating the insulin resistance, rather than by increasing insulin secretion. Sulfonylurea Compounds 56-68 insulin Homo sapiens 194-201 415745-10 1978 The significance of the one-chain precursor of insulin as a part of the sulfonylurea stimulated total insulin for glucose depression is discussed. Sulfonylurea Compounds 72-84 insulin Homo sapiens 47-54 582980-3 1979 insulin injection and after the release of endogenous insulin release induced by sulfonylurea derivates. Sulfonylurea Compounds 81-93 insulin Homo sapiens 0-7 582980-3 1979 insulin injection and after the release of endogenous insulin release induced by sulfonylurea derivates. Sulfonylurea Compounds 81-93 insulin Homo sapiens 54-61 752036-7 1978 Seven patients, in whom an insulin test was repeated after treatment with insulin, sulfonylurea, or diet had a small rise in peak plasma glucagon and an increase in the integrated area under the glucagon response curve. Sulfonylurea Compounds 83-95 insulin Homo sapiens 27-34 415745-10 1978 The significance of the one-chain precursor of insulin as a part of the sulfonylurea stimulated total insulin for glucose depression is discussed. Sulfonylurea Compounds 72-84 insulin Homo sapiens 102-109 179924-6 1976 Hypoglycemic reactions in patients being treated with oral anti-diabetic agents, on the other hand, should be regarded primarily as one of the side reactions intrinsic to the mechanism of action of some of these drugs, e.g. sulfonylureas, which act mainly via stimulation of secretion of endogenous insulin reserves not responding properly to postprandial blood glucose increments. Sulfonylurea Compounds 224-237 insulin Homo sapiens 299-306 930951-6 1977 The administration of diazoxide was effective in our patient, substantially reducing the plasma insulin level; this agent may be the "insulin-antagonist" of choice for use in sulfonylurea-induced hypoglycemia. Sulfonylurea Compounds 175-187 insulin Homo sapiens 134-141 903405-0 1977 Potentiation of insulin action: a probable mechanism for the anti-diabetic action of sulfonylurea drugs. Sulfonylurea Compounds 85-97 insulin Homo sapiens 16-23 903405-1 1977 Insulin action was assessed by measuring insulin-mediated glucose disposal (KI) in 13 non-ketotic diabetic patients both before treatment and after normalization of plasma glucose by diet (5 patients) or sulfonylurea (glipizide) therapy (8 patients). Sulfonylurea Compounds 204-216 insulin Homo sapiens 0-7 187516-5 1977 Insulin treatment of ketotic diabetes resulted in a rapid increase in the activity of LPL and decrease in serum triglycerdie level, whereas sulfonylurea treatment of non-insulin-requiring diabetics did not significantly influence the enzyme activity. Sulfonylurea Compounds 140-152 insulin Homo sapiens 170-177 337336-2 1977 The indication for sulfonylureas is symptomatic maturity-onset diabetes or excessive hyperglycemia--fasting blood sugar over 300 mg per 100 ml--in the elderly patient who cannot or will not take insulin. Sulfonylurea Compounds 19-32 insulin Homo sapiens 195-202 327147-3 1977 Moreover it was proved whether high levels of insulin would suppress the reactivity of the B-cell to sulphonylurea administration. Sulfonylurea Compounds 101-114 insulin Homo sapiens 46-53 1258487-5 1976 These results are a further indication that sulphonylurea agents should be administered only in the case of certain specific types of diabetes, because no therapeutic response can be expected in diabetes caused by insulinopenia and insulin resistance. Sulfonylurea Compounds 44-57 insulin Homo sapiens 214-221 175653-0 1976 Effects of sulfonylurea therapy on insulin binding to mononuclear leukocytes of diabetic patients. Sulfonylurea Compounds 11-23 insulin Homo sapiens 35-42 1233019-3 1975 Sulfonylureas furthering the secretion of insulin are to be used only as far as necessary. Sulfonylurea Compounds 0-13 insulin Homo sapiens 42-49 986008-0 1976 Circular dichroism studies on the interaction of sulfonylureas with insulin. Sulfonylurea Compounds 49-62 insulin Homo sapiens 68-75 986008-2 1976 It was found that all sulfonylureas investigated decrease the ellipticity band of insulin at 208 nm, whereas the band at 222 nm remains unaffected. Sulfonylurea Compounds 22-35 insulin Homo sapiens 82-89 4579624-0 1972 [Effect of a new sulfonylurea on insulin and glucagon secretion in the isolated perfused pancreas]. Sulfonylurea Compounds 17-29 insulin Homo sapiens 33-40 4573352-3 1973 In order to assess the participation of the microfilamentous cell web in the multiphasic response of the pancreatic beta cell, the effect of cytochalasin B upon both glucose- and sulfonylurea-induced insulin release was investigated in the perfused isolated pancreas. Sulfonylurea Compounds 179-191 insulin Homo sapiens 200-207 4208215-0 1973 [Insulin secretion following combined administration of glucose and different sulfonylurea compounds in equipotential doses in metabolically healthy persons]. Sulfonylurea Compounds 78-90 insulin Homo sapiens 1-8 4790140-0 1973 [Dose dependance of insulin liberated in early phase following sulfonylurea administration]. Sulfonylurea Compounds 63-75 insulin Homo sapiens 20-27 4353086-10 1973 The sulphonylureas, tolbutamide and glibenclamide, agents that increase insulin release, also increased the protein kinase activity; however, leucine, arginine and xylitol, which also stimulate insulin release, were without effect on the kinase activity. Sulfonylurea Compounds 4-18 insulin Homo sapiens 72-79 4212270-0 1973 Proceedings: Mechanism of insulin release: an approach to the mode of action of sulfonylurea. Sulfonylurea Compounds 80-92 insulin Homo sapiens 26-33 4203274-0 1973 [Secretion of insulin under the influence of sulfonylurea derivates (SH)]. Sulfonylurea Compounds 45-57 insulin Homo sapiens 14-21 5052977-0 1972 Effect of chronic sulfonylurea therapy on plasma insulin and proinsulin levels. Sulfonylurea Compounds 18-30 insulin Homo sapiens 49-56 5052977-0 1972 Effect of chronic sulfonylurea therapy on plasma insulin and proinsulin levels. Sulfonylurea Compounds 18-30 insulin Homo sapiens 61-71 5155895-0 1971 [Insulin, glucose and free fatty acids in the serum of healthy and diabetic subjects following solitary oral dose of the sulfonylurea derivative glibornuride]. Sulfonylurea Compounds 121-133 insulin Homo sapiens 1-8 4198780-0 1972 [Insulin secretion after oral and intravenous administration of various 1st and 2d generation sulfonylurea derivatives in equipotential dosage]. Sulfonylurea Compounds 94-106 insulin Homo sapiens 1-8 13473490-0 1957 [Casuistical contributions to the effect of sulfonylurea in various special forms of diabetes mellitus: steroid diabetes, diabetes with hemochromatosis, renal diabetes & diabetes with a high insulin resistance]. Sulfonylurea Compounds 44-56 insulin Homo sapiens 195-202 6072678-0 1967 [The presence of insulin antibodies and the influence on insulin-protein binding of sulfonylurea and glycodiazine]. Sulfonylurea Compounds 84-96 insulin Homo sapiens 57-64 13910496-0 1962 Quantitative effects of glucose, sulfonylureas, salicylate, and indole-3-acetic acid on the secretion of insulin activity into pancreatic venous blood. Sulfonylurea Compounds 33-46 insulin Homo sapiens 105-112 4990729-0 1970 [Serum insulin level after long-term therapy with sulphonyl ureas]. Sulfonylurea Compounds 50-65 insulin Homo sapiens 7-14 4945612-0 1970 [Arterial insulin after intravenous injection of a sulfonylurea derivative as a basis of quantitative analysis of early insulin incretion]. Sulfonylurea Compounds 51-63 insulin Homo sapiens 10-17 4945612-0 1970 [Arterial insulin after intravenous injection of a sulfonylurea derivative as a basis of quantitative analysis of early insulin incretion]. Sulfonylurea Compounds 51-63 insulin Homo sapiens 120-127 5346206-0 1969 Diurnal change of plasma insulin in diabetics with sulfonylurea treatment. Sulfonylurea Compounds 51-63 insulin Homo sapiens 25-32 4875710-0 1968 Insulin secretory blockade by benzothiadiazines and catecholamines: reversal by sulfonylureas. Sulfonylurea Compounds 80-93 insulin Homo sapiens 0-7 13637593-0 1959 The relationship between the mechanism of action of the sulfonylureas and the secretion of insulin into the portal circulation. Sulfonylurea Compounds 56-69 insulin Homo sapiens 91-98 13416370-0 1957 The hypoglycemic response to insulin in man after sulfonylurea by mouth. Sulfonylurea Compounds 50-62 insulin Homo sapiens 29-36 33464705-0 2021 An adult patient with permanent neonatal diabetes successfully discontinued insulin therapy after initiating sitagliptin added to sulphonylurea. Sulfonylurea Compounds 130-143 insulin Homo sapiens 76-83 33832649-7 2021 Since the different mutations result in diverse clinical presentations, patients usually need different treatments that range from just diet and exercise, to the requirement of exogenous insulin or other hypoglycemic drugs, e.g., sulfonylureas or glucagon-like peptide 1 analogs to control their glycemia. Sulfonylurea Compounds 230-243 insulin Homo sapiens 187-194 32594655-8 2021 On the other hand, HbA1c (beta = -0.398, P < 0.001) and use of antidiabetic drugs potentially associated with severe hypoglycemia (beta = 0.180, P = 0.028), such as sulfonylureas, glinides and insulin, were useful explanatory factors for TBR in the elderly patients with T2DM. Sulfonylurea Compounds 165-178 insulin Homo sapiens 193-200 32356495-6 2020 Of great importance, some of the identified genes encode proteins that can be therapeutically targeted by drugs per os, leading to transitioning from insulin to sulfonylureas. Sulfonylurea Compounds 161-174 insulin Homo sapiens 150-157 30213710-4 2020 RESULTS: A significant linear trend was associated with HbA1c levels and CAD events in the diet-only group, and CAD risks were significantly higher in insulin and SU groups with HbA1c <= 7.0% and > 8.0% than in the diet-only group with HbA1c <= 7.0%. Sulfonylurea Compounds 2-4 insulin Homo sapiens 151-158 32728893-10 2020 Results were consistent in models further adjusted for medications and comorbidities (myocardial infarction, stroke, peripheral artery disease, heart failure, atrial fibrillation, cancer), with sulfonylurea and insulin associated with increased mortality rates (from cause-specific hazard ratio of 1.06 [95% CI 0.99, 1.14] for cancer death with use of sulfonylurea to 1.42 [1.29, 1.56] for cardiovascular death with use of insulin). Sulfonylurea Compounds 194-206 insulin Homo sapiens 423-430 32728893-10 2020 Results were consistent in models further adjusted for medications and comorbidities (myocardial infarction, stroke, peripheral artery disease, heart failure, atrial fibrillation, cancer), with sulfonylurea and insulin associated with increased mortality rates (from cause-specific hazard ratio of 1.06 [95% CI 0.99, 1.14] for cancer death with use of sulfonylurea to 1.42 [1.29, 1.56] for cardiovascular death with use of insulin). Sulfonylurea Compounds 352-364 insulin Homo sapiens 211-218 33102403-11 2020 90% of the patients with an ABCC8 or KCNJ11 mutation as well as those with 6q24 anomalies are amenable to a successful switch from insulin injection to oral sulfonylureas. Sulfonylurea Compounds 157-170 insulin Homo sapiens 131-138 32518064-3 2020 The effect of SUs together with GIP or GLP-1, respectively, on insulin and glucagon secretion in patients with HNF1A diabetes is currently unknown. Sulfonylurea Compounds 14-17 insulin Homo sapiens 63-70 32518064-6 2020 Our study suggests that a combination of SU and incretin-based treatment may be efficacious in patients with HNF1A diabetes via potentiation of glucose-stimulated insulin secretion. Sulfonylurea Compounds 41-43 insulin Homo sapiens 163-170 31884929-4 2020 Over the past half century, these drugs, together with the subsequent non-sulfonylureas (glinides), have been the main oral drugs for insulin secretion. Sulfonylurea Compounds 74-87 insulin Homo sapiens 134-141 32598150-0 2020 Structural Determinants of Insulin Release: Disordered N-Terminal Tail of Kir6.2 Affects Potassium Channel Dynamics Through Interactions With Sulfonylurea Binding Region in a SUR1 Partner. Sulfonylurea Compounds 142-154 insulin Homo sapiens 27-34 32656029-3 2020 Insulin secretagogues such as sulfonylureas are associated with a high risk of hypoglycemia among diabetics. Sulfonylurea Compounds 30-43 insulin Homo sapiens 0-7 31390154-3 2020 After genetic diagnosis, insulin therapy was successfully transitioned to oral sulfonylurea therapy. Sulfonylurea Compounds 79-91 insulin Homo sapiens 25-32 32802709-1 2020 Abstract: Dipeptidyl peptidase-4 inhibitors (DPP-4Is) are one of the most frequently prescribed anti-diabetic agents in Japan, and they are often used in combination with insulin secretagogues, such as sulfonylureas and glinides. Sulfonylurea Compounds 202-215 insulin Homo sapiens 171-178 31956961-3 2020 Sodium-glucose cotransporter 2 (SGLT2) inhibitors lower insulin levels and sulfonylureas increase insulin levels, while both lower glucose levels. Sulfonylurea Compounds 75-88 insulin Homo sapiens 98-105 31566370-1 2020 Sulfonylureas and glinides are commonly used oral insulin secretagogues (ISs) that act on the pancreatic ATP-sensitive potassium (KATP) channel to promote insulin secretion in order to lower the blood glucose level. Sulfonylurea Compounds 0-13 insulin Homo sapiens 50-57 31566370-1 2020 Sulfonylureas and glinides are commonly used oral insulin secretagogues (ISs) that act on the pancreatic ATP-sensitive potassium (KATP) channel to promote insulin secretion in order to lower the blood glucose level. Sulfonylurea Compounds 0-13 insulin Homo sapiens 155-162 31567175-1 2020 BACKGROUND: Since the discovery of insulin, it was the only drug available for the treatment of diabetes until the development of sulfonylureas and biguanides 50 years later. Sulfonylurea Compounds 130-143 insulin Homo sapiens 35-42 27099902-8 2000 Endogenous hyperinsulinism is supported by insulin >=3 uU/mL, c-peptide >=0.2 nmol/L, proinsulin >=5 pmol/L, beta-hydroxybutyrate <=2.7 mmol/L and undetectable sulfonylurea/meglitinide in the setting of hypoglycemia. Sulfonylurea Compounds 172-184 insulin Homo sapiens 16-23 31562829-9 2020 CONCLUSIONS: Low-dose sulfonylurea therapy resulted in stable glycaemic control and the elimination of hypoglycaemic episodes attributable to insulin therapy. Sulfonylurea Compounds 22-34 insulin Homo sapiens 142-149 32001615-6 2020 Those with the homozygous variant had low hs-CRP levels (0.2-0.8 mg/L), and those tested demonstrated sensitivity to sulfonylurea given at a low dose, completely transitioning off insulin. Sulfonylurea Compounds 117-129 insulin Homo sapiens 180-187 31884929-7 2020 RESULT: Sulfonylureas and glinides not only stimulated the release of insulin from pancreatic cells, but also had many extrapanular hypoglycemic effect, such as reducing the clearance rate of insulin in liver, reducing the secretion of glucagon, and enhancing the sensitivity of peripheral tissues to insulin in type 2 diabetes mellitus. Sulfonylurea Compounds 8-21 insulin Homo sapiens 70-77 31884929-7 2020 RESULT: Sulfonylureas and glinides not only stimulated the release of insulin from pancreatic cells, but also had many extrapanular hypoglycemic effect, such as reducing the clearance rate of insulin in liver, reducing the secretion of glucagon, and enhancing the sensitivity of peripheral tissues to insulin in type 2 diabetes mellitus. Sulfonylurea Compounds 8-21 insulin Homo sapiens 192-199 31884929-7 2020 RESULT: Sulfonylureas and glinides not only stimulated the release of insulin from pancreatic cells, but also had many extrapanular hypoglycemic effect, such as reducing the clearance rate of insulin in liver, reducing the secretion of glucagon, and enhancing the sensitivity of peripheral tissues to insulin in type 2 diabetes mellitus. Sulfonylurea Compounds 8-21 insulin Homo sapiens 192-199 31649868-11 2019 Conclusion: Sulfonylureas and insulin through the insulin osteocalcin pathway show favorable effect on bone health, but the probability of increased fractures secondary to hypoglycemic falls should be borne in mind. Sulfonylurea Compounds 12-25 insulin Homo sapiens 50-57 32201446-0 2020 Fasting insulin levels correlate with the frequency of hypoglycemic events in people with type 2 diabetes on treatment with sulfonylureas: A pilot study. Sulfonylurea Compounds 124-137 insulin Homo sapiens 8-15 32201446-1 2020 AIMS AND OBJECTIVES: We aimed to explore whether fasting insulin levels correlate with the risk of hypoglycemia in people with Type 2 diabetes (T2D) receiving sulfonylureas (SUs). Sulfonylurea Compounds 159-172 insulin Homo sapiens 57-64 32201446-1 2020 AIMS AND OBJECTIVES: We aimed to explore whether fasting insulin levels correlate with the risk of hypoglycemia in people with Type 2 diabetes (T2D) receiving sulfonylureas (SUs). Sulfonylurea Compounds 174-177 insulin Homo sapiens 57-64 32201446-5 2020 CONCLUSION: Our results suggest that fasting insulin levels might be a predictor of the risk of hypoglycemia in people with T2D on treatment with SUs. Sulfonylurea Compounds 146-149 insulin Homo sapiens 45-52 31908791-10 2019 Conclusions: Individuals with sulfonylurea-treated KCNJ11 PNDM produce similar levels of insulin in response to both carbohydrate and protein/fat meals despite carbohydrate resulting in much higher glucose levels and protein/fat resulting in relatively low glucose levels. Sulfonylurea Compounds 30-42 insulin Homo sapiens 89-96 31828167-2 2019 It remains to be fully elucidated whether the use of metformin, an insulin sensitizer, and/or sulfonylureas, insulin secretagogues, affects cancer incidence in subjects with type 2 diabetes mellitus. Sulfonylurea Compounds 94-107 insulin Homo sapiens 109-116 31908791-0 2019 Patterns of postmeal insulin secretion in individuals with sulfonylurea-treated KCNJ11 neonatal diabetes show predominance of non-KATP-channel pathways. Sulfonylurea Compounds 59-71 insulin Homo sapiens 21-28 31908791-1 2019 Objective: Insulin secretion in sulfonylurea-treated KCNJ11 permanent neonatal diabetes mellitus (PNDM) is thought to be mediated predominantly through amplifying non-KATP-channel pathways such as incretins. Sulfonylurea Compounds 32-44 insulin Homo sapiens 11-18 31336501-8 2019 Results from available RCTs and observational studies in patients with type 2 diabetes showed lower risk of hypoglycemia, similar or better efficacy for glycemic and weight control with SGLT2 inhibitors, incretin mimetics and the newer insulin analogues compared to Sulfonylurea. Sulfonylurea Compounds 266-278 insulin Homo sapiens 236-243 31237133-1 2019 BACKGROUND: We aimed to investigate the effectiveness and safety of adding basal insulin to initiating dipeptidyl peptidase-4 (DPP-4) inhibitor and metformin and/or sulfonylurea (SU) in achieving the target glycosylated hemoglobin (HbA1c) in patients with type 2 diabetes mellitus (T2DM). Sulfonylurea Compounds 179-181 insulin Homo sapiens 81-88 30689785-2 2019 Iatrogenic hypoglycemia as a result of treatment with insulin or sulfonylureas is the most common cause of hypoglycemia in humans and is generally only seen in patients with diabetes who take these medications. Sulfonylurea Compounds 65-78 insulin Homo sapiens 54-61 30242599-0 2019 MIR4532 gene variant rs60432575 influences the expression of KCNJ11 and the sulfonylureas-stimulated insulin secretion. Sulfonylurea Compounds 76-89 insulin Homo sapiens 101-108 30242599-5 2019 We studied whether the genetic polymorphisms of MIR4532 rs60452575 would influence KCNJ11 expression and sulfonylurea-stimulated insulin secretion or not. Sulfonylurea Compounds 105-117 insulin Homo sapiens 129-136 30242599-7 2019 RESULTS: MIR4532 rs60452575 G>A variant appeared to disrupt the repression of KCNJ11 expression in both cell lines, and reduce the sulfonylurea-stimulated insulin secretion by breaking the binding of the hsa-miR-4532 to 3" UTR of KCNJ11 in MIN6 cells. Sulfonylurea Compounds 131-143 insulin Homo sapiens 155-162 30465123-8 2019 Thiazolidinediones, insulin secretagogues (sulfonylureas, meglitinides), and insulins are associated with weight gain. Sulfonylurea Compounds 43-56 insulin Homo sapiens 20-27 31326458-1 2019 AIM: The aim of this study was to analyze the efficacy, insulin sensitivity and safety in the event of administering sulfonylurea-based drugs and metformin in combination with basal insulin. Sulfonylurea Compounds 117-129 insulin Homo sapiens 56-63 31059802-6 2019 Adding patient preferences for treatment burden associated with insulin injections shifted the probability to favor SU over insulin (probability range, using conditional logit weights: 0.01-0.12). Sulfonylurea Compounds 116-118 insulin Homo sapiens 64-71 31196892-2 2019 The treatment of NDM may differ depending on the genetic etiology, with numerous studies showing the benefit of sulfonylurea therapy in cases caused by mutations in KCNJ11 or ABCC8 Mutations in the insulin gene (INS) have also been identified as causes of NDM; these cases are generally best treated with insulin alone. Sulfonylurea Compounds 112-124 insulin Homo sapiens 198-205 31196892-2 2019 The treatment of NDM may differ depending on the genetic etiology, with numerous studies showing the benefit of sulfonylurea therapy in cases caused by mutations in KCNJ11 or ABCC8 Mutations in the insulin gene (INS) have also been identified as causes of NDM; these cases are generally best treated with insulin alone. Sulfonylurea Compounds 112-124 insulin Homo sapiens 305-312 31231590-4 2019 Sulfonylureas enhance insulin release from pancreatic B-cells through binding to sulfonylurea receptor 1, encoded by ABCC8 gene. Sulfonylurea Compounds 0-13 insulin Homo sapiens 22-29 30115526-7 2018 Patients with 9-years duration of diabetes or with combination therapy of insulin-metformin-sulfonylureas differed in mean BMI for adequate or inadequate glycaemic control (29.5 versus 31.2kg/m2; P<0.001 and 29.8 versus 33.2; P<0.01, respectively). Sulfonylurea Compounds 92-105 insulin Homo sapiens 74-81 31366755-1 2019 Sulfonylureas, a potent stimulator of insulin release from pancreatic beta cells, can cause hypoglycemia, which is apt to recur with a prolonged duration in elderly patients. Sulfonylurea Compounds 0-13 insulin Homo sapiens 38-45 30264528-6 2018 CONCLUSION: The differences in hypoglycaemic risk among people with Type 2 diabetes prescribed insulin and/or sulfonylureas warrant further investigation of any differing biological responses and/or cultural attitudes to antidiabetes therapy among ethnic groups, and should be considered by clinicians evaluating the treatment goals of people with Type 2 diabetes using insulins or sulfonylureas. Sulfonylurea Compounds 382-395 insulin Homo sapiens 95-102 29675256-0 2018 A case with relapsed transient neonatal diabetes mellitus treated with sulfonylurea, ending chronic insulin requirement. Sulfonylurea Compounds 71-83 insulin Homo sapiens 100-107 30327785-8 2018 Results of tree analysis showed that patients on sulphonylurea, with high HbA1c, eGFR below 50 ml/min/1.73 m2, and at least 5-year disease duration, are at very high risk to start insulin treatment. Sulfonylurea Compounds 49-62 insulin Homo sapiens 180-187 29896782-2 2018 Complete transfer to sulfonylureas is not successful in all cases and can result in insulin monotherapy. Sulfonylurea Compounds 21-34 insulin Homo sapiens 84-91 30800266-2 2019 After the advent of long-acting insulin, the first oral agents, sulfonylureas became available in the mid-1950s, quickly followed (outside of the United States) by metformin. Sulfonylurea Compounds 64-77 insulin Homo sapiens 32-39 30062227-3 2018 In both randomized clinical trials and observational studies, antihyperglycemic drugs that act through insulin signaling (i.e., sulfonylureas, thiazolidinediones, and incretins) increase the risk or worsen the clinical course of heart failure, whereas drugs that ameliorate hyperinsulinemia and do not signal through insulin (i.e., metformin and sodium-glucose cotransporter 2 inhibitors) reduce the risk of heart failure. Sulfonylurea Compounds 128-141 insulin Homo sapiens 103-110 30062227-3 2018 In both randomized clinical trials and observational studies, antihyperglycemic drugs that act through insulin signaling (i.e., sulfonylureas, thiazolidinediones, and incretins) increase the risk or worsen the clinical course of heart failure, whereas drugs that ameliorate hyperinsulinemia and do not signal through insulin (i.e., metformin and sodium-glucose cotransporter 2 inhibitors) reduce the risk of heart failure. Sulfonylurea Compounds 128-141 insulin Homo sapiens 279-286 29675256-7 2018 Learning points: Genetic testing should be considered in any individuals or family with diabetes that occurred within the first year or so of life.Sulfonylurea can achieve good glycaemic control in patients with KATP channel mutations by restoring endogenous insulin secretion, even if they were treated with insulin for decades.Early screening and genetic testing are important to improve the prognosis of patients with neonatal diabetes mellitus arising from ABCC8 or KCNJ11 mutation. Sulfonylurea Compounds 147-159 insulin Homo sapiens 259-266 29675256-7 2018 Learning points: Genetic testing should be considered in any individuals or family with diabetes that occurred within the first year or so of life.Sulfonylurea can achieve good glycaemic control in patients with KATP channel mutations by restoring endogenous insulin secretion, even if they were treated with insulin for decades.Early screening and genetic testing are important to improve the prognosis of patients with neonatal diabetes mellitus arising from ABCC8 or KCNJ11 mutation. Sulfonylurea Compounds 147-159 insulin Homo sapiens 309-316 29805453-4 2018 In the primary evaluations, insulinoma was suspected considering the high plasma concentrations of insulin and C-peptide, besides negative urine and plasma sulfonylureas during hypoglycemic episodes. Sulfonylurea Compounds 156-169 insulin Homo sapiens 28-35 29305569-4 2018 However, this empiric sulfonylurea trial did not improve the patient"s glycemic control and resulted in resistance to exogenous insulin. Sulfonylurea Compounds 22-34 insulin Homo sapiens 128-135 29681852-1 2018 The treatment of Type 2 Diabetes Mellitus (T2DM) consists primarily of oral antidiabetic drugs (OADs) that stimulate insulin secretion, such as sulfonylureas (SUs) and reduce hepatic glucose production (e.g., biguanides), among others. Sulfonylurea Compounds 144-157 insulin Homo sapiens 117-124 29278452-2 2018 We aimed to compare sulfonylurea therapy with insulin treatment in two sulfonylurea-sensitive individuals with a KCNJ11 mutation who had poorly controlled permanent neonatal diabetes mellitus. Sulfonylurea Compounds 71-83 insulin Homo sapiens 46-53 28456998-6 2017 Several groups of drugs with different mechanisms of action, mostly prescribed orally, are used for the treatment of type 2 diabetes mellitus including, insulin sensitizers (thiazolidinediones), insulin secretagogues (sulfonylureas), and biguanides. Sulfonylurea Compounds 218-231 insulin Homo sapiens 195-202 29049639-3 2017 Adding a sulfonylurea or metformin to insulin was associated with a decrease in hemoglobin A1c of approximately 1.0%. Sulfonylurea Compounds 9-21 insulin Homo sapiens 38-45 28111849-1 2017 BACKGROUND: Patients with early onset diabetes because of defects in glucose-stimulated insulin secretion (GSIS) may respond better to sulfonylureas than insulin treatment. Sulfonylurea Compounds 135-148 insulin Homo sapiens 88-95 29108837-11 2017 With third-line treatment, advanced age and renal comorbidity were associated with the use of SU + insulin (NL, ES, UK). Sulfonylurea Compounds 94-98 insulin Homo sapiens 99-106 28880474-1 2017 Insulin secretagogues including sulfonylureas, glinides and incretin-related drugs such as dipeptidyl peptidase 4 (DPP-4) inhibitors and glucagon-like peptide-1 receptor agonists are widely used for treatment of type 2 diabetes. Sulfonylurea Compounds 32-45 insulin Homo sapiens 0-7 28295962-4 2017 Current strategies aim to improve glycaemic control, either by promoting endogenous insulin secretion, such as sulfonylureas, or by mechanisms that may impact the beta cell indirectly, for example, providing beta-cell rest through insulin treatment. Sulfonylurea Compounds 111-124 insulin Homo sapiens 84-91 28556992-5 2017 Due to the risk of stimulating increased insulin secretion in utero, we recommend that in women with HNF1A/ HNF4A maturity-onset diabetes of the young, those with good glycaemic control who are on a sulfonylurea per conception either transfer to insulin before conception (at the risk of a short-term deterioration of glycaemic control) or continue with sulfonylurea (glibenclamide) treatment in the first trimester and transfer to insulin in the second trimester. Sulfonylurea Compounds 199-211 insulin Homo sapiens 41-48 31149195-0 2017 PATIENTS TREATED WITH INSULIN AND SULPHONYLUREA ARE AT INCREASED MORTALITY RISK AS COMPARED WITH THOSE TREATED WITH INSULIN PLUS METFORMIN. Sulfonylurea Compounds 34-47 insulin Homo sapiens 116-123 28083968-0 2017 First case of neonatal diabetes with KCNJ11 Q52R mutation successfully switched from insulin to sulphonylurea treatment. Sulfonylurea Compounds 96-109 insulin Homo sapiens 85-92 28587604-5 2017 Because mutations of these genes could affect insulin secretion stimulated by sulfonylureas, the aim of this study is to assess associations between molecular variants of KCNJ11, ABCC8 and TCF7L2 genes and response to sulfonylurea treatment and to predict their potential functional effects. Sulfonylurea Compounds 78-91 insulin Homo sapiens 46-53 28587604-5 2017 Because mutations of these genes could affect insulin secretion stimulated by sulfonylureas, the aim of this study is to assess associations between molecular variants of KCNJ11, ABCC8 and TCF7L2 genes and response to sulfonylurea treatment and to predict their potential functional effects. Sulfonylurea Compounds 78-90 insulin Homo sapiens 46-53 28092788-9 2017 Insulin doses were higher when either insulin was added to sulfonylurea alone. Sulfonylurea Compounds 59-71 insulin Homo sapiens 0-7 27766795-0 2016 Reduction of Sulfonylurea with the Initiation of Basal Insulin in Patients with Inadequately Controlled Type 2 Diabetes Mellitus Undergoing Long-Term Sulfonylurea-Based Treatment. Sulfonylurea Compounds 13-25 insulin Homo sapiens 55-62 28431776-2 2017 It belongs to the sulfonylurea class that stimulates insulin secretion from pancreatic beta-cells by inhibiting ATP-dependent potassium channels. Sulfonylurea Compounds 18-30 insulin Homo sapiens 53-60 28093996-9 2017 Thiazolidinediones are known as insulin sensitizers and are effective for a longer duration in comparison to sulfonylureas, however, have side effects such as fluid retention, edema and heart failure. Sulfonylurea Compounds 109-122 insulin Homo sapiens 32-39 27766795-0 2016 Reduction of Sulfonylurea with the Initiation of Basal Insulin in Patients with Inadequately Controlled Type 2 Diabetes Mellitus Undergoing Long-Term Sulfonylurea-Based Treatment. Sulfonylurea Compounds 150-162 insulin Homo sapiens 55-62 27766795-2 2016 In this study, we aimed to evaluate the recovery of beta-cell function and the efficacy of concurrent sulfonylurea use after the start of long-acting insulin. Sulfonylurea Compounds 102-114 insulin Homo sapiens 150-157 27766795-12 2016 CONCLUSION: Long-acting basal insulin replacement could improve the glycemic status and restore beta-cell function in the T2DM patients undergoing sulfonylurea-based treatment, irrespective of the sulfonylurea dose reduction. Sulfonylurea Compounds 147-159 insulin Homo sapiens 30-37 27374266-11 2016 Because of the increased cardiovascular mortality associated with hypoglycemias, the long-term use of insulin or insulin-secretory agents (sulfonylureas, glinides) must be limited. Sulfonylurea Compounds 139-152 insulin Homo sapiens 113-120 27640062-14 2016 Only one trial assessed patients" treatment satisfaction and showed no substantial differences between the addition of either glimepiride or metformin and glimepiride to insulin compared with insulin monotherapy.Insulin-sulphonylurea combination therapy (CT) compared with insulin monotherapy (IM) showed a MD in glycosylated haemoglobin A1c (HbA1c) of -1% (95% confidence interval (CI) -1.6 to -0.5); P < 0.01; 316 participants; 9 trials; low-quality evidence. Sulfonylurea Compounds 220-233 insulin Homo sapiens 212-219 27175740-13 2016 Insulin use and hypoglycemia were associated with sulfonylurea therapy change. Sulfonylurea Compounds 50-62 insulin Homo sapiens 0-7 27329029-10 2016 Five of the patients with an ABCC8 or KCNJ11 mutation have successfully transferred from insulin to glibenclamide whist 1 child demonstrated a partial response to sulfonylurea treatment. Sulfonylurea Compounds 163-175 insulin Homo sapiens 89-96 26831749-9 2016 Moreover, as showed in the first two case-reports, when the treatment was switched from insulin to glibenclamide, according to identification of Kir 6.2 mutation and diagnosis of NPDM, the CSII therapy demonstrated to be helpful in allowing gradual insulin suspension and progressive introduction of sulfonylurea. Sulfonylurea Compounds 300-312 insulin Homo sapiens 88-95 26831749-9 2016 Moreover, as showed in the first two case-reports, when the treatment was switched from insulin to glibenclamide, according to identification of Kir 6.2 mutation and diagnosis of NPDM, the CSII therapy demonstrated to be helpful in allowing gradual insulin suspension and progressive introduction of sulfonylurea. Sulfonylurea Compounds 300-312 insulin Homo sapiens 249-256 27513562-8 2016 After a median follow-up of 1,357 days, the incidence of MI was significant increase in patients taking sulfonylureas (HR = 1.523, 95% confidence interval [CI] = 1.331-1.744), meglitinides (HR = 1.251, 95% CI = 1.048-1.494) and TZD (HR = 1.515, 95% CI = 1.071-2.145) by using patients receiving insulin therapy as the reference group. Sulfonylurea Compounds 104-117 insulin Homo sapiens 295-302 27033559-1 2016 AIMS/HYPOTHESIS: The finding that patients with diabetes due to potassium channel mutations can transfer from insulin to sulfonylureas has revolutionised the management of patients with permanent neonatal diabetes. Sulfonylurea Compounds 121-134 insulin Homo sapiens 110-117 27592478-3 2016 Glimepiride is a second-generation sulfonylurea excites pancreatic beta cells to discharge insulin. Sulfonylurea Compounds 35-47 insulin Homo sapiens 91-98 27327605-0 2016 Within-Sulfonylurea-Class Evaluation of Time to Intensification with Insulin (ZODIAC-43). Sulfonylurea Compounds 7-19 insulin Homo sapiens 69-76 26986544-5 2016 Vocational drivers were more likely to be treated with an insulin secretagogue (sulfonylureas and glinides) (52%) than diet alone (18%), a non-insulin secretagogue (26%) or insulin (16%). Sulfonylurea Compounds 80-93 insulin Homo sapiens 58-65 27033559-9 2016 RESULTS: In all, 112 out of 127 (88%) patients successfully transferred to sulfonylureas from insulin with an improvement in HbA1c from 8.2% (66 mmol/mol) on insulin, to 5.9% (41 mmol/mol) on sulphonylureas (p = 0.001). Sulfonylurea Compounds 75-88 insulin Homo sapiens 94-101 27033559-9 2016 RESULTS: In all, 112 out of 127 (88%) patients successfully transferred to sulfonylureas from insulin with an improvement in HbA1c from 8.2% (66 mmol/mol) on insulin, to 5.9% (41 mmol/mol) on sulphonylureas (p = 0.001). Sulfonylurea Compounds 75-88 insulin Homo sapiens 158-165 27033559-9 2016 RESULTS: In all, 112 out of 127 (88%) patients successfully transferred to sulfonylureas from insulin with an improvement in HbA1c from 8.2% (66 mmol/mol) on insulin, to 5.9% (41 mmol/mol) on sulphonylureas (p = 0.001). Sulfonylurea Compounds 192-206 insulin Homo sapiens 94-101 26811361-13 2016 INTERPRETATION: Among patients using metformin who could use either insulin or sulfonylurea, the addition of insulin was associated with a higher risk of hypoglycemia than the addition of sulfonylurea. Sulfonylurea Compounds 79-91 insulin Homo sapiens 109-116 26921160-3 2016 OBJECTIVE: To compare risk of cardiovascular disease (CVD) and hypoglycemia between sulfonylurea initiators who switch to or add insulin. Sulfonylurea Compounds 84-96 insulin Homo sapiens 129-136 26992707-0 2016 Capsule Commentary on Min et al., Comparative Effectiveness of Insulin versus Combination Sulfonylurea and Insulin: a Cohort Study of Veterans with Type 2 Diabetes: How to Escalate Therapy for Patients who Fail Sulfonylureas. Sulfonylurea Compounds 211-224 insulin Homo sapiens 63-70 26822262-3 2016 Due to the molecular diagnosis, the change from insulin to sulfonylurea therapy was performed successfully. Sulfonylurea Compounds 59-71 insulin Homo sapiens 48-55 26740120-2 2016 Anti-hyperglycemic treatments for type 2 diabetes mellitus that induce hyperinsulinemia (i.e., sulfonylureas) are thought to increase cancer risk, whereas treatments that lower insulin resistance and hyperinsulinemia (i.e., metformin) are considered cancer prevention strategies. Sulfonylurea Compounds 95-108 insulin Homo sapiens 76-83 31149081-6 2016 Conclusion: Screening for KCNJ 11 gene mutations could lead to identification of patients with mutations who can be successfully shifted from insulin therapy to sulfonylurea treatment improving their quality of life. Sulfonylurea Compounds 161-173 insulin Homo sapiens 142-149 26547662-2 2016 Among users of long-acting insulin, we conducted a population-based case-control study to evaluate the incident myocardial infarction (MI) and incident stroke risks associated with the use of sulfonylureas and the use of metformin. Sulfonylurea Compounds 192-205 insulin Homo sapiens 27-34 26132275-8 2015 The current results indicate that the combined use of small doses of a peripherally acting alpha2-adrenoceptor antagonist with a sulphonylurea drug could provide a novel option for the treatment of type 2 diabetes, especially in patients with increased tonic alpha2-adrenoceptor-mediated inhibition of insulin secretion. Sulfonylurea Compounds 129-142 insulin Homo sapiens 302-309 26881467-5 2016 EXPERT OPINION: New insulin secretagogues should offer major advantages over sulfonylureas and gliptins. Sulfonylurea Compounds 77-90 insulin Homo sapiens 20-27 26331221-2 2015 Sulfonylureas promote KATP closure and stimulate insulin secretion, being an alternative therapy in PNDM, instead of insulin. Sulfonylurea Compounds 0-13 insulin Homo sapiens 49-56 26579078-5 2015 Furthermore, anti-diabetic treatments such as metformin and sulfonylurea have been observed to modulate the gut microbiota or at least their metabolic profiles, thereby potentially affecting insulin resistance through indirect mechanisms still unknown. Sulfonylurea Compounds 60-72 insulin Homo sapiens 191-198 26013675-5 2015 The risk of HCC increased with increasing duration of insulin use (OR = 2.52 for <1 year, 5.41 for 1-2 years, and 6.01 for >=2 years; p for trend < 0.001), while no clear pattern with duration was observed for sulfonylureas, repaglinide, and metformin. Sulfonylurea Compounds 219-232 insulin Homo sapiens 54-61 25962401-0 2015 Progression to insulin therapy among patients with type 2 diabetes treated with sitagliptin or sulphonylurea plus metformin dual therapy. Sulfonylurea Compounds 95-108 insulin Homo sapiens 15-22 26142890-7 2015 RESULTS: The predictive parameters (sensitivity, specificity, PPV, and NPV) for improvements in HbA1c at week 24 for metformin were 0.83, 0.81, 0.44, and 0.96; for sulfonylurea, 0.79, 0.94, 0.71, and 0.96; and for insulin glargine, 0.67, 0.89, 0.65, and 0.90. Sulfonylurea Compounds 164-176 insulin Homo sapiens 214-221 26548081-4 2015 In the present study, we explored the binding interactions of antidiabetic drugs i.e., sulfonylurea drugs (glimepiride, glipizide, glyburide) and rapid acting insulin secretagogues viz., nateglinide, repaglinide and rosiglitazone; and Pgp inhibitors i.e., Generation I (verapamil and tamoxifen), III (tetradrine and tariquidar), and natural inhibitors (fumagillin and piperine) in mouse Pgp model. Sulfonylurea Compounds 87-99 insulin Homo sapiens 159-166 25893855-3 2015 In addition to insulin and its secretogogues, such as sulfonylureas, there are agents that improve insulin action, reduce gastric emptying, reduce glucagon concentrations, and sympathetic nervous system activity. Sulfonylurea Compounds 54-67 insulin Homo sapiens 15-22 25877689-1 2015 AIMS/HYPOTHESIS: Individuals with heterozygous activating mutations of the KCNJ11 gene encoding a subunit of the ATP-sensitive potassium channel (KATP) can usually be treated with oral sulfonylurea (SU) pills in lieu of insulin injections. Sulfonylurea Compounds 185-197 insulin Homo sapiens 220-227 25877689-11 2015 Declining sensitivity to SU may be due to loss of beta cell mass over time in those treated with insulin. Sulfonylurea Compounds 25-27 insulin Homo sapiens 97-104 26316711-7 2015 RESULTS: Sulfonylureas in combination (P=0.002) and sulfonylurea monotherapy (P<0.001) were found to be associated with good glycemic control, whereas insulin in combination (P=0.051), and combination biguanides and insulin therapy (P=0.012) were found to be associated with poor glycemic control. Sulfonylurea Compounds 9-22 insulin Homo sapiens 219-226 25325279-9 2015 Patients with dominant insulin resistance may be good candidates for switching from a sulfonylurea to sitagliptin to reduce hypoglycemia. Sulfonylurea Compounds 86-98 insulin Homo sapiens 23-30 25483937-6 2015 HbA1c was highest with insulin treatment (insulin = 58 mmol/mol, 7.5%; sulfonylurea = 55 mmol/mol, 7.2%; meglitinides = 52 mmol/mol, 6.9%; P = 0.008), whereas weight (BMI SD score), serum lipids and blood pressure were not different. Sulfonylurea Compounds 71-83 insulin Homo sapiens 23-30 26445623-8 2015 RESULTS: Adding sulphonylurea to metformin targeted both insulin resistance and insulin deficiency. Sulfonylurea Compounds 16-29 insulin Homo sapiens 57-64 25765720-6 2015 RESULTS: Insulin and C-peptide levels were increased (p<0.05) during euglycemia in both sulfonylurea groups as compared to placebo. Sulfonylurea Compounds 91-103 insulin Homo sapiens 9-16 25744824-1 2015 Azobenzene photoresponsive elements can be installed on sulfonylureas, yielding optical control over pancreatic beta cell function and insulin release. Sulfonylurea Compounds 56-69 insulin Homo sapiens 135-142 25796278-3 2015 However, with the introduction of incretin type insulin secretagogues it is often arises, whether is still there a place for sulfonylureas in the today"s therapy. Sulfonylurea Compounds 125-138 insulin Homo sapiens 48-55 26024708-4 2015 A 63-year-old female was diagnosed to have diabetes mellitus six years ago, she was given metformin and sulphonylurea to control her glycemia, she had adequate glycemic control for many years, but thereafter, the patient has experienced hypoglycemia after cessation of the treatment since 8 months ago and was hospitalized for further examination, endogenous hypoglycemia was confirmed and the level of serum insulin and C-peptide were elevated. Sulfonylurea Compounds 104-117 insulin Homo sapiens 409-416 25767401-0 2015 Withdrawal of sulfonylureas from patients with type 2 diabetes receiving long-term sulfonylurea and insulin combination therapy results in deterioration of glycemic control: a randomized controlled trial. Sulfonylurea Compounds 14-27 insulin Homo sapiens 100-107 25767401-0 2015 Withdrawal of sulfonylureas from patients with type 2 diabetes receiving long-term sulfonylurea and insulin combination therapy results in deterioration of glycemic control: a randomized controlled trial. Sulfonylurea Compounds 14-26 insulin Homo sapiens 100-107 25767401-11 2015 CONCLUSION: Withdrawal of SU from patients with type 2 diabetes receiving long-term combination treatment with SU and insulin resulted in deterioration of glycemic control and insulin secretion. Sulfonylurea Compounds 26-28 insulin Homo sapiens 118-125 24809622-3 2015 RESULTS: The most common OADs in use were insulin secretagogues (70.2%) such as sulfonylureas (SUs; 42.7%) or glinides (27.5%), followed by metformin (53.7%), alpha-glucosidase inhibitors (35.9%), thiazolidinediones (17.2%), and dipeptidyl peptidase-4 (DPP-4) inhibitors (0.8%). Sulfonylurea Compounds 80-93 insulin Homo sapiens 42-49 25812368-5 2015 In addition, basal insulin therapy could be switched to the combination therapy with DPP-4 inhibitor and sulfonyl- urea in Japanese type 2 diabetes in cases where insulin secretion capacity is sufficiently preserved. Sulfonylurea Compounds 105-119 insulin Homo sapiens 19-26 26024708-4 2015 A 63-year-old female was diagnosed to have diabetes mellitus six years ago, she was given metformin and sulphonylurea to control her glycemia, she had adequate glycemic control for many years, but thereafter, the patient has experienced hypoglycemia after cessation of the treatment since 8 months ago and was hospitalized for further examination, endogenous hypoglycemia was confirmed and the level of serum insulin and C-peptide were elevated. Sulfonylurea Compounds 104-117 insulin Homo sapiens 421-430 25213702-8 2014 The proportion of LADA patients requiring insulin was significantly higher in the group of subjects treated also with sulfonylurea in the first year from diagnosis compared with those treated with diet and/or insulin sensitizers (P<0.001). Sulfonylurea Compounds 118-130 insulin Homo sapiens 42-49 26664768-1 2015 Insulin, proinsulin, and C-peptide levels increase with sulfonylurea exposure but the acuity of increase has not been described in dialysis patients. Sulfonylurea Compounds 56-68 insulin Homo sapiens 0-7 26664768-1 2015 Insulin, proinsulin, and C-peptide levels increase with sulfonylurea exposure but the acuity of increase has not been described in dialysis patients. Sulfonylurea Compounds 56-68 insulin Homo sapiens 9-19 26664768-9 2015 The 72-hour fast conducted gives insight into the clearance of insulin, proinsulin, and C-peptide after sulfonylurea ingestion in ESRD. Sulfonylurea Compounds 104-116 insulin Homo sapiens 63-70 25205223-6 2015 RESULTS: A total of 11,081 patients used SU + insulin and 16,910 used metformin + insulin. Sulfonylurea Compounds 41-45 insulin Homo sapiens 46-53 25205223-8 2015 SU + insulin was associated with higher mortality rates compared with metformin + insulin (76-126 vs 23 per 1,000 person-years). Sulfonylurea Compounds 0-4 insulin Homo sapiens 5-12 25205223-9 2015 In adjusted analyses, SU + insulin was associated with increased all-cause mortality (RR 1.81 [1.63, 2.01]), cardiovascular death (RR 1.35 [1.14, 1.60]) and the composite endpoint (RR 1.25 [1.09, 1.42]) compared with metformin + insulin. Sulfonylurea Compounds 22-26 insulin Homo sapiens 27-34 25205223-9 2015 In adjusted analyses, SU + insulin was associated with increased all-cause mortality (RR 1.81 [1.63, 2.01]), cardiovascular death (RR 1.35 [1.14, 1.60]) and the composite endpoint (RR 1.25 [1.09, 1.42]) compared with metformin + insulin. Sulfonylurea Compounds 22-26 insulin Homo sapiens 229-236 25205223-10 2015 Hypoglycaemia was more frequent with SU + insulin than with metformin + insulin (17-23 vs six events per 1,000 person-years) and was associated with increased mortality (RR 2.13 [1.97, 2.37]). Sulfonylurea Compounds 37-41 insulin Homo sapiens 42-49 25205223-12 2015 CONCLUSIONS/INTERPRETATION: In combination with insulin, the use of SUs was associated with increased mortality compared with metformin. Sulfonylurea Compounds 68-71 insulin Homo sapiens 48-55 26106623-4 2015 Treatment with insulin sensitizing medications such as thiazolidinediones and metformin was more effective in improving glycemic control, particularly in the more insulin resistant patient, when compared to the insulin provision strategy using insulin and or sulfonylureas. Sulfonylurea Compounds 259-272 insulin Homo sapiens 15-22 25213702-10 2014 CONCLUSIONS: High GADA titer, BMI <= 25, ZnT8 and IA-2IC positivity and sulfonylurea treatment, in the first year from diagnosis, significantly increase the progression toward insulin requirement in LADA patients. Sulfonylurea Compounds 75-87 insulin Homo sapiens 179-186 27200691-0 2014 Factors Associated With Discontinuation of Sulfonylurea Therapy In Type 2 Diabetes Patients Who Initiate Insulin. Sulfonylurea Compounds 43-55 insulin Homo sapiens 105-112 25238204-5 2014 MAIN OUTCOME MEASURES: Response to sulfonylurea (determined by whether insulin could be discontinued) and treatment side effects in those treated empirically. Sulfonylurea Compounds 35-47 insulin Homo sapiens 71-78 25238204-10 2014 A genetic cause was subsequently found in eight cases, and insulin was discontinued within 14 days of sulfonylurea initiation in all of these cases. Sulfonylurea Compounds 102-114 insulin Homo sapiens 59-66 27200692-0 2014 Impact of Hypoglycemia on Discontinuing or Down-Titrating Sulfonylurea Among Type 2 Diabetes Patients Without Insulin. Sulfonylurea Compounds 58-70 insulin Homo sapiens 110-117 24931673-6 2014 We note that insulin therapy and an additional hour of exercise will reduce the patient s need for sulfonylureas. Sulfonylurea Compounds 99-112 insulin Homo sapiens 13-20 25311795-0 2014 Optical control of insulin release using a photoswitchable sulfonylurea. Sulfonylurea Compounds 59-71 insulin Homo sapiens 19-26 25311795-2 2014 Through their actions on ATP-sensitive potassium (KATP) channels, sulfonylureas boost insulin release from the pancreatic beta cell mass to restore glucose homeostasis. Sulfonylurea Compounds 66-79 insulin Homo sapiens 86-93 24876433-4 2014 Insulin treatment was started in 394 (4.3%) metformin and in 162 (14.5%) sulfonylurea users within 6 years (P < .001). Sulfonylurea Compounds 73-85 insulin Homo sapiens 0-7 24876433-6 2014 A substantial eGFR decline (category: 15-<30 ml/min/1.73 m(2)) was significantly associated with a higher likelihood to have insulin initiated (adjusted hazard ratio [HR]: 2.39; 95% CI: 1.09-5.23) in metformin but not in sulfonylurea (HR: 0.45; 95% CI: 0.16-1.30) users. Sulfonylurea Compounds 224-236 insulin Homo sapiens 128-135 24876433-7 2014 New users of sulfonylurea monotherapy in primary care practices in Germany were about 3-fold more likely to start insulin therapy than those with metformin. Sulfonylurea Compounds 13-25 insulin Homo sapiens 114-121 23959658-6 2014 Metabolic control provided by low-dose sulfonylurea therapy is likely due to early age at transition from insulin to sulfonylurea therapy and possible preservation of endogenous insulin secretion. Sulfonylurea Compounds 39-51 insulin Homo sapiens 106-113 24563333-2 2014 The sulfonylureas stimulate the release of insulin from pancreatic beta-cells and have a number of extrapancreatic effects, including decreasing hepatic insulin clearance and reducing glucagon secretion in patients with type 2 diabetes. Sulfonylurea Compounds 4-17 insulin Homo sapiens 43-50 24329524-7 2014 Final insulin doses were significantly greater in patients discontinuing treatment with sulphonylureas (0 29 vs. 0 26 IU/kg, P < 0 001), glinides (0 28 vs. 0 26 IU/kg, P < 0 01), thiazolidinediones (0 31 vs. 0 26 IU/kg, P < 0 001) and DPP-IV inhibitors (0 35 vs. 0 29 IU/kg, P < 0 001) compared with patients continuing these respective agents. Sulfonylurea Compounds 88-102 insulin Homo sapiens 6-13 24150606-5 2014 Sulfonylurea derivatives exert their insulinotropic effect by binding to the SUR1 subunit of the KATP channels inducing insulin secretion in beta-cells. Sulfonylurea Compounds 0-12 insulin Homo sapiens 37-44 24101534-2 2014 Guidelines from the American Diabetes Association and the European Association for the Study of Diabetes recommend that insulin secretagogues such as sulfonylureas be discontinued at the time of insulin initiation to reduce the risk of hypoglycemia, and that treatment be intensified if HbA1c levels remain above-target 3 months after insulin initiation. Sulfonylurea Compounds 150-163 insulin Homo sapiens 120-127 25782302-7 2014 Sulfonylurea derivatives enhance secretion of insulin by beta-cell. Sulfonylurea Compounds 0-12 insulin Homo sapiens 46-53